WO2023247590A1 - Triazolopyridine and benzoisoxazole carboxamides and their uses as pdgfr inhibitors - Google Patents
Triazolopyridine and benzoisoxazole carboxamides and their uses as pdgfr inhibitors Download PDFInfo
- Publication number
- WO2023247590A1 WO2023247590A1 PCT/EP2023/066725 EP2023066725W WO2023247590A1 WO 2023247590 A1 WO2023247590 A1 WO 2023247590A1 EP 2023066725 W EP2023066725 W EP 2023066725W WO 2023247590 A1 WO2023247590 A1 WO 2023247590A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- triazolo
- pyridine
- carboxamide
- methyl
- optionally substituted
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 15
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 title description 2
- KORMEWQCUWNSMF-UHFFFAOYSA-N 1,2-benzoxazole-3-carboxamide Chemical class C1=CC=C2C(C(=O)N)=NOC2=C1 KORMEWQCUWNSMF-UHFFFAOYSA-N 0.000 title 1
- 101150093908 PDGFRB gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 380
- 238000000034 method Methods 0.000 claims abstract description 84
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 38
- -1 cyano, cyclopropyl Chemical group 0.000 claims description 1202
- 229910052757 nitrogen Inorganic materials 0.000 claims description 219
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 197
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 139
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 94
- 201000010099 disease Diseases 0.000 claims description 74
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 67
- 208000035475 disorder Diseases 0.000 claims description 65
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 59
- 125000001072 heteroaryl group Chemical group 0.000 claims description 57
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 claims description 55
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 52
- 125000004076 pyridyl group Chemical group 0.000 claims description 42
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 25
- 125000004122 cyclic group Chemical group 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 125000003107 substituted aryl group Chemical group 0.000 claims description 16
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 13
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 12
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 12
- 230000011664 signaling Effects 0.000 claims description 11
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000001544 thienyl group Chemical group 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 8
- 125000001425 triazolyl group Chemical group 0.000 claims description 8
- 208000019693 Lung disease Diseases 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 206010021143 Hypoxia Diseases 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 238000000423 cell based assay Methods 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 230000007954 hypoxia Effects 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 208000035977 Rare disease Diseases 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 210000001147 pulmonary artery Anatomy 0.000 claims description 4
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 3
- 125000003725 azepanyl group Chemical group 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000005961 oxazepanyl group Chemical group 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 3
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical class C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- 150000002780 morpholines Chemical class 0.000 claims description 2
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims description 2
- 150000003527 tetrahydropyrans Chemical class 0.000 claims description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- GOLCAGIALURFLH-UHFFFAOYSA-N triazolo[1,5-a]pyridine-3-carboxamide Chemical compound C1=CC=CC2=C(C(=O)N)N=NN21 GOLCAGIALURFLH-UHFFFAOYSA-N 0.000 claims 3
- 238000002360 preparation method Methods 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 description 181
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 131
- 239000007787 solid Substances 0.000 description 99
- 239000000243 solution Substances 0.000 description 85
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 82
- 239000002904 solvent Substances 0.000 description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 75
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 73
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 72
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 69
- 229910001868 water Inorganic materials 0.000 description 69
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 41
- 239000012043 crude product Substances 0.000 description 39
- 239000011541 reaction mixture Substances 0.000 description 38
- 238000005160 1H NMR spectroscopy Methods 0.000 description 36
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 36
- 239000002585 base Substances 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 34
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 30
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 29
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 28
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- 235000019439 ethyl acetate Nutrition 0.000 description 28
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 27
- 235000014113 dietary fatty acids Nutrition 0.000 description 26
- 239000000194 fatty acid Substances 0.000 description 26
- 229930195729 fatty acid Natural products 0.000 description 26
- 238000002953 preparative HPLC Methods 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000004480 active ingredient Substances 0.000 description 22
- 238000003556 assay Methods 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 22
- 208000029523 Interstitial Lung disease Diseases 0.000 description 21
- 239000002253 acid Substances 0.000 description 21
- 238000003756 stirring Methods 0.000 description 21
- 239000004094 surface-active agent Substances 0.000 description 21
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- 150000001412 amines Chemical class 0.000 description 19
- 239000003921 oil Substances 0.000 description 19
- 229920001223 polyethylene glycol Polymers 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 18
- 239000000843 powder Substances 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- 239000012131 assay buffer Substances 0.000 description 17
- 229910000027 potassium carbonate Inorganic materials 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 229910000024 caesium carbonate Inorganic materials 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000007858 starting material Substances 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 239000002202 Polyethylene glycol Substances 0.000 description 14
- 239000003054 catalyst Substances 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- 238000010898 silica gel chromatography Methods 0.000 description 14
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 14
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 13
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 13
- 239000003208 petroleum Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 12
- 150000001721 carbon Chemical group 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 235000011187 glycerol Nutrition 0.000 description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 11
- 108091000080 Phosphotransferase Proteins 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 11
- 102000020233 phosphotransferase Human genes 0.000 description 11
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 11
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 10
- 229910002666 PdCl2 Inorganic materials 0.000 description 10
- 239000000969 carrier Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 10
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 10
- 235000013772 propylene glycol Nutrition 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 239000011369 resultant mixture Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229930182558 Sterol Natural products 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 9
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 125000000168 pyrrolyl group Chemical group 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 150000003432 sterols Chemical class 0.000 description 9
- 235000003702 sterols Nutrition 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 8
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 125000001246 bromo group Chemical group Br* 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 125000001041 indolyl group Chemical group 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- RKBXKOPRBRRUNO-UHFFFAOYSA-N tert-butyl n-(6-methyl-5-nitropyridin-3-yl)carbamate Chemical compound CC1=NC=C(NC(=O)OC(C)(C)C)C=C1[N+]([O-])=O RKBXKOPRBRRUNO-UHFFFAOYSA-N 0.000 description 8
- JNOVZPGBPRDTHN-UHFFFAOYSA-N (4-bromopyridin-2-yl)hydrazine Chemical compound NNC1=CC(Br)=CC=N1 JNOVZPGBPRDTHN-UHFFFAOYSA-N 0.000 description 7
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
- 239000007832 Na2SO4 Substances 0.000 description 7
- 108010058846 Ovalbumin Proteins 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 7
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 239000007884 disintegrant Substances 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 7
- 229940092253 ovalbumin Drugs 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- RZPSBEGGSZWYAN-UHFFFAOYSA-N 6-methyl-5-nitropyridin-3-amine Chemical compound CC1=NC=C(N)C=C1[N+]([O-])=O RZPSBEGGSZWYAN-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- NXQGGXCHGDYOHB-UHFFFAOYSA-L [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) Substances [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 235000010443 alginic acid Nutrition 0.000 description 6
- 229920000615 alginic acid Polymers 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- DWVFYOPSELYQRX-UHFFFAOYSA-N ethyl 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate Chemical compound BrC1=CC=2N(C=C1)C(=NN=2)C(=O)OCC DWVFYOPSELYQRX-UHFFFAOYSA-N 0.000 description 6
- 125000003709 fluoroalkyl group Chemical group 0.000 description 6
- 125000002541 furyl group Chemical group 0.000 description 6
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 6
- 229960002411 imatinib Drugs 0.000 description 6
- 125000002883 imidazolyl group Chemical group 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- 229940049964 oleate Drugs 0.000 description 6
- 229920005862 polyol Polymers 0.000 description 6
- 150000003077 polyols Chemical class 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 125000002098 pyridazinyl group Chemical group 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 239000000700 radioactive tracer Substances 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 6
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 6
- 239000012224 working solution Substances 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 5
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- KVBMACVEIMMVHH-UHFFFAOYSA-N 6-bromotriazolo[1,5-a]pyridine-3-carboxylic acid Chemical compound C1=C(Br)C=CC2=C(C(=O)O)N=NN21 KVBMACVEIMMVHH-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
- XPLMTOSXRFMFBN-VIFPVBQESA-N N-(5-amino-6-methylpyridin-3-yl)-2-[(2S)-2-methylpyrrolidin-1-yl]acetamide Chemical compound C[C@@H]1N(CC(NC2=CC(N)=C(C)N=C2)=O)CCC1 XPLMTOSXRFMFBN-VIFPVBQESA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 description 5
- 235000010216 calcium carbonate Nutrition 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000007822 coupling agent Substances 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 5
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 239000000787 lecithin Chemical class 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 5
- 108090000765 processed proteins & peptides Chemical class 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- NUIGEPXSRGNKQX-UHFFFAOYSA-N tert-butyl N-(5-amino-6-methylpyridin-3-yl)carbamate Chemical compound Cc1ncc(NC(=O)OC(C)(C)C)cc1N NUIGEPXSRGNKQX-UHFFFAOYSA-N 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- JRGNBMZOHLHILU-UHFFFAOYSA-N 1-[2-(2,2-dimethylpyrrolidin-1-yl)ethyl]-3-(6-methyl-5-nitropyridin-3-yl)urea Chemical compound CC1(C)N(CCNC(NC2=CC([N+]([O-])=O)=C(C)N=C2)=O)CCC1 JRGNBMZOHLHILU-UHFFFAOYSA-N 0.000 description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 4
- GDSQTWDUCDSZEY-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indazole Chemical compound C1CCCC2=C1C=NN2 GDSQTWDUCDSZEY-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- JCSJWSJDIPIKHS-UHFFFAOYSA-N N-(5-amino-6-methylpyridin-3-yl)-2-(2,2-dimethylpyrrolidin-1-yl)acetamide Chemical compound CC1(C)N(CC(NC2=CC(N)=C(C)N=C2)=O)CCC1 JCSJWSJDIPIKHS-UHFFFAOYSA-N 0.000 description 4
- VKTZCRRIRYDMJG-UHFFFAOYSA-N N-(6-methyl-5-nitropyridin-3-yl)prop-2-enamide Chemical compound CC(N=CC(NC(C=C)=O)=C1)=C1[N+]([O-])=O VKTZCRRIRYDMJG-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 239000000783 alginic acid Substances 0.000 description 4
- 229960001126 alginic acid Drugs 0.000 description 4
- 150000004781 alginic acids Chemical class 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 4
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 description 4
- 125000005956 isoquinolyl group Chemical group 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229940070765 laurate Drugs 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- MMNCJSRLWRBJRG-UHFFFAOYSA-N phenyl N-[2-(2,2-dimethylpyrrolidin-1-yl)ethyl]carbamate Chemical compound CC1(C)N(CCNC(OC2=CC=CC=C2)=O)CCC1 MMNCJSRLWRBJRG-UHFFFAOYSA-N 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 4
- 125000005493 quinolyl group Chemical group 0.000 description 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000009518 sodium iodide Nutrition 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000008117 stearic acid Chemical group 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- CKXXYYAKSAMZDR-UHFFFAOYSA-N tert-butyl N-[5-[(2-chloroacetyl)amino]-2-methylpyridin-3-yl]carbamate Chemical compound CC(C)(C)OC(NC1=CC(NC(CCl)=O)=CN=C1C)=O CKXXYYAKSAMZDR-UHFFFAOYSA-N 0.000 description 4
- XTVBGJBWSNBBMY-UHFFFAOYSA-N tert-butyl N-[5-[(6-bromotriazolo[1,5-a]pyridine-3-carbonyl)amino]-6-methylpyridin-3-yl]carbamate Chemical compound CC(C)(C)OC(NC1=CC(NC(C2=C(C=CC(Br)=C3)N3N=N2)=O)=C(C)N=C1)=O XTVBGJBWSNBBMY-UHFFFAOYSA-N 0.000 description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 description 4
- 125000005306 thianaphthenyl group Chemical group 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- 238000005809 transesterification reaction Methods 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical class CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 3
- XOBGFCWAVKCNMV-UHFFFAOYSA-N 1-(5-amino-6-methylpyridin-3-yl)-3-[2-(2,2-dimethylpyrrolidin-1-yl)ethyl]urea Chemical compound CC1(C)N(CCNC(NC2=CC(N)=C(C)N=C2)=O)CCC1 XOBGFCWAVKCNMV-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- TWMYYKMPSYOTET-UHFFFAOYSA-N 3-(2,2-dimethylpyrrolidin-1-yl)-N-(6-methyl-5-nitropyridin-3-yl)propanamide Chemical compound CC1(C)N(CCC(NC2=CC([N+]([O-])=O)=C(C)N=C2)=O)CCC1 TWMYYKMPSYOTET-UHFFFAOYSA-N 0.000 description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 3
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 3
- PTPTZLXZHPPVKG-UHFFFAOYSA-N 4-bromo-2-fluoropyridine Chemical compound FC1=CC(Br)=CC=N1 PTPTZLXZHPPVKG-UHFFFAOYSA-N 0.000 description 3
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 3
- IASRYLKZYZPWRV-UHFFFAOYSA-N 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine Chemical compound C1CCOC2=CC=NN21 IASRYLKZYZPWRV-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- XPLMTOSXRFMFBN-SECBINFHSA-N N-(5-amino-6-methylpyridin-3-yl)-2-[(2R)-2-methylpyrrolidin-1-yl]acetamide Chemical compound C[C@H]1N(CC(NC2=CC(N)=C(C)N=C2)=O)CCC1 XPLMTOSXRFMFBN-SECBINFHSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091008606 PDGF receptors Proteins 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 description 3
- 206010042953 Systemic sclerosis Diseases 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 235000010338 boric acid Nutrition 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical class CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 3
- 229940113088 dimethylacetamide Drugs 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 3
- 229940093471 ethyl oleate Drugs 0.000 description 3
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 235000011087 fumaric acid Nutrition 0.000 description 3
- 239000000174 gluconic acid Chemical group 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 125000005456 glyceride group Chemical class 0.000 description 3
- 239000001087 glyceryl triacetate Substances 0.000 description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000002563 ionic surfactant Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- NTMHWRHEGDRTPD-UHFFFAOYSA-N n-(4-azidosulfonylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(S(=O)(=O)N=[N+]=[N-])C=C1 NTMHWRHEGDRTPD-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- DZFZXPPHBWCXPQ-UHFFFAOYSA-N n-[5-[2-(cyclopropanecarbonylamino)imidazo[1,2-b]pyridazin-6-yl]oxy-2-methylphenyl]-2,5-dimethylpyrazole-3-carboxamide Chemical compound CN1N=C(C)C=C1C(=O)NC1=CC(OC2=NN3C=C(NC(=O)C4CC4)N=C3C=C2)=CC=C1C DZFZXPPHBWCXPQ-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 150000002828 nitro derivatives Chemical class 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 229960001367 tartaric acid Drugs 0.000 description 3
- 150000003899 tartaric acid esters Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- 229960002622 triacetin Drugs 0.000 description 3
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- WJTCHBVEUFDSIK-NWDGAFQWSA-N (2r,5s)-1-benzyl-2,5-dimethylpiperazine Chemical compound C[C@@H]1CN[C@@H](C)CN1CC1=CC=CC=C1 WJTCHBVEUFDSIK-NWDGAFQWSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- OEZPKXDBWNXBRE-UHFFFAOYSA-N 2,3-bis(2-hydroxyethoxy)propyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(OCCO)COCCO OEZPKXDBWNXBRE-UHFFFAOYSA-N 0.000 description 2
- ZSHAGSDVWLLMSY-UHFFFAOYSA-N 2-(2,2-dimethylpyrrolidin-1-yl)ethanamine Chemical compound CC1(C)CCCN1CCN ZSHAGSDVWLLMSY-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- KHICUSAUSRBPJT-UHFFFAOYSA-N 2-(2-octadecanoyloxypropanoyloxy)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(O)=O KHICUSAUSRBPJT-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- TWHBBMSMSDZUQX-UHFFFAOYSA-N 3-(5-bromopyridin-2-yl)oxetan-3-ol Chemical compound C=1C=C(Br)C=NC=1C1(O)COC1 TWHBBMSMSDZUQX-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 2
- FZZLWWNOYMHSIS-UHFFFAOYSA-N 5-bromo-2-methyl-3-nitropyridine Chemical compound CC1=NC=C(Br)C=C1[N+]([O-])=O FZZLWWNOYMHSIS-UHFFFAOYSA-N 0.000 description 2
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- ZUXUGPIWKKBPCT-UHFFFAOYSA-N N-(5-amino-6-methylpyridin-3-yl)-3-(2,2-dimethylpyrrolidin-1-yl)propanamide Chemical compound CC1(C)N(CCC(NC2=CC(N)=C(C)N=C2)=O)CCC1 ZUXUGPIWKKBPCT-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical class CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000011623 Obstructive Lung disease Diseases 0.000 description 2
- 108010038807 Oligopeptides Chemical class 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 2
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000021066 Pulmonary arterial hypertension associated with connective tissue disease Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000030934 Restrictive pulmonary disease Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 208000032594 Vascular Remodeling Diseases 0.000 description 2
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 235000010350 erythorbic acid Nutrition 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- DBPFRRFGLYGEJI-UHFFFAOYSA-N ethyl glyoxylate Chemical compound CCOC(=O)C=O DBPFRRFGLYGEJI-UHFFFAOYSA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940074046 glyceryl laurate Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 description 2
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 description 2
- 208000018578 heart valve disease Diseases 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 229940026239 isoascorbic acid Drugs 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- NIAATLPQSKGUBG-UHFFFAOYSA-N methyl 2-(5-bromopyridin-2-yl)acetate Chemical compound COC(=O)CC1=CC=C(Br)C=N1 NIAATLPQSKGUBG-UHFFFAOYSA-N 0.000 description 2
- YOKIHPOOMRXMGS-UHFFFAOYSA-N methyl 6-bromotriazolo[1,5-a]pyridine-3-carboxylate Chemical compound BrC=1C=CC=2N(C=1)N=NC=2C(=O)OC YOKIHPOOMRXMGS-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- VLZLEPNAKIFDQJ-UHFFFAOYSA-N n-pyridin-2-ylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=N1 VLZLEPNAKIFDQJ-UHFFFAOYSA-N 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- YYZUSRORWSJGET-UHFFFAOYSA-N octanoic acid ethyl ester Natural products CCCCCCCC(=O)OCC YYZUSRORWSJGET-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229940116315 oxalic acid Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920001184 polypeptide Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical class [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- YWCDCAQHVMPYIJ-UHFFFAOYSA-N tert-butyl N-[5-[[2-(2,2-dimethylpyrrolidin-1-yl)acetyl]amino]-2-methylpyridin-3-yl]carbamate Chemical compound CC(C)(C)OC(NC1=CC(NC(CN2C(C)(C)CCC2)=O)=CN=C1C)=O YWCDCAQHVMPYIJ-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009424 thromboembolic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JNEIFWYJFOEKIM-NUBCRITNSA-N (2r)-2-methylpyrrolidine;hydrochloride Chemical compound Cl.C[C@@H]1CCCN1 JNEIFWYJFOEKIM-NUBCRITNSA-N 0.000 description 1
- RGHPCLZJAFCTIK-YFKPBYRVSA-N (2s)-2-methylpyrrolidine Chemical compound C[C@H]1CCCN1 RGHPCLZJAFCTIK-YFKPBYRVSA-N 0.000 description 1
- JNEIFWYJFOEKIM-JEDNCBNOSA-N (2s)-2-methylpyrrolidine;hydrochloride Chemical compound Cl.C[C@H]1CCCN1 JNEIFWYJFOEKIM-JEDNCBNOSA-N 0.000 description 1
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- WDQFELCEOPFLCZ-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrolidin-2-one Chemical compound OCCN1CCCC1=O WDQFELCEOPFLCZ-UHFFFAOYSA-N 0.000 description 1
- FIWVAISHBIQYOU-RWPZCVJISA-N 1-(4-amino-1,2,5-oxadiazol-3-yl)-n-[(e)-[4-[(3-methylphenyl)methoxy]phenyl]methylideneamino]-5-(piperidin-1-ylmethyl)triazole-4-carboxamide Chemical compound CC1=CC=CC(COC=2C=CC(\C=N\NC(=O)C3=C(N(N=N3)C=3C(=NON=3)N)CN3CCCCC3)=CC=2)=C1 FIWVAISHBIQYOU-RWPZCVJISA-N 0.000 description 1
- AOWCOHYBGYRYGE-UHFFFAOYSA-N 1-[2,3-bis(2-oxopropoxy)propoxy]propan-2-one Chemical compound CC(=O)COCC(OCC(C)=O)COCC(C)=O AOWCOHYBGYRYGE-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- JVCBVWTTXCNJBJ-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCN1C2 JVCBVWTTXCNJBJ-UHFFFAOYSA-N 0.000 description 1
- PYYANZUYIUWBKF-UHFFFAOYSA-N 1-azaspiro[3.3]heptane;hydrochloride Chemical compound Cl.C1CCC21NCC2 PYYANZUYIUWBKF-UHFFFAOYSA-N 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 description 1
- PHODFIDDEBEGCS-UHFFFAOYSA-N 2,2-dimethylpyrrolidine Chemical compound CC1(C)CCCN1 PHODFIDDEBEGCS-UHFFFAOYSA-N 0.000 description 1
- MZQJSLYOHPXTJR-UHFFFAOYSA-N 2,2-dimethylpyrrolidine;hydrochloride Chemical compound Cl.CC1(C)CCCN1 MZQJSLYOHPXTJR-UHFFFAOYSA-N 0.000 description 1
- YTORMSBGFMQNEO-UHFFFAOYSA-N 2,3-dihydroxypropyl decanoate;2,3-dihydroxypropyl octanoate;(3-hydroxy-2-octanoyloxypropyl) octanoate;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(=O)OCC(O)CO.CCCCCCCCCC(=O)OCC(O)CO.CCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCC YTORMSBGFMQNEO-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- UGDAWAQEKLURQI-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethanol;hydrate Chemical compound O.OCCOCCO UGDAWAQEKLURQI-UHFFFAOYSA-N 0.000 description 1
- UMUSYFTZUULERM-UHFFFAOYSA-N 2-(3,3-dimethylmorpholin-4-yl)ethanamine Chemical compound CC1(C)COCCN1CCN UMUSYFTZUULERM-UHFFFAOYSA-N 0.000 description 1
- UUDNITWWYBIYOX-UHFFFAOYSA-N 2-(3-azabicyclo[2.2.1]heptan-3-yl)acetic acid Chemical compound C1CC2N(CC(=O)O)CC1C2 UUDNITWWYBIYOX-UHFFFAOYSA-N 0.000 description 1
- NEJACQAEUDFFBS-UHFFFAOYSA-N 2-(4-ethyl-4,5,5-trimethyl-1,3,2-dioxaborolan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(CC)(C)OB1B1OC(C)(C)C(C)(C)O1 NEJACQAEUDFFBS-UHFFFAOYSA-N 0.000 description 1
- NNWUEBIEOFQMSS-UHFFFAOYSA-N 2-Methylpiperidine Chemical compound CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 1
- GDWKIRLZWQQMIE-QMMMGPOBSA-N 2-[(2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]acetic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CC(O)=O GDWKIRLZWQQMIE-QMMMGPOBSA-N 0.000 description 1
- MQFYRUGXOJAUQK-UHFFFAOYSA-N 2-[2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC MQFYRUGXOJAUQK-UHFFFAOYSA-N 0.000 description 1
- IBRLSABGLKHIKN-UHFFFAOYSA-N 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]acetic acid Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC(O)=O)N=C1 IBRLSABGLKHIKN-UHFFFAOYSA-N 0.000 description 1
- QEHDAUWYRNEWBF-UHFFFAOYSA-N 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]ethanol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CCO)N=C1 QEHDAUWYRNEWBF-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- PPPFYBPQAPISCT-UHFFFAOYSA-N 2-hydroxypropyl acetate Chemical compound CC(O)COC(C)=O PPPFYBPQAPISCT-UHFFFAOYSA-N 0.000 description 1
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Chemical class CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- DVPXDZWZLKNLJX-UHFFFAOYSA-N 3,3-dimethylazetidine;hydrochloride Chemical compound Cl.CC1(C)CNC1 DVPXDZWZLKNLJX-UHFFFAOYSA-N 0.000 description 1
- MWKFODZYSUOCMQ-UHFFFAOYSA-N 3,5-dimethyl-1-(oxetan-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CC1=NN(C(=C1B1OC(C)(C)C(C)(C)O1)C)C1COC1 MWKFODZYSUOCMQ-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- KPUSZZFAYGWAHZ-UHFFFAOYSA-N 3-azabicyclo[2.2.2]octane Chemical compound C1CC2CCC1NC2 KPUSZZFAYGWAHZ-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KCABEFWZFQEYNC-UHFFFAOYSA-N 3-thia-1-azabicyclo[3.1.1]heptane Chemical compound C1C2CN1CSC2 KCABEFWZFQEYNC-UHFFFAOYSA-N 0.000 description 1
- IECMOFZIMWVOAS-UHFFFAOYSA-N 4,4-dimethylpiperidine Chemical compound CC1(C)CCNCC1 IECMOFZIMWVOAS-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- UWLNGLZSXULFBT-UHFFFAOYSA-N 4-methylpiperidine-4-carbonitrile;hydrochloride Chemical compound Cl.N#CC1(C)CCNCC1 UWLNGLZSXULFBT-UHFFFAOYSA-N 0.000 description 1
- GIBPTWPJEVCTGR-UHFFFAOYSA-N 6-azaspiro[2.5]octane Chemical compound C1CC11CCNCC1 GIBPTWPJEVCTGR-UHFFFAOYSA-N 0.000 description 1
- MTNXSWYFNMWKQE-UHFFFAOYSA-N 6-bromo-1,2-benzoxazole-3-carboxylic acid Chemical compound BrC1=CC=C2C(C(=O)O)=NOC2=C1 MTNXSWYFNMWKQE-UHFFFAOYSA-N 0.000 description 1
- SOIDQYXQSTZLHM-UHFFFAOYSA-N 6-oxa-1-azabicyclo[3.1.1]heptane Chemical compound C1N2OC1CCC2 SOIDQYXQSTZLHM-UHFFFAOYSA-N 0.000 description 1
- BSQKGAVROUDOTE-UHFFFAOYSA-N 7-azaspiro[3.5]nonane Chemical compound C1CCC21CCNCC2 BSQKGAVROUDOTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 101100291385 Drosophila melanogaster p38a gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 238000003043 HTRF KinEASE-TK Methods 0.000 description 1
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Chemical class 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000021076 Pulmonary arterial hypertension associated with congenital heart disease Diseases 0.000 description 1
- 208000021068 Pulmonary arterial hypertension associated with portal hypertension Diseases 0.000 description 1
- 208000021083 Pulmonary arterial hypertension associated with schistosomiasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000038012 SFKs Human genes 0.000 description 1
- 108091008118 SFKs Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000001833 Succinylated monoglyceride Substances 0.000 description 1
- XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- GSCLMSFRWBPUSK-UHFFFAOYSA-N beta-Butyrolactone Chemical compound CC1CC(=O)O1 GSCLMSFRWBPUSK-UHFFFAOYSA-N 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- SBGUYEPUJPATFD-UHFFFAOYSA-N bromo(tripyrrolidin-1-yl)phosphanium Chemical compound C1CCCN1[P+](N1CCCC1)(Br)N1CCCC1 SBGUYEPUJPATFD-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical class CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 108700043024 cholylsarcosine Proteins 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008271 cosmetic emulsion Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- XLIDPNGFCHXNGX-UHFFFAOYSA-N dialuminum;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Si+4] XLIDPNGFCHXNGX-UHFFFAOYSA-N 0.000 description 1
- PFBUKDPBVNJDEW-UHFFFAOYSA-N dichlorocarbene Chemical group Cl[C]Cl PFBUKDPBVNJDEW-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UYAAVKFHBMJOJZ-UHFFFAOYSA-N diimidazo[1,3-b:1',3'-e]pyrazine-5,10-dione Chemical compound O=C1C2=CN=CN2C(=O)C2=CN=CN12 UYAAVKFHBMJOJZ-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229940018602 docusate Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- QFKXJOMCJPISBG-UHFFFAOYSA-N ethyl 2-(5-bromopyridin-2-yl)acetate Chemical compound CCOC(=O)CC1=CC=C(Br)C=N1 QFKXJOMCJPISBG-UHFFFAOYSA-N 0.000 description 1
- LKGZPPSZEDDGAG-UHFFFAOYSA-N ethyl 5-amino-6-methylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(C)C(N)=C1 LKGZPPSZEDDGAG-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229940037959 monooctanoin Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JVRXXYOJMOWFNP-UHFFFAOYSA-N n'-(5-chloro-2-hydroxyphenyl)-n-[3-(dimethylamino)propyl]oxamide Chemical compound CN(C)CCCNC(=O)C(=O)NC1=CC(Cl)=CC=C1O JVRXXYOJMOWFNP-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- OJEOJUQOECNDND-UHFFFAOYSA-N oxetan-3-amine Chemical compound NC1COC1 OJEOJUQOECNDND-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940077412 peg-12 laurate Drugs 0.000 description 1
- 229940008456 peg-32 oleate Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001693 poly(ether-ester) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229940097941 polyglyceryl-10 laurate Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Chemical class 0.000 description 1
- 150000007519 polyprotic acids Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Chemical class 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940116423 propylene glycol diacetate Drugs 0.000 description 1
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical compound [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 229940071209 stearoyl lactylate Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000019327 succinylated monoglyceride Nutrition 0.000 description 1
- 229940032085 sucrose monolaurate Drugs 0.000 description 1
- 229940035023 sucrose monostearate Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- FFKYIERZHFXSHA-UHFFFAOYSA-N tert-butyl n-(5-amino-2-methylpyridin-3-yl)carbamate Chemical compound CC1=NC=C(N)C=C1NC(=O)OC(C)(C)C FFKYIERZHFXSHA-UHFFFAOYSA-N 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000006300 thietan-3-yl group Chemical group [H]C1([H])SC([H])([H])C1([H])* 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical compound OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
The disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
Description
TRIAZOLOPYRIDINE AND BENZOISOXAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS CROSS-REFERENCE TO RELATED APPLICATION [0001] This application claims the benefit of United States Provisional Application No.63/354,343, filed June 22, 2022, the entirety of which is incorporated by reference herein. TECHNICAL FIELD [0002] The disclosure is directed to PDGFR inhibitors and methods of their use. BACKGROUND [0003] Protein kinases are a family of enzymes that catalyze the phosphorylation of specific residues in proteins. Protein kinases play a critical role in the control cell growth, proliferation, differentiation, metabolism, apoptosis, cell mobility, transcription, translation and other signaling processes. The overexpression or inappropriate expression of protein kinases plays a significant role in the development of many diseases and disorders including central nervous system disorders, inflammatory disorders, metabolic disorders, autoimmune diseases, cardiovascular diseases, fibrotic diseases, transplantation rejection, cancer and infectious diseases. [0004] Growth factors (GF) are important regulators of human homeostasis involved in maintaining a delicate balance between cell growth, differentiation, and proliferation. Consequently, dysregulation of GF signaling are implicated in many diseases including oncology, immunology, fibroproliferative, cardiovascular, vascular disorders and pulmonary hypertension. GF bind to several different receptors that amplify the signal through activation of the specific receptor through phosphorylation, leading to confirmation changes increasing the affinity for ATP and the phosphorylation of downstream proteins leading to activation of several signaling cascades. Therefore, small changes in GF or the cognate receptors can significantly alter the local signaling and have dramatic effects on initiation and progression of many diseases. [0005] Platelet-derived growth factor (PDGF) is one of many GFs that regulate cell growth and division. PDGF exerts its biological responses via activation of two highly
specific, transmembrane receptor tyrosine kinases, termed PDGFR α and PDGFR β, which can form three different dimeric receptors – αα, ββ and αβ. These receptors can interact with the different dimeric PDGF ligands (PDGF-AA, PDGF-BB, PDGF-CC, PDGF-DD and PDGF-AB) with different specificities and efficacies. The receptors are activated by ligand- induced dimerization, leading to autophosphorylation on specific tyrosine residues. PDGFR phosphorylation recruits signaling proteins containing Tyr(P)-binding domains. Several of these signaling proteins include Src kinase family members, phospholipase C-y1, the p38a subunit of PI3K, GTPase-activating protein. The formation of receptor-signaling complexes then initiates the activation of various signaling pathways, including the Ras-mitogen activated protein (MAP) kinase pathway, the PI3kinase-Akt pathway, the PLC-y1 and the Src pathway. Activation of PDGFRα or PDGFRβ by PDGFs, leads to protein synthesis, proliferation, migration, protection against apoptosis and cellular transformation, key mechanisms associated with several vascular diseases including pulmonary hypertension. Platelet-derived growth factor (PDGF) and its receptors (PDGFR), including PDGFRα and PDGFRβ, play important roles in tumorigenesis, tumor progression, and the regulation of stromal cell function. Constitutive activation of PDGFR signaling, gene rearrangement, and activating mutations of PDGFR have been identified in various types of human tumors and malignancies. [0006] PDGFR signaling is implicated in the development and progression of pulmonary hypertension. PDGFs are expressed in ECs, SMCs and macrophages and are strong mitogens and chemokines. Increased signaling through PDGFRβ leads to smooth muscle cell proliferation which contributes to the development of vascular remodeling. PDGF and PDGF receptors (α and β) are upregulated in human and animals with pulmonary hypertension. Preclinically, efficacy in preventing and reversing vascular remodeling in experimentally induced pulmonary hypertension was demonstrated through non-selective inhibition of PDGF receptors. Clinically, imatinib (also known as Gleevec), a non-selective tyrosine kinase inhibitor including PDGF receptors improved exercise capacity and hemodynamics in patients with advanced pulmonary hypertension. Conversely, dasatinib, a receptor tyrosine kinases inhibitor, was linked to cardiotoxicity and the development of pulmonary hypertension, emphasizing the importance of the appropriate kinase selectivity, and associated differentiated profile.
[0007] A need exists for additional PDGFR inhibitors for the treatment of pulmonary hypertension and other conditions in which PDGFR signaling is implicated. SUMMARY [0008] The present disclosure provides PDGFR inhibitors. [0009] In some aspects, the disclosure is directed to compounds of formula (I):
or pharmaceutically acceptable salts thereof, wherein A is
wherein *2 is the point of attachment to R2, and *1 is the point of attachment to the amide carbonyl carbon atom; R1 is H, C1-C6alkyl, C3-C6cycloalkyl, halogen, -CN, or C1-C4fluoroalkyl; R2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted fused heterocycloalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, halo, -O-(3- to 5-membered heterocycloalkyl), -NH-(3- to 5-membered heterocycloalkyl), or optionally substituted heterocycloalkyl; R3 and R4 are each independently optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; or one of R3 or R4 may be H; or R3 and R4, together with the nitrogen atom to which they are both attached, form an optionally substituted 3-12-membered heterocycloalkyl ring, an optionally
substituted 5-12-membered bridged heterocycloalkyl ring, an optionally substituted 4- 12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12- membered spiroheterocycloalkyl ring system, wherein said 3-12-membered heterocycloalkyl ring, 5-12-membered bridged heterocycloalkyl ring, 4-12-membered fused heterocycloalkyl ring system, or 5-12-membered spiroheterocycloalkyl ring system may include, in addition to the nitrogen atom to which both R3 and R4 are attached, 1-3 other heteroatoms that are each independently O, S, or N; each R5 and each R6 is independently H, C1-C6alkyl, or C3-C5cycloalkyl; or an R5 and R6 attached to the same carbon atom, together with that carbon atom, may form a C3-C6cycloalkyl ring; or an R5 or R6, together with an R3 or R4 may form an optionally substituted 3- 12-membered heterocycloalkyl ring, an optionally substituted 5-12-membered bridged heterocycloalkyl ring, an optionally substituted 4-12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12-membered spiroheterocycloalkyl ring system; n is 1, 2, 3, 4, or 5; and L is C(O)NH, NHC(O), NHC(O)O, or NHC(O)NH. [0010] In some aspects, the disclosure is directed to compounds of formula (I) that are compounds of formula (IA):
or pharmaceutically acceptable salts thereof. [0011] In other aspects, the disclosure is directed to compounds of formula (I) that are compound of formula (IB):
or a pharmaceutically acceptable salt thereof. [0012] Pharmaceutical compositions comprising such compounds, and methods of using such compounds in treating conditions in which PDGFR signaling is implicated are also provided. DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS [0013] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. The terminology used in the description is for describing particular embodiments only and is not intended to be limiting of the disclosure. [0014] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise (such as in the case of a group containing a number of carbon atoms in which case each carbon atom number falling within the range is provided), between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either both of those included limits are also included in the disclosure. [0015] The following terms are used to describe the present disclosure. In instances where a term is not specifically defined herein, that term is given an art-recognized meaning by those of ordinary skill applying that term in context to its use in describing the present disclosure. [0016] The articles “a” and “an” as used herein and in the appended claims are used herein to refer to one or to more than one (e.g., to at least one) of the grammatical object of the article unless the context clearly indicates otherwise. By way of example, “an element” means one element or more than one element.
[0017] The term “compound”, as used herein, unless otherwise indicated, refers to any specific chemical compound disclosed herein and includes tautomers, optical isomers (enantiomers) and other stereoisomers (diastereomers) thereof, as well as pharmaceutically acceptable salts and derivatives, including prodrug and/or deuterated forms thereof where applicable. Deuterated small molecules contemplated are those in which one or more of the hydrogen atoms contained in the drug molecule have been replaced by deuterium. It is understood by those of ordinary skill that molecules which are described herein are stable compounds as generally described hereunder. [0018] “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, e.g., in humans. [0019] “Pharmaceutically acceptable salt” refers to a salt of a compound of the disclosure that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2- hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2- naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4- methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N- methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when
the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like. [0020] A “pharmaceutically acceptable excipient” refers to a substance that is non- toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith. [0021] A “solvate” refers to a physical association of a compound of formula (I) or formula (Io) with one or more solvent molecules. [0022] The term “alkyl,” when used alone or as part of a substituent group, refers to a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“C1- C12”), preferably 1 to 6 carbons atoms (“C1-C6”), in the group. Examples of alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n- hexyl, n-heptyl, n-octyl, and the like. In some embodiments, the alkyl group is a C1-C6 alkyl; in some embodiments, it is a C1-C4 alkyl. [0023] When a range of carbon atoms is used herein, for example, C1-C6, all ranges, as well as individual numbers of carbon atoms are encompassed. For example, “C1-C3” includes C1-C3, C1-C2, C2-C3, C1, C2, and C3. [0024] The term “cycloalkyl” when used alone or as part of a substituent group refers to cyclic-containing, non-aromatic hydrocarbon groups having from 3 to 10 carbon atoms (“C3-C10”), preferably from 3 to 6 carbon atoms (“C3-C6”). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, indenyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[4.1.0]heptanyl, spiro[3.3]heptanyl, and spiro[3.4]octanyl. [0025] The term “fluoroalkyl” when used alone or as part of a substituent group refers to an alkyl group wherein one or more of the hydrogen atoms has been replaced with one or more fluorine atoms. Examples of fluoroalkyl groups include -CF3, CHF2, -CH2F and the like. [0026] The term “heterocycloalkyl” when used alone or as part of a substituent group refers to any three to twelve-membered monocyclic, saturated or partially unsaturated ring containing at least one heteroatom that is O, N or S. The heterocycloalkyl group may be
attached at any heteroatom or carbon atom of the ring such that the result is a stable structure. Examples of heterocycloalkyl groups include, but are not limited to, azepanyl, aziridinyl, azetidinyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, piperazinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, oxazepanyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, and the like. [0027] The term “bridged heterocycloalkyl ring” refers to any 5 to 12 membered heterocycloalkyl ring system that contains at least one bridged ring. Examples of bridged heterocycloalkyl rings include azabicyclo[3.1.1]heptane, azabicyclo[3.1.1]heptane, azabicyclo[2.2.2]octane, azabicyclo[2.2.1]heptane, azabicyclo[2.1.1]hexane, azabicyclo[1.1.1]pentane, azabicyclo[1.1.1]pentane, 6-oxa-azabicyclo[3.1.1]heptane, 6- diazabicyclo[3.1.1]heptane, 3-thia-azabicyclo[3.1.1]heptane, and the like. [0028] The term “fused heterocycloalkyl ring system” refers to a heterocycloalkyl ring to which another ring is fused. The other ring that is fused to the heterocycle ring may be another heterocycloalkyl ring, a cycloalkyl ring, an aryl ring, or a heteroaryl ring. In some embodiments, the fused heterocycloalkyl ring system is a 4 to 12 membered fused heterocycloalkyl ring system. [0029] The term “spiroheterocycloalkyl ring system” refers to a heterocycloalkyl ring that is substituted with a spirocyclic ring. The spirocyclic ring can be a cycloalkyl ring of a heterocycloalkyl ring. In some embodiments, the spiroheterocycloalkyl ring system is a 5-12-membered spiroheterocycloalkyl ring system. [0030] The terms “halo” or “halogen”, by itself or as part of another substituent, means a fluorine, chlorine, bromine, or iodine atom. [0031] The term “aryl” when used alone or as part of a substituent group also refers to a mono- or bicyclic- aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein one or more of the carbon atoms in the ring is optionally substituted. The term “aryl” also includes a mono- or bicyclic- aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein two adjacent carbon atoms in the ring are optionally substituted such that said two adjacent carbon atoms and their respective substituents form a cycloalkyl or heterocycloalkyl ring. Non-limiting examples of aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, 1, 2, 3,4-tetrahydronaphthyl, and the like. [0032] The term “heteroaryl” when used alone or as part of a substituent group refers to a mono- or bicyclic- aromatic ring structure including carbon atoms as well as up to
four heteroatoms that are each independently nitrogen, oxygen, or sulfur. Heteroaryl rings can include a total of 5, 6, 9, or 10 ring atoms. The heteroaryl moiety can be unsubstituted, or one or more of the carbon atoms in the ring can be substituted. Exemplary heteroaryls include but are not limited to pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl, benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2,3- b]pyridinyl, quinazolinyl-4(3H)-one, triazolyl, 4,5,6,7-tetrahydro-1H-indazole. [0033] The term “optionally substituted,” as used herein to describe a substituent defined herein, means that the substituent may, but is not required to be, substituted with one or more suitable functional groups or other substituents as provided herein. For example, a substituent may be optionally substituted with one or more of: halo (i.e., -F, -Cl, -Br, -I), cyano, -OH, hydroxyalkyl, -C1-C6alkyl, C3-C6cycloalkyl, C2-C6alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, -C1-C6 alkoxy, -C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 alkylamino, -NH2, SO2NH2, -NH(C1-C6 alkyl), -N(C1-C-6 alkyl)2, -NH(C1-C6 alkoxy), -C(O)NHC1-C6 alkyl, - C(O)N(C1-C6 alkyl)2, -COOH, -C1-C6alkylCOOH, -C3-C6cycloalkylCOOH, -C(O)NH2, C1- C6alkylCONH2, -C3-C6cycloalkylCONH2, C1-C6alkylCONHC1-C6alkyl, C1-C6alkylCON(C1- C6alkyl)2, -C(O)C1-C6 alkyl, -C(O)OC1-C6 alkyl, -NHCO(C1-C6 alkyl), -N(C1-C6 alkyl)C(O)(C1-C6 alkyl), -S(O)C1-C6 alkyl, -S(O)2C1-C6 alkyl, oxo (carbonyl (i.e., =O)), 6-12 membered aryl, or 5 to 12 membered heteroaryl groups. [0034] In particular, a substituent may be optionally substituted with one or more of: halo (i.e., -F, -Cl, -Br, -I), cyano, -C1-C6alkyl, C3-C6cycloalkyl, C2-C6alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, -C1-C6 alkoxy, -C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 alkylamino, -NH2, -NH(C1-C6 alkyl), -N(C1-C-6 alkyl)2, -NH(C1-C6 alkoxy), -C(O)NHC1-C6 alkyl, -C(O)N(C1-C6 alkyl)2, -COOH, -C1-C6alkylCOOH, -C3-C6cycloalkylCOOH, - C(O)NH2, C1-C6alkylCONH2, -C3-C6cycloalkylCONH2, C1-C6alkylCONHC1-C6alkyl, C1- C6alkylCON(C1-C6alkyl)2, -C(O)C1-C6 alkyl, -C(O)OC1-C6 alkyl, -NHCO(C1-C6 alkyl), - N(C1-C6 alkyl)C(O)(C1-C6 alkyl), -S(O)C1-C6 alkyl, -S(O)2C1-C6 alkyl, oxo, 6-12 membered aryl, or 5 to 12 membered heteroaryl groups. In some embodiments, each of the above optional substituents are themselves optionally substituted by one or two groups. [0035] In other embodiments, a substituent may be optionally substituted with one or more of: halo (i.e., -F, -Cl, -Br, -I), cyano, -OH, -C1-C6alkyl, -CH2CH2OH, -
CH2CH2CH(OH)CH2(OH), -CH2CH(OH)CH2(OH), -CH2CH(OH)CH3, -CH2OH, -C (CH3)2CH2(OH), -CH2OCH3, -CH2CH2OCH3, -CH2-(C3-C6cycloalkyl), -C3-C6cycloalkyl, C2- C6alkenyl, C2-C6 alkynyl, -C1-C6 haloalkyl, -C1-C6 alkoxy, -OCH3, -C1-C6 haloalkoxy, - OCH2CH2F, -C1-C6 alkylthio, C1-C6 alkylamino, -NH2, -NH(C1-C6 alkyl), -N(C1-C-6 alkyl)2, - NH(C1-C6 alkoxy), -C(O)NHC1-C6 alkyl, -CH2C(O)NHC1-C6 alkyl, -C(O)N(C1-C6 alkyl)2, - COOH, -C1-C6alkylCOOH, -C3-C6cycloalkylCOOH, -C(O)NH2, -C1-C6alkylCONH2, -C1- C6alkyl-CN, -C3-C6cycloalkylCONH2, -C1-C6alkylCONHC1-C6alkyl, C1-C6alkylCON(C1- C6alkyl)2, -C(O)C1-C6 alkyl, -C(O)OC1-C6 alkyl, -NHCO(C1-C6 alkyl), -N(C1-C6 alkyl)C(O)(C1-C6 alkyl), -S(O)C1-C6 alkyl, -S(O)2C1-C6 alkyl, -C1-C6 alkyl-S(O)2C1-C6 alkyl, oxo, C1-C6alkylNHS(O)2-C1-C6alkyl, C1-C6alkyl-O-C1-C6alkyl, a 4-7 membered heterocycloalkyl group, hydroxy-substituted-4-membered heterocycloalkyl, spirocyclopropyl
-CH2-(4-7 membered heterocycloalkyl), 6-12 membered aryl, 5 to 12 membered heteroaryl groups, -CH2-(5 to 12 membered heteroaryl)-O-CH2-(6-12 membered aryl), -CH2- (5 to 12 membered heteroaryl)-OH. In some embodiments, each of the above optional substituents are themselves optionally substituted by one or two groups. [0036] As used herein, the term “alkenyl” refers to a straight- or branched-chain group having from 2 to 12 carbon atoms (“C2-C12”), preferably 2 to 4 carbons atoms (“C2- C4”), in the group, wherein the group includes at least one carbon-carbon double bond. Examples of alkenyl groups include vinyl (-CH=CH2; C2alkenyl) allyl (-CH2- CH=CH2; C3alkenyl), propenyl (-CH=CHCH3; C3alkenyl); isopropenyl (-C(CH3)=CH2; C3alkenyl), butenyl (-CH=CHCH2CH3; C4alkenyl), sec-butenyl (-C(CH3)=CHCH3; C4alkenyl), iso- butenyl (-CH=C(CH3)2; C4alkenyl), 2-butenyl (-CH2CH=CHCH3; C4alkyl), pentenyl (-CH=CHCH2CH2CH3; C5alkenyl), and the like. [0037] As used herein, the term “alkynyl” refers to a straight- or branched-chain group having from 1 to 12 carbon atoms (“C1-C12”), preferably 1 to 4 carbons atoms (“C2- C4”), in the group, and wherein the group includes at least one carbon-carbon triple bond. Examples of alkynyl groups include ethynyl (-C≡CH; C2alkynyl); propargyl (-CH2-C≡CH; C3alkynyl), propynyl (-C≡CCH3; C3alkynyl); butynyl (-C≡CCH2CH3; C4alkynyl), pentynyl (-C≡CCH2CH2CH3; C5alkynyl), and the like.
[0038] As used herein, the term “alkoxy” refers to an oxygen radical attached to an alkyl group by a single bond. Examples of alkoxy groups include methoxy (-OCH3), ethoxy (-OCH2CH3), isopropoxy (-OCH(CH3)2) and the like. [0039] As used herein, the term “haloalkoxy” refers to an oxygen radical attached to a haloalkyl group by a single bond. Examples of haloalkoxy groups include -OCF3, - OCH2CF3, -OCH(CF3)2, and the like. [0040] The term “haloalkyl” refers to an alkyl group wherein one or more of the hydrogen atoms has been replaced with one or more halogen atoms. [0041] The term “haloalkoxy” refers to an alkoxy group wherein one or more of the hydrogen atoms has been replaced with one or more halogen atoms. [0042] As used herein, the term “stereoisomers” refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space, e.g., enantiomers, diastereomers or tautomers. [0043] The term “patient” or “subject” is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present disclosure is provided. For treatment of those conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc. In general, in the present disclosure, the term patient refers to a human patient unless otherwise stated or implied from the context of the use of the term. [0044] The term “effective” is used to describe an amount of a compound, composition or component which, when used within the context of its intended use, effects an intended result. The term effective subsumes all other effective amount or effective concentration terms, which are otherwise described or used in the present application. [0045] “Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (e.g., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or
both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder. [0046] In some aspects, the disclosure is directed to a compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein A is
wherein *2 is the point of attachment to R2, and *1 is the point of attachment to the amide carbonyl carbon atom; R1 is H, C1-C6alkyl, C3-C6cycloalkyl, halogen, -CN, or C1-C4fluoroalkyl; R2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted fused heterocycloalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, halo, -O-(3- to 5-membered heterocycloalkyl), -NH-(3- to 5-membered heterocycloalkyl), or optionally substituted heterocycloalkyl; R3 and R4 are each independently optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; or one of R3 or R4 may be H; or R3 and R4, together with the nitrogen atom to which they are both attached, form an optionally substituted 3-12-membered heterocycloalkyl ring, an optionally substituted 5-12-membered bridged heterocycloalkyl ring, an optionally substituted 4- 12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12- membered spiroheterocycloalkyl ring system, wherein said 3-12-membered
heterocycloalkyl ring, 5-12-membered bridged heterocycloalkyl ring, 4-12-membered fused heterocycloalkyl ring system, or 5-12-membered spiroheterocycloalkyl ring system may include, in addition to the nitrogen atom to which both R3 and R4 are attached, 1-3 other heteroatoms that are each independently O, S, or N; each R5 and each R6 is independently H, C1-C6alkyl, or C3-C5cycloalkyl; or an R5 and R6 attached to the same carbon atom, together with that carbon atom, may form a C3-C6cycloalkyl ring; or an R5 or R6, together with an R3 or R4 may form an optionally substituted 3- 12-membered heterocycloalkyl ring, an optionally substituted 5-12-membered bridged heterocycloalkyl ring, an optionally substituted 4-12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12-membered spiroheterocycloalkyl ring system; n is 1, 2, 3, 4, or 5; and L is C(O)NH, NHC(O), NHC(O)O, or NHC(O)NH. [0047] In some embodiments, A in the compound of formula (I) is
[0048] In some embodiments, A in the compound of formula (I) is
[0049] In other embodiments, A in the compound of formula (I) is
[0050] In some embodiments, A in the compound of formula (I) is
[0051] In some embodiments, A in the compound of formula (I) is
[0052] In some embodiments, A in the compound of formula (I) is
. [0053] It will be noted that A in the compounds of formula (I) have and *1 and *2. As used herein, *2 indicates the point of attachment of A to R2, and *1 indicates the point of attachment of A to the amide carbonyl carbon atom (i.e., the moiety, other than R2, to which A is attached). [0054] In some aspects, R1 in the compounds of formula (I) is H, C1-C6alkyl, C3- C6cycloalkyl, halogen, -CN, or C1-C4fluoroalkyl. [0055] In some embodiments, R1 is H. [0056] In other embodiments, R1 is C1-C6alkyl, such as, for example, C1-C6alkyl, C1-C5alkyl, C1-C4alkyl, C1-C3alkyl, C1-C2alkyl, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n- hexyl, and the like. [0057] In some embodiments, R1 is methyl. [0058] In some embodiments, R1 is C3-C6cycloalkyl, such as, for example, C3- C5cycloalkyl, C3cycloalkyl, C4cycloalkyl, C5cycloalkyl, C6cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. [0059] In some embodiments, R1 is halogen, such as, for example, -F, -Cl, -Br, or -I. [0060] In some embodiments, R1 is cyano, i.e., -CN.
[0061] In some embodiments, R1 is C1-C4fluoroalkyl, such as, for example, C4 fluoroalkyl, C3 fluoroalkyl, C2 fluoroalkyl, C1 fluoroalkyl, -CF3, -CHF2, or -CH2F. [0062] In some aspects, R2 in the compounds of formula (I) is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted fused heterocycloalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, halo, -O-(3- to 5-membered heterocycloalkyl), -NH-(3- to 5-membered heterocycloalkyl), or optionally substituted heterocycloalkyl; [0063] In some embodiments, R2 in the compounds of formula (I) is optionally substituted aryl, such as, for example, phenyl, indenyl, naphthyl, 1, 2, 3,4-tetrahydronaphthyl, and the like. [0064] In some embodiments wherein R2 is optionally substituted aryl, the optionally substituted aryl is an optionally substituted phenyl. [0065] In some embodiments, the optionally substituted phenyl is substituted with - C1-C6alkyl-NHS(O)2-C1-C6alkyl, hydroxyalkyl, -NHC(O) C1-C6alkyl, 5-membered heterocycloalkyl, -SO2NH2, -C(O)NH2, -S(O)C1-C6alkyl, SO2-C1-C6alkyl, C1-C6alkC(O)NH2, -C(O)N(C1-C6alkyl)2, 5-membered heteroaryl, or hydroxy-substituted-4-membered heterocycloalkyl. [0066] Thus, in some embodiments, the optionally substituted phenyl is substituted with one or more of
wherein represents the point(s) of attachment to the phenyl ring. [0067] In some embodiments, R2 in the compounds of formula (I) is optionally substituted heteroaryl, such as, for example, an optionally substituted pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl, benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl-4(3H)- one, triazolyl, 4,5,6,7-tetrahydro-1H-indazole, or 6,7-dihydro-5H-pyrazolo[5,1- b][1,3]oxazine, and in particular an optionally substituted pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl,
benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl, benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl-4(3H)- one, triazolyl, or 4,5,6,7-tetrahydro-1H-indazole. [0068] In some embodiments of R2, the optionally substituted heteroaryl is benzo[d]oxazol-2(3H)-one-5-yl. [0069] In other embodiments, R2 is 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl. [0070] In other embodiments, R2 is 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3- yl. [0071] In other embodiments, R2 is 4,5,6,7-tetrahydro-3-pyrazolo[1,5-a]pyridine. [0072] In some embodiments wherein R2 is optionally substituted heteroaryl, the optionally substituted heteroaryl is an optionally substituted 5-membered heteroaryl. [0073] In some embodiments, R2 is an optionally substituted pyrazolyl, an optionally substituted triazolyl, an optionally substituted isoxazolyl, an optionally substituted oxadiazolyl, an optionally substituted thiophenyl, or an optionally substituted thiazolyl. [0074] In some embodiments wherein R2 is optionally substituted heteroaryl, the optionally substituted heteroaryl is an optionally substituted 6-membered heteroaryl. [0075] In some embodiments, R2 is an optionally substituted pyridinyl, or an optionally substituted pyrimidinyl. [0076] In some embodiments, the optionally substituted heteroaryl is substituted with C1-C6alkyl, C1-C6haloalkyl, C1-C6haloalkoxyl, C1-C6alkoxyl, -C1-C6alkyl-O-C1-C6alkyl, hydroxyl, hydroxyalkyl, halo, cyano, cyclopropyl, 6-membered heterocycloalkyl, 5- membered heterocycloalkyl, 4-membered heterocycloalkyl, -C1-C6alkyl-SO2-C1-C6alkyl, 6- membered heteroaryl, 5-membered heteroaryl, -C(O)NH2, hydroxy-substituted-4-membered heterocycloalkyl, -C1-C6alkyl-CO2H, or -NH2. [0077] Thus, in some embodiments, the optionally substituted heteroaryl is substituted with one or more of
wherein represents the point(s) of attachment to the heteroaryl ring. [0078] In some embodiments of R2, the optionally substituted heteroaryl is substituted with an optionally substituted C1-C6alkyl, such as, for example, C1-C6alkyl, C1- C5alkyl, C1-C4alkyl, C1-C3alkyl, C1-C2alkyl, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n-
hexyl, and the like; or an optionally substituted C3-C5cycloalkyl, such as, for example, C3cycloalkyl, C4cycloalkyl, C5cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, and the like. [0079] In some embodiments of R2, the optionally substituted heteroaryl is an optionally substituted 5-membered heteroaryl. [0080] In some embodiments of R2, the optionally substituted 5-membered heteroaryl is substituted with an optionally substituted C1-C6alkyl, such as, for example, C1- C6alkyl, C1-C5alkyl, C1-C4alkyl, C1-C3alkyl, C1-C2alkyl, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n- pentyl, n-hexyl, and the like; or an optionally substituted C3-C5cycloalkyl, such as, for example, C3cycloalkyl, C4cycloalkyl, C5cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, and the like. [0081] In some embodiments of R2, the optionally substituted 5-membered heteroaryl is an is an optionally substituted pyrrolyl. [0082] In some embodiments of R2, the optionally substituted pyrrolyl is an unsubstituted pyrrolyl. [0083] In some embodiments of R2, unsubstituted pyrrolyl is pyrrol-3-yl. [0084] In some embodiments of R2, the optionally substituted pyrrolyl is 1- (methylsulfonyl)-1H-pyrrol-3-yl. [0085] In some embodiments of R2, the optionally substituted 5-membered heteroaryl is an is an optionally substituted pyrazolyl. [0086] In some embodiments of R2, the optionally substituted pyrazolyl is an unsubstituted pyrazolyl. [0087] In some embodiments of R2, the unsubstituted pyrazolyl is pyrazol-3-yl. [0088] In some embodiments of R2, the unsubstituted pyrazolyl is pyrazol-4-yl. [0089] In some embodiments of R2, the optionally substituted pyrazolyl is substituted with an optionally substituted C1-C6alkyl, such as, for example, C1-C6alkyl, C1- C5alkyl, C1-C4alkyl, C1-C3alkyl, C1-C2alkyl, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n- hexyl, and the like; or an optionally substituted C3-C5cycloalkyl, such as, for example, C3cycloalkyl, C4cycloalkyl, C5cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, and the like. [0090] In some embodiments of R2, the optionally substituted pyrazolyl is substituted with a methyl group, i.e., -CH3.
[0091] In some embodiments of R2, the optionally substituted pyrazolyl is substituted with a 2-hydroxyethyl group, i.e., -CH2CH2OH. [0092] In some embodiments of R2, the optionally substituted pyrazolyl is substituted with a 2-(C1-C6alkoxy)ethyl group, i.e., -CH2CH2O(C1-C6alkyl). [0093] In some embodiments of R2, the optionally substituted pyrazolyl is substituted with a 2-methoxyethyl group, i.e., -CH2CH2OCH3. [0094] In other embodiments of R2, the optionally substituted pyrazolyl is substituted with a cyclopropyl group. [0095] In some embodiments of R2, the optionally substituted pyrazolyl is 1-methyl- pyrazol-3-yl, 1-methyl-pyrazol-4-yl, 1-methyl-pyrazol-5-yl, 1-cyclopropyl-pyrazol-3-yl, 1- cyclopropyl-pyrazol-4-yl, 1-cyclopropyl-pyrazol-5-yl, 1-(2-hydroxyethyl)-pyrazol-3-yl, 1-(2- hydroxyethyl)-pyrazol-4-yl, 1-(2-hydroxyethyl)-pyrazol-5-yl, or 1-(2-methoxyethyl)-1H- pyrazol-4-yl, and in particular optionally substituted pyrazolyl is 1-methyl-pyrazol-3-yl, 1- methyl-pyrazol-4-yl, 1-methyl-pyrazol-5-yl, 1-cyclopropyl-pyrazol-3-yl, 1-cyclopropyl- pyrazol-4-yl, 1-cyclopropyl-pyrazol-5-yl, 1-(2-hydroxyethyl)-pyrazol-3-yl, 1-(2- hydroxyethyl)-pyrazol-4-yl, 1-(2-hydroxyethyl)-pyrazol-5-yl. [0096] In some embodiments of R2, the optionally substituted pyrazolyl is 3- methylpyrazol-4-yl. [0097] In some embodiments of R2, the optionally substituted pyrazolyl is 1- ethylpyrazol-5-yl. [0098] In some embodiments of R2, the optionally substituted pyrazolyl is 1- (cyclopropylmethyl)pyrazol-4-yl. [0099] In some embodiments of R2, the optionally substituted pyrazolyl is 1- cyclobutanyl-pyrazol-4-yl. [00100] In other embodiments of R2, the optionally substituted pyrazolyl is substituted with two or three methyl groups. [00101] In other embodiments of R2, the optionally substituted pyrazolyl is 1,5- dimethyl-pyrazol-4-yl, 1,3-dimethyl-pyrazol-4-yl, 1-(2-methoxyethyl)-3,5-dimethyl-pyrazol- 4-yl, 3,5-dimethyl-pyrazol-4-yl, 1,4-dimethyl-pyrazol-5-yl, or 1,3,5-trimethyl-pyrazol-4-yl. [00102] In other embodiments of R2, the optionally substituted pyrazolyl is 1- methyl-3-trifluoromethyl-pyrazol-4-yl.
[00103] In other embodiments of R2, the optionally substituted pyrazolyl is 1- trifluoromethyl-pyrazol-4-yl. [00104] In other embodiments of R2, the optionally substituted pyrazolyl is 1-(2,2,2- trifluoroeth-1-yl)-pyrazol-4-yl. [00105] In some embodiments of R2, the optionally substituted pyrazolyl is 1- difluoromethylpyrazol-4-yl. [00106] In other embodiments of R2, the optionally substituted pyrazolyl is 3,5- dimethyl-1-(2-methoxyethyl)-pyrazol-4-yl. [00107] In other embodiments of R2, the optionally substituted pyrazolyl is 3,5- dimethyl-1-(oxetan-3-yl)-1H-pyrazol-4-yl. [00108] In other embodiments of R2, the optionally substituted pyrazolyl is 1- (thietan-3-yl 1,1-dioxide)-pyrazol-4-yl, i.e.,
. [00109] In other embodiments of R2, the optionally substituted pyrazolyl is 1- (oxetan-3-yl)-1H-pyrazol-4-yl. [00110] In other embodiments of R2, the optionally substituted pyrazolyl is 1- (oxetan-3-yl-methyl)-pyrazol-4yl. [00111] In other embodiments of R2, the optionally substituted pyrazolyl is 1- ((methylsulfonyl)methyl)-pyrazol-4-yl. [00112] In other embodiments of R2, the optionally substituted pyrazolyl is 1- ((cyano)methyl)-pyrazol-4-yl. [00113] In other embodiments of R2, the optionally substituted pyrazolyl is 1-(1- (cyano)eth-1-yl)-pyrazol-4-yl. [00114] In other embodiments of R2, the optionally substituted pyrazolyl is (1- hydroxy-2-methylpropan-2-yl)-1H-pyrazol-4-yl [00115] In other embodiments of R2, the optionally substituted pyrazolyl is 1- (acetamid-2-yl)-pyrazol-4-yl. [00116] In other embodiments of R2, the optionally substituted pyrazolyl is 1-(N- methylacetamid-2-yl)-pyrazol-4-yl. [00117] In other embodiments of R2, the optionally substituted pyrazolyl is 1-(4- piperidinyl)-pyrazol-4-yl.
[00118] In other embodiments of R2, the optionally substituted pyrazolyl is 1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-4-yl. [00119] In other embodiments of R2, the optionally substituted pyrazolyl is 1-(2,3- dihydroxy-propan-1-yl)-pyrazol-3-yl. [00120] In other embodiments of R2, the optionally substituted pyrazolyl is 1-(2,3- dihydroxy-propan-1-yl)-pyrazol-4-yl. [00121] In other embodiments of R2, the optionally substituted pyrazolyl is 1-(2- hydroxy-propan-1-yl)-pyrazol-4-yl. [00122] In other embodiments of R2, the optionally substituted pyrazolyl is 1-(3,4- dihydroxy-butan-1yl)-pyrazol-4-yl. [00123] In other embodiments of R2, the optionally substituted pyrazolyl is 1-((3- hydroxy-isoxazol-5-yl)methyl)-pyrazol-4-yl. [00124] In other embodiments of R2, the optionally substituted pyrazolyl is 1-((3- benzyloxy-isoxazol-5-yl)methyl)-pyrazol-4-yl. [00125] In other embodiments of R2, the optionally substituted pyrazolyl is 1- (pyridin-3-yl)-pyrazol-4-yl. [00126] In other embodiments of R2, the optionally substituted pyrazolyl is 3- (hydroxymethyl)-1-methyl-pyrazol-4-yl. [00127] In other embodiments of R2, the optionally substituted pyrazolyl is 1-(1- hydroxy-2-methylpropan-2-yl)-pyrazol-4-yl. [00128] In other embodiments of R2, the optionally substituted pyrazolyl is 1-(4- tetrahydro-2H-thiopyran 1,1-dioxide)-pyrazol-4-yl, i.e.,
[00129] In some embodiments of R2, the optionally substituted 5-membered heteroaryl is an is an optionally substituted triazolyl. [00130] In some embodiments of R2, the optionally substituted triazolyl is substituted with an optionally substituted C1-C6alkyl, such as, for example, C1-C6alkyl, C1- C5alkyl, C1-C4alkyl, C1-C3alkyl, C1-C2alkyl, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n- hexyl, and the like; or an optionally substituted C3-C5cycloalkyl, such as, for example, C3cycloalkyl, C4cycloalkyl, C5cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, and the like.
[00131] In some embodiments of R2, the optionally substituted 5-membered heteroaryl is 2,4-dimethyl-1,2,3-triazol-5-yl. [00132] In some embodiments of R2, the optionally substituted 5-membered heteroaryl is 2-methyl-1,2,3-triazol-4-yl. [00133] In some embodiments of R2, the optionally substituted 5-membered heteroaryl is an optionally substituted imidazolyl. [00134] In some embodiments of R2, the optionally substituted imidazolyl is 1- methyl-imidazol-4-yl. [00135] In some embodiments of R2, the optionally substituted 5-membered heteroaryl is an optionally substituted isoxazolyl. [00136] In some embodiments of R2, the optionally substituted isoxazolyl is 3,5- dimethyl-isoxazol-4-yl. [00137] In some embodiments of R2, the optionally substituted 5-membered heteroaryl is an optionally substituted furanyl. [00138] In some embodiments of R2, the optionally substituted furanyl is 2- (hydroxymethyl)-furan-5-yl. [00139] In some embodiments of R2, the optionally substituted 5-membered heteroaryl is furan-3-yl. [00140] In some embodiments of R2, the optionally substituted 5-membered heteroaryl is an optionally substituted thiophenyl. [00141] In some embodiments of R2, the optionally substituted thiophenyl is thiopheny-3-yl. [00142] In some embodiments of R2, the optionally substituted thiophenyl is 2- hydroxymethyl-thiophen-5-yl. [00143] In some embodiments, R2 in the compounds of formula (Io) or the compounds of formula (I) is an optionally substituted 6-membered heteroaryl. [00144] In some embodiments of R2, the optionally substituted 6-membered heteroaryl is an optionally substituted pyridinyl, an optionally substituted pyridazinyl, or an optionally substituted pyrimidinyl. [00145] In some embodiments of R2, the optionally substituted 6-membered heteroaryl is substituted with an optionally substituted C1-C6alkyl, such as, for example, C1- C6alkyl, C1-C5alkyl, C1-C4alkyl, C1-C3alkyl, C1-C2alkyl, C6alkyl, C5alkyl, C4alkyl, C3alkyl,
C2alkyl, C1alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n- pentyl, n-hexyl, and the like; or an optionally substituted C3-C5cycloalkyl, such as, for example, C3cycloalkyl, C4cycloalkyl, C5cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, and the like. [00146] In some embodiments of R2, the optionally substituted 6-membered heteroaryl is an is an optionally substituted pyridinyl. [00147] In some embodiments of R2, the optionally substituted pyridinyl is substituted with an optionally substituted C1-C6alkyl, such as, for example, C1-C6alkyl, C1- C5alkyl, C1-C4alkyl, C1-C3alkyl, C1-C2alkyl, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n- hexyl, and the like; or an optionally substituted C3-C5cycloalkyl, such as, for example, C3cycloalkyl, C4cycloalkyl, C5cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, and the like. [00148] In some embodiments of R2, the optionally substituted pyridinyl is unsubstituted pyridinyl. [00149] In some embodiments of R2, the unsubstituted pyridinyl is pyridine-2-yl. [00150] In some embodiments of R2, the unsubstituted pyridinyl is pyridine-3-yl. [00151] In some embodiments of R2, the unsubstituted pyridinyl is pyridine-4-yl. [00152] In some embodiments of R2, the optionally substituted pyridinyl is C1- C6alkoxyl substituted pyridinyl. [00153] In some embodiments of R2, the optionally substituted pyridinyl is methoxy substituted pyridinyl, such as, for example, 4-methoxypyridin-3-yl. [00154] In some embodiments of R2, the optionally substituted pyridinyl is 2- methoxypyridin-3-yl. [00155] In some embodiments of R2, the optionally substituted pyridinyl is 2- methoxypyridin-5-yl. [00156] In some embodiments of R2, the optionally substituted pyridinyl is 2- methoxypyridin-6-yl. [00157] In some embodiments of R2, the optionally substituted pyridinyl is 4- methoxypyridin-3-yl. [00158] In some embodiments of R2, the optionally substituted pyridinyl is 3- methoxypyridin-4-yl.
[00159] In some embodiments of R2, the optionally substituted pyridinyl is 2- ethoxypyridin-3-yl. [00160] In some embodiments of R2, the optionally substituted pyridinyl is 2- trifluoromethoxypyridin-3-yl. [00161] In some embodiments of R2, the optionally substituted pyridinyl is 2- hydroxypyridin-3-yl. [00162] In some embodiments of R2, the optionally substituted pyridinyl is 2- hydroxypyridin-5-yl. [00163] In some embodiments of R2, the optionally substituted pyridinyl is 2- methylpyridin-3-yl. [00164] In some embodiments of R2, the optionally substituted pyridinyl is 2- methylpyridin-5-yl. [00165] In some embodiments of R2, the optionally substituted pyridinyl is 2- ethylpyridin-3-yl. [00166] In some embodiments of R2, the optionally substituted pyridinyl is 2-(2- fluoroethoxy)pyridin-3-yl. [00167] In some embodiments of R2, the optionally substituted pyridinyl is 2- amino-3-fluoro-pyridin-5-yl. [00168] In some embodiments of R2, the optionally substituted pyridinyl is 2- amino-pyridin-5-yl or 6-aminopyridin-3-yl. [00169] In some embodiments of R2, the optionally substituted pyridinyl is 2-(4- morpholinyl)-pyridin-4-yl. [00170] In some embodiments of R2, the optionally substituted pyridinyl is 2- (dimethylamino)pyridin-4-yl. [00171] In some embodiments of R2, the optionally substituted pyridinyl is 3- (methylsulfonyl)pyridin-5-yl. [00172] In some embodiments of R2, the optionally substituted pyridinyl is 4- (acetylamino)-pyridin-2-yl. [00173] In some embodiments of R2, the optionally substituted pyridinyl is 3- (acetylamino)-pyridin-5-yl. [00174] In some embodiments of R2, the optionally substituted pyridinyl is 2- (acetylamino)-pyridin-4-yl.
[00175] In some embodiments of R2, the optionally substituted pyridinyl is 2-(N- methylacetamid)-pyridin-4-yl, i.e.,
[00176] In some embodiments of R2, the optionally substituted 6-membered heteroaryl is an is an optionally substituted pyridazinyl. [00177] In some embodiments of R2, the optionally substituted pyridaziny is 3- methyl-pyridazin-5-yl. [00178] In some embodiments of R2, the optionally substituted pyridaziny is 3,6- dimethoxy-pyridazin-4-yl. [00179] In some embodiments of R2, the optionally substituted pyridaziny is 3- hydroxy-pyridazin-6-yl. [00180] In some embodiments of R2, the optionally substituted 6-membered heteroaryl is an is an optionally substituted pyrimidinyl. [00181] In some embodiments of R2, the optionally substituted pyrimidinyl is pyrimidin-5-yl. [00182] In some embodiments of R2, the optionally substituted pyrimidinyl is 2- methoxy-4-hydroxy-pyrimidin-5-yl. [00183] In some embodiments of R2, the optionally substituted pyrimidinyl is 2,4- dimethoxy-pyrimidin-5-yl. [00184] In some embodiments of R2, the optionally substituted pyrimidinyl is 4- methyl-pyrimidin-5-yl. [00185] In some embodiments of R2, the optionally substituted heteroaryl is an optionally substituted 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine. [00186] In some embodiments of R2, the optionally substituted 6,7-dihydro-5H- pyrazolo[5,1-b][1,3]oxazine is 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl. [00187] In some embodiments of R2, the optionally substituted heteroaryl is 6,7- dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-3-yl. [00188] In some embodiments of R2, the optionally substituted heteroaryl is 5,6- dihydro-8H-imidazo[2,3-c][1,4]oxazin-3-yl.
[00189] In some embodiments of R2, the optionally substituted heteroaryl is 7,8- dihydro-5H-imidazo[3,2-c][1,3]oxazin-3-yl. [00190] In some embodiments of R2, the optionally substituted heteroaryl is an optionally substituted 1-methylindazol-4-yl. [00191] In some embodiments of R2, the optionally substituted heteroaryl is an optionally substituted 1H-pyrazolo[3,4-b]pyridin-1-yl. [00192] In some embodiments of R2, the optionally substituted 1H-pyrazolo[3,4- b]pyridin-1-yl is unsubstituted 1H-pyrazolo[3,4-b]pyridin-1-yl. [00193] In some embodiments of R2, the optionally substituted heteroaryl is an optionally substituted 1H-pyrazolo[3,4-b]pyridine-5-yl [00194] In some embodiments of R2, the optionally substituted heteroaryl is an optionally substituted indolyl. [00195] In some embodiments of R2, the optionally substituted indolyl is an unsubstituted indolyl. [00196] In some embodiments of R2, the unsubstituted indolyl is indol-3-yl. [00197] In some embodiments of R2, the optionally substituted heteroaryl is 2-oxo- 2,3-dihydrobenzo[d]oxazol-5-yl. [00198] In some embodiments, R2 in the compounds of formula (I) is optionally substituted fused heterocycloalkyl. [00199] In some embodiments, R2 in the compounds of formula (I) or the compounds of formula (I) is optionally substituted alkyl. [00200] In some embodiments, R2 in the optionally substituted alkyl is 3- methoxyprop-1-yl. [00201] In some embodiments, R2 in the compounds of formula (I) is optionally substituted cycloalkyl. [00202] In some embodiments, R2 is -O-(3- to 5-membered heterocycloalkyl). [00203] In some embodiments, the -O-(3- to 5-membered heterocycloalkyl) is , or
[00204] In some embodiments, R2 is halo. In some embodiments, the halo is -Br.
[00205] In some embodiments, R2 in the compounds of formula (I) is optionally substituted alkenyl. [00206] In some embodiments, the optionally substituted alkenyl is
[00207] In some embodiments of R2 the optionally substituted alkenyl is (E)-3- methoxyprop-1-en-1-yl. [00208] In some embodiments, R2 is -NH-(3- to 5-membered heterocycloalkyl). [00209] In some embodiments, the - NH-(3- to 5-membered heterocycloalkyl) is , or
[00210] In some embodiments, R2 in the compounds of formula (I) is optionally substituted heterocycloalkyl. [00211] In some embodiments, the optionally substituted heterocycloalkyl is an optionally substituted dihydropyran, an optionally substituted tetrahydropyran, or an optionally substituted morpholine. [00212] In some embodiments the optionally substituted heterocycloalkyl is substituted with hydroxy, hydroxyalkyl, C1-C6alkoxyl, or -C1-C6alkyl-O-C1-C6alkyl. [00213] In some embodiments, the optionally substituted heterocycloalkyl is
[00214] In some embodiments of R2, the optionally substituted heterocycloalkyl is 1-(2-fluoroethyl)-2-oxo-1,2-dihydropyridin-3-yl. [00215] In some embodiments of R2, the optionally substituted heterocycloalkyl is 1-methyl-6-oxo-1,6-dihydropyridin-3-yl. [00216] In some aspects, n in the compounds of formula (I) is 1, 2, 3, 4, or 5. [00217] In some embodiments, n in the compounds of formula (I) is 1. [00218] In some embodiments, n in the compounds of formula (I) is 2. [00219] In some embodiments, n in the compounds of formula (I) is 3. [00220] In some embodiments, n in the compounds of formula (I) is 4. [00221] In some embodiments, n in the compounds of formula (I) is 5. [00222] In some aspects of the compounds of formula (I), L is -C(O)NH-, - NHC(O)-, -NHC(O)O-, or -NHC(O)NH-, such that when n is 1, L is NHC(O), and when n is 2, 3, 4, or 5, L is -C(O)NH-, -NHC(O)-, -NHC(O)O-, or -NHC(O)NH-. [00223] The diradicals “-L-,” as used herein, are written from left-to-right such that the left hand side of L is attached to the pyridinyl moiety in the compounds of the disclosure. [00224] In some embodiments of the compounds of formula (I), n is 1 and L is - NHC(O)-. [00225] In some embodiments of the compounds of formula (I), n is 2, 3, 4, or 5 and L is -NHC(O)-.
[00226] In some embodiments of the compounds of formula (I), n is 2 and L is - NHC(O)-. [00227] In some embodiments of the compounds of formula (I), n is 3 and L is - NHC(O)-. [00228] In some embodiments of the compounds of formula (I), n is 4 and L is - NHC(O)-. [00229] In some embodiments of the compounds of formula (I), n is 5 and L is - NHC(O)-. [00230] In some embodiments of the compounds of formula (I), n is 2, 3, 4, or 5 and L is -C(O)NH-. [00231] In some embodiments of the compounds of formula (I), n is 2 and L is - C(O)NH-. [00232] In some embodiments of the compounds of formula (I), n is 3 and L is - C(O)NH-. [00233] In some embodiments of the compounds of formula (I), n is 4 and L is - C(O)NH-. [00234] In some embodiments of the compounds of formula (I), n is 5 and L is - C(O)NH-. [00235] In some embodiments of the compounds of formula (I), n is 2, 3, 4, or 5 and L is -NHC(O)O-. [00236] In some embodiments of the compounds of formula (I), n is 2 and L is - NHC(O)O-. [00237] In some embodiments of the compounds of formula (I), n is 3 and L is - NHC(O)O-. [00238] In some embodiments of the compounds of formula (I), n is 4 and L is - NHC(O)O-. [00239] In some embodiments of the compounds of formula (I), n is 5 and L is - NHC(O)O-. [00240] In some embodiments of the compounds of formula (I), n is 2, 3, 4, or 5 and L is -NHC(O)NH. [00241] In some embodiments of the compounds of formula (I), n is 2 and L is - NHC(O)NH.
[00242] In some embodiments of the compounds of formula (I), n is 3 and L is - NHC(O)NH. [00243] In some embodiments of the compounds of formula (I), n is 4 and L is - NHC(O)NH. [00244] In some embodiments of the compounds of formula (I), n is 5 and L is - NHC(O)NH. [00245] In some aspects, R3 and R4 in the compounds of formula (I) are each independently optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; or one of R3 or R4 in the compounds of formula (I) may be H. [00246] In some embodiments, one of R3 or R4 in compounds of formula (I) is H. [00247] In some embodiments, R3 or R4 in the compounds of formula (I) is optionally substituted aryl, such as, for example, optionally substituted phenyl, indenyl, naphthyl, or 1,2,3,4-tetrahydronaphthyl. [00248] In some embodiments, R3 or R4 in the compounds of formula (I) is optionally substituted heteroaryl, such as, for example, optionally substituted pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8- tetrahydroisoquinolinyl benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2,3- b]pyridinyl, quinazolinyl-4(3H)-one, triazolyl, or 4,5,6,7-tetrahydro-1H-indazole. [00249] In some embodiments, R3 or R4 in the compounds of formula (I) is pyridinyl. In some embodiments, R3 or R4 in the compounds of formula (I) is 2-pyridinyl. [00250] In some embodiments, R3 or R4 in the compounds of formula (I) or the compounds of formula (I) is optionally substituted alkyl, such as, for example, optionally substituted C1-C6alkyl, C1-C5alkyl, C1-C4alkyl, C1-C3alkyl, C1-C2alkyl, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso- butyl, sec-butyl, n-pentyl, n-hexyl, and the like. [00251] In some embodiments, R3 or R4 in the compounds of formula (I) or the compounds of formula (I) is -CH3. [00252] In some embodiments, R3 or R4 in the compounds of formula (I) or the compounds of formula (I) is -CH2CH(CH3)2.
[00253] In some embodiments, R3 or R4 in the compounds of formula (I) or the compounds of formula (I) is -CH2CH2CH3. [00254] In some embodiments, R3 or R4 in the compounds of formula (I) or the compounds of formula (I) is -CH(CH3)2. [00255] In some embodiments, R3 or R4 in the compounds of formula (I) or the compounds of formula (I) is -C(CH3)3. [00256] In some embodiments, R3 or R4 in the compounds of formula (I) or the compounds of formula (I) is -CH2CH2OCH3. [00257] In some embodiments, R3 or R4 in the compounds of formula (I) or the compounds of formula (I) is -CH2CH2OH. [00258] In some embodiments, R3 or R4 in the compounds of formula (I) or the compounds of formula (I) is -CH2-cyclohexyl. [00259] In some embodiments, R3 or R4 in the compounds of formula (I) or the compounds of formula (I) is -CH2-cyclopropyl. [00260] In some embodiments, R3 or R4 in the compounds of formula (I) is optionally substituted cycloalkyl, such as, for example, optionally substituted C3- C6cycloalkyl, C3cycloalkyl, C4cycloalkyl, C5cycloalkyl, C6cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. [00261] In some embodiments, R3 or R4 in the compounds of formula (I) is optionally substituted cyclopentyl. [00262] In some embodiments, R3 or R4 in the compounds of formula (I) is unsubstituted cyclopentyl. [00263] In some embodiments, R3 or R4 in the compounds of formula (I) is optionally substituted cyclobutyl. [00264] In some embodiments, R3 or R4 in the compounds of formula (I) is 1- methyl-cyclobut-1-yl. [00265] In some embodiments, R3 or R4 in the compounds of formula (I) is unsubstituted cyclobutyl. [00266] In some embodiments, R3 or R4 in the compounds of formula (I) is optionally substituted cyclohexyl. [00267] In some embodiments, R3 or R4 in the compounds of formula (I) is unsubstituted cyclohexyl.
[00268] In some embodiments, R3 or R4 in the compounds of formula (I) is optionally substituted heterocycloalkyl, such as, for example, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, isoxazolidinyl, oxazolidinyl, pyrazolidinyl, imidazolidinyl, or thiazolidinyl. [00269] In some embodiments, R3 or R4 in the compounds of formula (I) is tetrahydropyran-4-yl. [00270] In some embodiments, R3 is optionally substituted alkyl or optionally substituted C4-C5cycloalkyl; and R4 is optionally substituted C4-C5cycloalkyl or optionally substituted heteroaryl. [00271] In some aspects, R3 and R4 in the compounds of formula (I), together with the nitrogen atom to which they are both attached, form an optionally substituted 3-12- membered heterocycloalkyl ring, an optionally substituted 5-12-membered bridged heterocycloalkyl ring, an optionally substituted 4-12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12-membered spiroheterocycloalkyl ring system, wherein said 3-12-membered heterocycloalkyl ring, 5-12-membered bridged heterocycloalkyl ring, 4-12-membered fused heterocycloalkyl ring system, or 5-12-membered spiroheterocycloalkyl ring system may include, in addition to the nitrogen atom to which both R3 and R4 are attached, 1-3 other heteroatoms that are each independently O, S, or N. [00272] In some aspects, R3 and R4 in the compounds of formula (I), together with the nitrogen atom to which they are both attached, form an optionally substituted 3-12- membered heterocycloalkyl ring. Non-limiting examples of such heterocycloalkyl rings include the following:
[00273] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is an optionally substituted azetidinyl, an optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted azepanyl, optionally substituted piperazinyl, optionally substituted oxazepanyl, optionally substituted thiomorpholinyl 1,1-dioxide, or optionally substituted morpholinyl. [00274] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is
[00275] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is
[00276] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is
[00277] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is
[00278] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is
[00279] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is
[00280] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is
[00281] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is
[00282] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is
[00283] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is substituted with C1-C6alkyl, C1-C6alkoxyl, -C1-C6alkyl-O-C1-C6alkyl, hydroxyl, hydroxyalkyl, halo, carbonyl (i.e., (=O)), cyano, cyclopropyl, or 5-membered heteroaryl. [00284] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is substituted with at least one C1-C6alkyl group, such as, for example, C1-C6alkyl, C1-C5alkyl, C1-C4alkyl, C1-C3alkyl, C1-C2alkyl, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec- butyl, n-pentyl, n-hexyl, and the like. [00285] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is substituted with at least one -CH3 group. [00286] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2,2-dimethylpyrrolidin-1-yl group,
[00287] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form,
[00288] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3,3-dimethylpyrrolidin-1-yl group,
[00289] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3,3-dimethylazetidin-1-yl group,
[0001] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2,2-dimethylazetidin-1-yl group,
[0002] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form
[0003] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-isopropylazetidin-1-yl group,
[0004] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-methyl-pyrrolidin-1-yl group,
[0005] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (R)-2-methyl-pyrrolidin-1-yl group. [0006] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (S)-2-methyl-pyrrolidin-1-yl group. [0007] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-methyl-piperidin-1-yl group,
[0008] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (R)-2-methyl-piperidin-1-yl group. [0009] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (S)-2-methyl-piperidin-1-yl group. [0010] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3-methyl-piperidin-1-yl group,
[0011] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (R)-3-methyl-piperidin-1-yl group. [0012] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (S)-3-methyl-piperidin-1-yl group. [0013] [0014] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 4-methyl-piperidin-1-yl group,
[0015] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (R)-4-methyl-piperidin-1-yl group. [0016] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (S)-4-methyl-piperidin-1-yl group. [0017] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 4-methoxy-piperidin-1-yl group,
[0018] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (R)-4- methoxy -piperidin-1-yl group. [0019] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (S)-4- methoxy -piperidin-1-yl group. [0020] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form
[0021] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form
[0022] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[0023] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 1,2,5-trimethyl-4-piperazinyl:
[0024] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (2S, 5R)-1,2,5-trimethyl-4-piperazinyl. [0025] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (2S, 5S)-1,2,5-trimethyl-4-piperazinyl. [0026] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (2R, 5R)-1,2,5-trimethyl-4-piperazinyl. [0027] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (2R, 5S)-1,2,5-trimethyl-4-piperazinyl. [0028] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[0029] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form
[0030] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form
[0031] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is substituted with a cyclopropyl group. [0032] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a
[0033] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a
[0034] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a
[0035] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[0036] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[0037] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[0038] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[0039] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is substituted with at least one halogen atom. In some embodiments, the halogen atom is -F. [0040] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 4,4-difluoropiperidin-1-yl group,
[0041] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 4-fluoropiperidin-1-yl group,
[0042] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 4-hydroxypiperidin-1-yl group,
[0043] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 4,4-dimethylpiperidin-1-yl group,
[0044] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2,2-dimethylpiperidin-1-yl group,
[0045] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2,2-dimethylpiperidin-1-yl group,
[0046] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3,3-difluoropiperidin-1-yl group,
[0047] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a lmorpholino group,
[0048] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3-methylmorpholino group,
[0049] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(R)-methylmorpholino group. [0050] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(S)-methylmorpholino group. [0051] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3-ethylmorpholino group,
[0052] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(R)-ethylmorpholino group. [0053] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(S)-ethylmorpholino group. [0054] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3,5-dimethylmorpholino group,
[0055] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(R),5(R)-dimethylmorpholino group. [0056] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(S),5(S)-dimethylmorpholino group.
[0057] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(R),5(S)-dimethylmorpholino group. [0058] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(S),5(R)-dimethylmorpholino group. [0059] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3,5-dimethylpiperidinyl group,
[0060] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(R),5(R)- dimethylpiperidinyl group. [0061] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(S),5(S)- dimethylpiperidinyl group. [0062] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(R),5(S)- dimethylpiperidinyl group. [0063] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(S),5(R)- dimethylpiperidinyl group. [0064] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[0065] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[0066] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3,3-dimethylmorpholino group,
[0067] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form,
[0068] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2,2-dimethylmorpholino group,
[0069] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2,6-dimethylmorpholino group,
[0070] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2(R),6(R)-dimethylmorpholino group. [0071] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2(S),6(S)-dimethylmorpholino group. [0072] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2(R),6(S)-dimethylmorpholino group. [0073] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2(S),6(R)-dimethylmorpholino group. [0074] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3-methylmorpholino group,
[0075] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(R)-methylmorpholino group. [0076] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3(S)-methylmorpholino group. [0077] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is substituted with a 5-membered heteroaryl group. [0078] In some embodiments, the 3-12-membered heterocycloalkyl ring substituted with a 5-membered heteroaryl group is a pyrrolidinyl ring substituted with a 5-membered heteroaryl group or a piperidinyl ring substituted with a 5-membered heteroaryl group. [0079] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[0080] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[0081] In some aspects, R3 and R4 in the compounds of formula (I), together with the nitrogen atom to which they are both attached, form an optionally substituted 5-12- membered bridged heterocycloalkyl ring. Non-limiting examples of such bridged heterocycloalkyl ring systems include:
[0082] In some embodiments, the optionally substituted 5- to 12-membered bridged heterocycloalkyl ring is an optionally substituted 7-azabicyclo[2.2.2]octan-7-yl, an optionally
substituted 7-azabicyclo[2.2.1]heptan-7-yl, an optionally substituted 2- azabicyclo[2.2.1]heptan-2-yl, an optionally substituted azabicyclo[3.1.1]heptane, an optionally substituted 8-azabicyclo[3.2.1]octan-8-yl, an optionally substituted 2,5- diazabicyclo[2.2.1]heptan-5-yl, an optionally substituted 6-azabicyclo[3.2.1]octan-6-yl, an optionally substituted 3-azabicyclo[3.2.1]octan-3-yl, an optionally substituted 2- azabicyclo[2.2.2]octan-2yl, an optionally substituted diazabicyclo[2.2.1]heptanyl, an optionally substituted 2-oxa-5-azabicyclo[2.2.2]octan-5-yl, an optionally substituted 2-oxa-5- azabicyclo[2.2.1]heptan-5-yl, an optionally substituted 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, an optionally substituted 6-oxa-3-azabicyclo[3.1.1]heptan-3-yl, an optionally substituted 8- oxa-3-azabicyclo[3.2.1]octan-3-yl, an optionally substituted 3,9-diazabicyclo[4.2.1]nonan-3- yl, an optionally substituted 2-oxa-6-azaadamantan-6-yl, (an optionally substituted 3-oxa- azabicyclo[3.2.1]octanyl, or an optionally substituted 2-oxa-azabicyclo[2.2.1]heptanyl. [0083] In some embodiments, the optionally substituted 5-12-membered bridged heterocycloalkyl ring is substituted with C1-C6alkyl, hydroxy, or hydroxyalkyl. [0084] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-azabicyclo[2.2.2]octan-2-yl group:
[0085] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form an 9-azabicyclo[3.3.1]nonan-9-yl group:
[0086] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form an 3-azabicyclo[3.1.1]heptan-3-yl group,
[0087] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form an 3-azabicyclo[3.2.1]octan-3-yl group,
[0088] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[0089] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form an 3-oxa-8-azabicyclo[3.2.1]octan-8-yl group,
[0090] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form an 6-oxa-3-azabicyclo[3.1.1]heptan-3-yl group,
[0091] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form (1S,4R)-2-azabicyclo[2.2.1]heptan-2-yl group,
[0092] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (1R,4S)-2-azabicyclo[2.2.1]heptan-2-yl group,
[0093] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form (1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl group,
[0094] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl group,
[0095] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 8-oxa-3-azabicyclo[3.2.1]octan-3-yl group,
[0096] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-oxa-5-azabicyclo[2.2.2]octan-5-yl group,
[0097] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 7-azabicyclo[2.2.1]heptan-7-yl group,
[0098] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-azabicyclo[2.2.1]heptan-2-yl group,
[0099] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[00100] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[00101] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[00102] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[00103] In other embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[00104] In some aspects, R3 and R4 in the compounds of formula (I), together with the nitrogen atom to which they are both attached, form an optionally substituted 5-12- membered spiroheterocycloalkyl ring. Non-limiting examples of such ring systems include:
[00105] In some embodiments, the optionally substituted 5-12-membered spiroheterocycloalkyl ring is an optionally substituted 7-azaspiro[3.5]nonan-7-yl, an optionally substituted 4-azaspiro[2.4]heptan-4-yl, an optionally substituted 1- azaspiro[3.3]heptan-1-yl, an optionally substituted 2-azaspiro[3.3]heptan-2-yl, an optionally substituted 6-azaspiro[2.5]octan-6-yl, an optionally substituted 2-oxa-7-azaspiro[4.4]nonan- 7-yl, an optionally substituted 1-oxa-7-azaspiro[4.4]nonan-7-yl, an optionally substituted 2-
oxa-6-azaspiro[3.4]octan-6-yl, an optionally substituted 5-azaspiro[2.4]heptan-5-yl, an optionally substituted 4-azaspiro[2.4]heptan-4-yl, an optionally substituted 2- azaspiro[4.5]decan-2-yl, an optionally substituted 8-azaspiro[4.5]decan-8-yl, an optionally substituted 2-azaspiro[4.4]nonan-2-yl, an optionally substituted 5-azaspiro[3.5]nonan-5-yl, an optionally substituted 7-oxa-4-azaspiro[2.5]octan-4-yl, an optionally substituted 5- azaspiro[3.4]octan-5-yl, an optionally substituted 1-oxa-7-azaspiro[3.5]nonan-7-yl, an optionally substituted 2-oxa-6-azaspiro[3.4]octan-6-yl, an optionally substituted 2-oxa-7- azaspiro[3.5]nonan-7-yl, an optionally substituted 2-oxa-5-azaspiro[3.4]octan-5-yl, an optionally substituted 8-oxa-5-azaspiro[3.5]nonan-5-yl, an optionally substituted 1- azaspiro[4.4]nonan-1-yl, an optionally substituted 7-oxa-4-azaspiro[2.5]octan-4-yl, an optionally substituted 2,5-dioxa-8-azaspiro[3.5]nonan-8-yl, an optionally substituted 8-oxa-2- azaspiro[4.5]decan-2-yl, an optionally substituted 2-oxa-5-azaspiro[3.5]nonan-5-yl, an optionally substituted 4-oxa-7-azaspiro[2.5]octan-7-yl, an optionally substituted 1- azaspiro[4.5]decan-1-yl, an optionally substituted 6-azaspiro[4.5]decan-6-yl, an optionally substituted 7-azaspiro[3.5]nonan-7-yl, an optionally substituted 3-oxa-9- azaspiro[5.5]undecane-9-yl, an optionally substituted 8-oxa-1-azaspiro[4.5]decan-1-yl, an optionally substituted 1,8-diazaspiro[4.5]decan-1-yl, or an optionally substituted 5-oxa-8- azaspiro[3.5]nonan-8-yl. [00106] In some embodiments, the optionally substituted 5-12-membered spiroheterocycloalkyl ring is substituted with C1-C6alkyl, halo, or hydroxyalkyl. [00107] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 4-azaspiro[2.4]heptan-4-yl group,
[00108] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5-azaspiro[3.4]octan-5-yl group,
[00109] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 6-azaspiro[3.4]octan-6-yl group,
[00110] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 6-azaspiro[2.5]octan-6-yl group,
[00111] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 7-azaspiro[3.5]nonan-7-yl group,
[00112] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 4-azaspiro[2.5]octan-4-yl group,
[00113] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5-azaspiro[2.5]octan-5-yl group,
[00114] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 1-azaspiro[3.3]heptan-1-yl group,
[00115] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-azaspiro[3.3]heptan-2-yl group,
[00116] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 6-fluoro-2-azaspiro[3.3]heptan-2-yl group,
[00117] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 7-oxa-2-azaspiro[3.5]nonan-2-yl group,
[00118] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-oxa-6-azaspiro[3.3]heptan-6-yl group,
[00119] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5-oxa-2-azaspiro[3.5]nonan-2-yl group,
[00120] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5-azaspiro[2.4]heptan-5-yl group,
[00121] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-oxa-5-azaspiro[3.5]nonan-5-yl group,
[00122] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-oxa-6-azaspiro[3.5]nonan-6-yl group,
[00123] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 7-azaspiro[4.4]nonan-7-yl group,
[00124] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 1-azaspiro[4.4]nonan-1-yl group,
[00125] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-oxa-7-azaspiro[4.4]nonan-7-yl group,
[00126] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 1-oxa-7-azaspiro[4.4]nonan-7-yl group,
[00127] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-oxa-5-azaspiro[3.4]octan-5-yl group,
[00128] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-oxa-6-azaspiro[3.4]octan-6-yl group,
[00129] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 8-oxa-1-azaspiro[4.5]decan-1-yl group,
[00130] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 8-oxa-2-azaspiro[4.5]decan-2-yl group,
[00131] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 8-methyl-1,8-diazaspiro[4.5]decan-1-yl group,
[00132] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-oxa-7-azaspiro[3.5]nonan-7-yl group,
[00133] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 7-oxa-4-azaspiro[2.5]octan-4-yl group,
[00134] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 4-oxa-7-azaspiro[2.5]octan-7-yl group,
[00135] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 8-oxa-5-azaspiro[3.5]nonan-5-yl group,
[00136] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5-oxa-8-azaspiro[3.5]nonan-8-yl group,
[00137] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2,5-dioxa-8-azaspiro[3.5]nonan-8-yl group,
[00138] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 1-oxa-7-azaspiro[3.5]nonan-7-yl group,
[00139] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form:
[00140] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-azaspiro[4.5]decan-2-yl group:
[00141] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 1-azaspiro[4.5]decan-1-yl group:
[00142] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5-azaspiro[3.5]nonan-5-yl group,
[00143] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 6-azaspiro[4.5]decan-6-yl group,
[00144] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3-oxa-9-azaspiro[5.5]undecan-9-yl group,
[00145] In some aspects, R3 and R4 in the compounds of formula (I), together with the nitrogen atom to which they are both attached, form an optionally substituted 4-12- membered fused heterocycloalkyl ring system. Non-limiting examples of such ring systems include:
[00146] In some embodiments, the optionally substituted 4-12-membered fused heterocycloalkyl ring system is an optionally substituted 3-azabicyclo[3.2.0]heptan-3-yl, an optionally substituted 3-azabicyclo[3.1.0]hexan-3-yl, an optionally substituted 2- azabicyclo[3.1.0]hexan-2-yl, an optionally substituted hexahydro-1H-2-pyrrolo[2,1- c]pyrazinyl, an optionally substituted 5,8-dihydro-6H-7-1,7-naphthyridinyl, an optionally substituted hexahydro-2H-6-furo[2,3-c]pyridinyl, an optionally substituted tetrahydro-1H,3H- 5-furo[3,4-c]pyrrolyl, an optionally substituted 2-oxa-5-azabicyclo[4.1.0]heptanyl, an optionally substituted 4,7-dihydro-5H-6-thieno[2,3-c]pyridinyl, an optionally substituted 2- isoindolinyl, an optionally substituted 3,4-dihydro-1H-2-2,7-naphthyridinyl, an optionally
substituted 3,4-dihydro-1H-2-2,6-naphthyridinyl, an optionally substituted 1,4,5,7-tetrahydro- 6-pyrazolo[3,4-c]pyridinyl, 3,4,6,7-tetrahydro-5-imidazo[4,5-c]pyridinyl, an optionally substituted 5,6-dihydro-8H-7-imidazo[2,1-c]pyrazinyl, an optionally substituted 3,4-dihydro- 1H-2-2,6-naphthyridinyl, an optionally substituted 6,7-dihydro-4H-5-thiazolo[4,5- c]pyridinyl, an optionally substituted 7,8-dihydro-5H-6-pyrido[3,4-b]pyrazinyl, an optionally substituted 5,8-dihydro-6H-7-pyrido[3,4-d]pyrimidinyl, an optionally substituted 1,4,6,7- tetrahydro-5-pyrazolo[4,3-c]pyridinyl, an optionally substituted 3,4-dihydro-1H-2- isoquinolinyl, an optionally substituted 1,4,6,7-tetrahydro-5-pyrrolo[3,2-c]pyridinyl, an optionally substituted 6,7-dihydro-4H-5-thiazolo[5,4-c]pyridinyl, an optionally substituted 5,7-dihydro-6-pyrrolo[3,4-b]pyridinyl, an optionally substituted 5,6-dihydro-8H-7- [1,2,4]triazolo[5,1-c]pyrazinyl, an optionally substituted 7,8-dihydro-5H-6-pyrido[4,3- d]pyrimidinyl, an optionally substituted 4,6-dihydro-5-pyrrolo[3,4-d]thiazolyl, an optionally substituted 6,7-dihydro-4H-5-[1,2,3]triazolo[5,1-c]pyrazinyl, an optionally substituted 5,7- dihydro-6-pyrrolo[3,4-d]pyrimidinyl, an optionally substituted 5,6-dihydro-8H-7- imidazo[5,1-c]pyrazinyl, an optionally substituted 6,7-dihydro-4H-5-pyrazolo[5,1- c]pyrazinyl, an optionally substituted 5,6-dihydro-8H-7-[1,2,4]triazolo[3,4-c]pyrazinyl, an optionally substituted 6,7-dihydro-4H-5-oxazolo[4,5-c]pyridinyl, an optionally substituted 1,3-dihydro-2-pyrrolo[3,4-c]pyridinyl, an optionally substituted 6,7-dihydro-4H-5- oxazolo[5,4-c]pyridinyl, or an optionally substituted 4-azatricyclo[3.3.0.01,3]octanyl. [00147] In some embodiments, the optionally substituted 4-12-membered fused heterocycloalkyl ring system is substituted with a C1-C6alkyl, halo, carbonyl (i.e., (=O)), or spirocyclopropyl
[00148] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3,4-dihydro-2,7-naphthyridin-2(1H)-yl group:
[00149] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 1-methyl-4,5-dihydro-1H-pyrazolo[3,4-c]pyridin-6(7H)-yl group:
[00150] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5H-pyrrolo[3,4-b]pyridin-6(7H)-yl group:
[00151] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl group:
[00152] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5,7-dihydro-pyrrolo[3,4-b]pyrazin-6-yl group:
[00153] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-isoindoline group:
[00154] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 1-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl group:
[00155] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3-methyl-3,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-yl group:
[00156] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 1-methyl-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-yl group:
[00157] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 1-methyl-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridine-5-yl group:
[00158] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5,6-dihydro-8H-[1,2,4]triazolo[5,1-c]pyrazin-7-yl group:
[00159] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 7,8-dihydro-5H-[1,2,4]triazolo[1,5-c]pyrimidin-6-yl group:
[00160] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl group:
[00161] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 4,7-dihydro-5H-6-thieno[2,3-c]pyridine-6-yl group:
[00162] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5,6-dihydro-1,7-naphthyridin-7(8H)-yl group:
[00163] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 7,8-dihydro-5H-pyrido[3,4-b]pyrazin-6-yl group:
[00164] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl group:
[00165] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-methyl-6,7-dihydro-4H-oxazolo[4,5-c]pyridin-5-yl group:
[00166] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-methyl-6,7-dihydro-4H-oxazolo[5,4-c]pyridine-5-yl group:
[00167] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3,4-dihydro-2,6-naphthyridin-2(1H)-yl group:
[00168] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 7,8-dihydro-1,6-naphthyridin-6(5H)-yl group:
[00169] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl group:
[00170] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5,6-dihydro-8H-imidazo[5,1-c]pyrazin-7-yl group:
[00171] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 6,7-dihydro-4H-pyrazolo[5,1-c]pyrazin-5-yl group:
[00172] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 6,7-dihydro-4H-[1,2,3]triazolo[5,1-c]pyrazin-5-yl group:
[00173] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 4H-pyrrolo[3,4-d]thiazol-5(6H)-yl group:
[00174] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 1H-pyrrolo[3,4-c]pyridin-2(3H)-yl group:
[00175] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl group:
[00176] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a hexahydro-2H-6-furo[2,3-c]pyridine-6-yl group:
[00177] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a tetrahydro-1H-2-pyrrolo[2,1-c]pyrazin-4(3H)-one group:
[00178] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (S)-tetrahydro-1H-2-pyrrolo[2,1-c]pyrazin-4(3H)-one group:
[00179] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3-azabicyclo[3.2.0]heptan-3-yl group:
[00180] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a (1R,5S)-3-azabicyclo[3.2.0]heptan-3-yl group:
[00181] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-azabicyclo[3.1.0]hexan-2-yl group:
[00182] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 4-azatricyclo[3.3.0.01,3]octanyl group:
[00183] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-3-yl group:
[00184] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl group:
[00185] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3,4-dihydroisoquinolin-2(1H)-yl group:
[00186] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl group:
[00187] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl group:
[00188] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 3',4'-dihydro-spirocyclopropane-1,1'-isoquinolin-2-yl group:
[00189] In some embodiments, R3 and R4, together with the nitrogen atom to which they are both attached, form a 2-oxa-5-azabicyclo[4.1.0]heptan-5-yl group:
[00190] In some aspects, each R5 and each R6 in the compounds of formula (I) independently H, C1-C6alkyl, or C3-C5cycloalkyl; or an R5 and R6 attached to the same carbon atom, together with that carbon atom, may form a C3-C6cycloalkyl ring, or an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, an optionally substituted 5-12-membered bridged heterocycloalkyl ring, an optionally substituted 4-12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12-membered spiroheterocycloalkyl ring system. [00191] In some embodiments, R5 or R6 in the compounds of formula (I) is H. [00192] In some embodiments, R5 or R6 in the compounds of formula (I) is C1- C6alkyl, such as, for example, C1-C6alkyl, C1-C5alkyl, C1-C4alkyl, C1-C3alkyl, C1-C2alkyl, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, methyl, ethyl, n-propyl, iso-propyl, n- butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n-hexyl, and the like. [00193] In some embodiments, R5 or R6 is methyl (i.e., -CH3). [00194] In some embodiments, an R5 and an R6 are methyl (i.e., -CH3). [00195] In some embodiments, R5 or R6 in the compounds of formula (I) is C3- C5cycloalkyl, such as, for example, C3cycloalkyl, C4cycloalkyl, C5cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, and the like. [00196] In some embodiments, an R5 and R6 in the compounds of formula (I) attached to the same carbon atom, together with that carbon atom, form a C3-C6cycloalkyl ring, such as, for example, C3cycloalkyl, C4cycloalkyl, C5cycloalkyl, C6cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. [00197] In some embodiments, an R5 and R6 in the compounds of formula (I) attached to the same carbon atom, together with that carbon atom, form a cyclopropyl group. [00198] In some embodiments of the compounds of formula (I), an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, an optionally substituted 5-12-membered bridged heterocycloalkyl ring, an optionally substituted 4-12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12-membered spiroheterocycloalkyl ring system. [00199] In some embodiments of the compounds of formula (I), an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered
heterocycloalkyl ring, such as, for example, an optionally substituted azetidnyl ring, an optionally substituted pyrrolidinyl ring, or an optionally substituted piperidinyl ring. [00200] In some embodiments, the optionally substituted 3-12-membered heterocycloalkyl ring is a 4-8 membered heterocycloalkyl ring. [00201] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure
in formula (I) is
or
[00202] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure
in formula (I) is
or
[00203] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure
in formula (I) is or
[00204] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure in formula (I) is
or [00205] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure
in formula (I) is
, , , , or
[00206] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure
in formula (Io) is
[00207] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure
in formula (I) is
[00208] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure
in formula (I) is
[00209] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure
in formula (I) is or
[00210] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure in formula (I) is
, or
[00211] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure
in formula (I) is , or
[00212] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 3-12-membered heterocycloalkyl ring, the structure
in formula (Io) is , or
[00213] In some embodiments of the compounds of formula (I), an R5 or R6, together with an R3 or R4 may form an optionally substituted 4-12-membered fused heterocycloalkyl ring system. [00214] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 4-12-membered fused heterocycloalkyl ring system, the structure in formula (Io) is
[00215] In some embodiments of the compounds of formula (I) wherein an R5 or R6, together with an R3 or R4 may form an optionally substituted 4-12-membered fused heterocycloalkyl ring system, the structure
in formula (I) is , or
[00216] In some embodiments of the compounds of formula (I), an R5 or R6, together with an R3 or R4 may form an optionally substituted 5-12-membered bridged heterocycloalkyl ring. [00217] In some embodiments of the compounds of formula (I), an R5 or R6, together with an R3 or R4 may form an optionally substituted 5-12-membered spiroheterocycloalkyl ring system. [00218] In some aspects, the compounds of formula (I) are compounds of formula (IA):
or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L and n are as shown above with respect to formula (I). [00219] In some embodiments, the compound of formula (IA) are compounds of formula (IA-1):
or a pharmaceutically acceptable salt thereof, wherein R7 is C1-C6alkyl, C1- C6haloalkyl, -C1-C6alkyl-O-C1-C6alkyl, hydroxyalkyl, cyclopropyl, 6-membered heterocycloalkyl, 5-membered heterocycloalkyl, 4-membered heterocycloalkyl, -C1- C6alkyl-SO2-C1-C6alkyl, or -C1-C6alkyl-CO2H. [00220] In some embodiments, R7 is C1-C6alkyl. In some embodiments, R7 is -CH3. [00221] In some aspects, the compounds of formula (I) are compounds of formula (IB):
or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L and n are as shown above with respect to formula (I). [00222] In some embodiments, the compound of formula (IB) are compounds of formula (IB-1):
or a pharmaceutically acceptable salt thereof, wherein R7 is C1-C6alkyl, C1- C6haloalkyl, -C1-C6alkyl-O-C1-C6alkyl, hydroxyalkyl, cyclopropyl, 6-membered heterocycloalkyl, 5-membered heterocycloalkyl, 4-membered heterocycloalkyl, -C1- C6alkyl-SO2-C1-C6alkyl, or -C1-C6alkyl-CO2H. [00223] In some embodiments, R7 is C1-C6alkyl. In some embodiments, R7 is -CH3. [00224] In some aspects, the compounds according to formula (I) are those that have an IC50 <20 nM in a PDGFR cellular assay such as, for example, that described in the Examples section below. [00225] In some embodiments, the compounds according to formula (I) are those that have an IC50 <5 nM in a PDGFR cellular assay such as, for example, that described in the Examples section below.
[00226] In some aspects, the compound of the disclosure is one of Examples 1-391, or a pharmaceutically acceptable salt thereof, as described in the Examples section below. [00227] References to formula (I) herein encompass any subgenera of those formula disclosed herein (e.g., formula (IA), (IA-1), (IB), and (IB-1)). [00228] Stereoisomers of compounds of formula (I) are also contemplated by the present disclosure. Thus, the disclosure encompasses all stereoisomers and constitutional isomers of any compound disclosed or claimed herein, including all enantiomers and diastereomers. [00229] Pharmaceutically acceptable salts and solvates of the compounds of formula (I) are also within the scope of the disclosure. [00230] Isotopic variants of the compounds of formula (I) are also contemplated by the present disclosure. Pharmaceutical compositions and methods of administration [00231] The subject pharmaceutical compositions are typically formulated to provide a therapeutically effective amount of a compound of the present disclosure as the active ingredient, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof. In some embodiments, the pharmaceutical compositions contain a compound of the present disclosure or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. [00232] The subject pharmaceutical compositions can be administered alone or in combination with one or more other agents, which are also typically administered in the form of pharmaceutical compositions. Where desired, the one or more compounds of the invention and other agent(s) may be mixed into a preparation or both components may be formulated into separate preparations to use them in combination separately or at the same time. [00233] In some embodiments, the concentration of one or more compounds provided in the pharmaceutical compositions of the present invention is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%,
0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above) w/w, w/v or v/v. [00234] In some embodiments, the concentration of one or more compounds of the invention is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25%, 13%, 12.75%, 12.50%, 12.25%, 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25%, 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25%, 7%, 6.75%, 6.50%, 6.25%, 6%, 5.75%, 5.50%, 5.25%, 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 1.25% , 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above) w/w, w/v, or v/v. [00235] In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.0001% to approximately 50%, approximately 0.001% to approximately 40%, approximately 0.01% to approximately 30%, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%, approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, approximately 1% to approximately 10% w/w, w/v or v/v. [00236] In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately
0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, approximately 0.1% to approximately 0.9% w/w, w/v or v/v. [00237] In some embodiments, the amount of one or more compounds of the invention is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g (or a number in the range defined by and including any two numbers above). [00238] In some embodiments, the amount of one or more compounds of the invention is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g, , 0.15 g, 0.2 g, , 0.25 g, 0.3 g, , 0.35 g, 0.4 g, , 0.45 g, 0.5 g, 0.55 g, 0.6 g, , 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g, 0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5g, 7 g, 7.5g, 8 g, 8.5 g, 9 g, 9.5 g, or 10 g (or a number in the range defined by and including any two numbers above). [00239] In some embodiments, the amount of one or more compounds of the invention is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g. [00240] In some embodiments, the compounds according to the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from 0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and from 5 to 40 mg per day are examples of dosages that may be used. An exemplary dosage is 10 to 30 mg per day. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician. [00241] Unless otherwise noted, the amounts of the compounds described herein are set forth on a free base basis. That is, the amounts indicate that amount of the compound
administered, exclusive of, for example, solvent (such as in solvates) or counterions (such as in pharmaceutically acceptable salts). [00242] Described below are non- limiting exemplary pharmaceutical compositions and methods for preparing the same. Pharmaceutical compositions for oral administration. [00243] In some embodiments, the invention provides a pharmaceutical composition for oral administration containing a compound of the invention, and a pharmaceutical excipient suitable for oral administration. [00244] In some embodiments, the invention provides a solid pharmaceutical composition for oral administration containing: (i) an effective amount of a compound of the invention; optionally (ii) an effective amount of a second agent; and (iii) a pharmaceutical excipient suitable for oral administration. In some embodiments, the composition further contains: (iv) an effective amount of a third agent. [00245] In some embodiments, the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral consumption. Pharmaceutical compositions of the invention suitable for oral administration can be presented as discrete dosage forms, such as capsules, cachets, or tablets, or liquids or aerosol sprays each containing a predetermined amount of an active ingredient as a powder or in granules, a solution, or a suspension in an aqueous or non-aqueous liquid, an oil-in- water emulsion, or a water-in-oil liquid emulsion. Such dosage forms can be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as powder or granules, optionally mixed with an excipient such as, but not limited to, a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
[00246] This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising an active ingredient, since water can facilitate the degradation of some compounds. For example, water may be added (e.g., 5%) in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf- life or the stability of formulations over time. Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms of the invention which contain lactose can be made anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions may be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastic or the like, unit dose containers, blister packs, and strip packs. [00247] An active ingredient can be combined in an intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending on the form of preparation desired for administration. In preparing the compositions for an oral dosage form, any of the usual pharmaceutical media can be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used in the case of oral solid preparations, in some embodiments without employing the use of lactose. For example, suitable carriers include powders, capsules, and tablets, with the solid oral preparations. If desired, tablets can be coated by standard aqueous or nonaqueous techniques. [00248] Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone,
methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof. [00249] Examples of suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. [00250] Disintegrants may be used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Too much of a disintegrant may produce tablets which may disintegrate in the bottle. Too little may be insufficient for disintegration to occur and may thus alter the rate and extent of release of the active ingredient(s) from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor too much to detrimentally alter the release of the active ingredient(s) may be used to form the dosage forms of the compounds disclosed herein. The amount of disintegrant used may vary based upon the type of formulation and mode of administration, and may be readily discernible to those of ordinary skill in the art. About 0.5 to about 15 weight percent of disintegrant, or about 1 to about 5 weight percent of disintegrant, may be used in the pharmaceutical composition. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums or mixtures thereof. [00251] Lubricants which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures thereof. Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof. A lubricant can optionally be added, in an amount of less than about 1 weight percent of the pharmaceutical composition.
[00252] When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof. [00253] The tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil. [00254] Surfactant which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be employed, a mixture of lipophilic surfactants may be employed, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be employed. [00255] A suitable hydrophilic surfactant may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of or less than about 10. An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance (" HLB" value). Surfactants with lower HLB values are more lipophilic or hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions. [00256] Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable. Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10. However, HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical and cosmetic emulsions.
[00257] Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; lecithins and hydrogenated lecithins; lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acyl lactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di- glycerides; and mixtures thereof. [00258] Within the aforementioned group, ionic surfactants include, by way of example: lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acylactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof. [00259] Ionic surfactants may be the ionized forms of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG- phosphatidylethanolamine, PVP -phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholylsarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, lauroyl carnitines, palmitoyl carnitines, myristoyl carnitines, and salts and mixtures thereof. [00260] Hydrophilic non-ionic surfactants may include, but are not limited to, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid
esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylated vitamins and derivatives thereof; polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; polyethylene glycol sorbitan fatty acid esters and hydrophilic transesterification products of a polyol with at least one member of the group consisting of triglycerides, vegetable oils, and hydrogenated vegetable oils. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a saccharide. [00261] Other hydrophilic-non-ionic surfactants include, without limitation, PEG- 10 laurate, PEG- 12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG- 12 oleate, PEG- 15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG- 15 stearate, PEG-32 distearate, PEG-40 stearate, PEG- 100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG- 100 succinate, PEG-24 cholesterol, polyglyceryl-lOoleate, Tween 40, Tween 60, sucrose monostearate, sucrose mono laurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, and poloxamers. [00262] Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable
oils, fatty acids and sterols; oil-soluble vitamins/vitamin derivatives; and mixtures thereof. Within this group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or are hydrophobic transesterification products of a polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides. [00263] In one embodiment, the composition may include a solubilizer to ensure good solubilization and/or dissolution of the compound of the present invention and to minimize precipitation of the compound of the present invention. This can be especially important for compositions for non-oral use, e.g., compositions for injection. A solubilizer may also be added to increase the solubility of the hydrophilic drug and/or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion. [00264] Examples of suitable solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG ; amides and other nitrogen-containing compounds such as 2- pyrrolidone, 2-piperidone, ε-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, ε-caprolactone and isomers thereof, δ-valerolactone and isomers thereof, β-butyrolactone and isomers thereof; and other solubilizers known in the art, such as dimethyl acetamide, dimethyl isosorbide, N-methyl pyrrolidones, monooctanoin, diethylene glycol monoethyl ether, and water. [00265] Mixtures of solubilizers may also be used. Examples include, but not limited to, triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N- methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-100,
glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol. [00266] The amount of solubilizer that can be included is not particularly limited. The amount of a given solubilizer may be limited to a bioacceptable amount, which may be readily determined by one of skill in the art. In some circumstances, it may be advantageous to include amounts of solubilizers far in excess of bioacceptable amounts, for example to maximize the concentration of the drug, with excess solubilizer removed prior to providing the composition to a subject using conventional techniques, such as distillation or evaporation. Thus, if present, the solubilizer can be in a weight ratio of 10%, 25%o, 50%), 100%o, or up to about 200%> by weight, based on the combined weight of the drug, and other excipients. If desired, very small amounts of solubilizer may also be used, such as 5%>, 2%>, 1%) or even less. Typically, the solubilizer may be present in an amount of about 1%> to about 100%, more typically about 5%> to about 25%> by weight. [00267] The composition can further include one or more pharmaceutically acceptable additives and excipients. Such additives and excipients include, without limitation, detackifiers, anti-foaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof. [00268] In addition, an acid or a base may be incorporated into the composition to facilitate processing, to enhance stability, or for other reasons. Examples of pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, trimethylamine, tris(hydroxymethyl)aminomethane (TRIS) and the like. Also suitable are bases that are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para- bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid,
succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like. Salts of polyprotic acids, such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used. When the base is a salt, the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like. Example may include, but not limited to, sodium, potassium, lithium, magnesium, calcium and ammonium. [00269] Suitable acids are pharmaceutically acceptable organic or inorganic acids. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, and the like. Examples of suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acids, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid and the like. Pharmaceutical compositions for injection. [00270] In some embodiments, the invention provides a pharmaceutical composition for injection containing a compound of the present invention and a pharmaceutical excipient suitable for injection. Components and amounts of agents in the compositions are as described herein. [00271] The forms in which the novel compositions of the present invention may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles. [00272] Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, for the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various
antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. [00273] Sterile injectable solutions are prepared by incorporating the compound of the present invention in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, certain desirable methods of preparation are vacuum-drying and freeze- drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. [00274] Pharmaceutical compositions for topical (e.g. transdermal) delivery. [00275] In some embodiments, the invention provides a pharmaceutical composition for transdermal delivery containing a compound of the present invention and a pharmaceutical excipient suitable for transdermal delivery. [00276] Compositions of the present invention can be formulated into preparations in solid, semisolid, or liquid forms suitable for local or topical administration, such as gels, water soluble jellies, creams, lotions, suspensions, foams, powders, slurries, ointments, solutions, oils, pastes, suppositories, sprays, emulsions, saline solutions, dimethylsulfoxide (DMSO)-based solutions. In general, carriers with higher densities are capable of providing an area with a prolonged exposure to the active ingredients. In contrast, a solution formulation may provide more immediate exposure of the active ingredient to the chosen area. [00277] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients, which are compounds that allow increased penetration of, or assist in the delivery of, therapeutic molecules across the stratum corneum permeability barrier of the skin. There are many of these penetration- enhancing molecules known to those trained in the art of topical formulation. [00278] Examples of such carriers and excipients include, but are not limited to, humectants (e.g., urea), glycols (e.g., propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleic acid), surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), pyrrolidones, glycerol monolaurate, sulfoxides, terpenes (e.g., menthol), amines, amides,
alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols. [00279] Another exemplary formulation for use in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of a compound of the present invention in controlled amounts, either with or without another agent. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos.5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. Pharmaceutical compositions for inhalation. [00280] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner. [00281] Compositions for inhalation may be delivered as a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant. Such devices are referred to in, for example, WO2013030802. [00282] Where the inhalable form of the active ingredient is an aerosol composition, the inhalation device may be an aerosol vial provided with a valve adapted to deliver a metered dose, i.e. a metered dose inhaler. Where the inhalable form of the active ingredient is a nebulizable aqueous, organic or aqueous/organic dispersion, the inhalation device may be a nebulizer, such as an airjet nebulizer, or an ultrasonic nebulizer, or a hand- held nebulizer, sometimes referred to as a soft mist or soft spray inhaler, or a mechanical
device which allows much smaller nebulized volumes than conventional nebulizers. Such devices are referred to in, for example, WO2013030802. [00283] Where the inhalable form of the active ingredient is the finely divided particulate form, the inhalation device may be, for example, a dry powder inhalation device adapted to deliver dry powder from a capsule or blister containing a dry powder comprising a dosage unit or a multidose dry powder inhalation (MDPI) device adapted to deliver dry powder comprising a dosage unit upon actuation. The dry powder composition preferably contains a diluent or carrier, such as lactose, and a compound that helps to protect against product performance deterioration due to moisture e.g. magnesium stearate. Dry powder inhalation devices are referred to in, for example, WO2013030802 [00284] Thus, in some embodiments, the invention also includes (A) a compound of the invention, or a pharmaceutically acceptable salt thereof, in inhalable form; (B) an inhalable medicament comprising the compound in inhalable form together with a pharmaceutically acceptable carrier in inhalable form; (C) a pharmaceutical product comprising such a compound in inhalable form in association with an inhalation device; and (D) an inhalation device containing such a compound in inhalable form. Other pharmaceutical compositions. [00285] Pharmaceutical compositions may also be prepared from compositions described herein and one or more pharmaceutically acceptable excipients suitable for sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration. Preparations for such pharmaceutical compositions are well-known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, New York, 1990; Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition, McGraw Hill, 20037ybg; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001 ; Remingtons Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999); all of which are incorporated by reference herein in their entirety. [00286] Administration of the compounds or pharmaceutical composition of the present invention can be effected by any method that enables delivery of the compounds to
the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical (e.g. transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation. Compounds can also be administered intraadiposally or intrathecally. [00287] The amount of the compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g/day, preferably about 0.05 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g. by dividing such larger doses into several small doses for administration throughout the day. [00288] In some embodiments, a compound of the invention is administered in a single dose. [00289] Typically, such administration will be by injection, e.g., intravenous injection, in order to introduce the agent quickly. However, other routes may be used as appropriate. A single dose of a compound of the invention may also be used for treatment of an acute condition. [00290] In some embodiments, a compound of the invention is administered in multiple doses. Dosing may be about once, twice, three times, four times, five times, six times, or more than six times per day. Dosing may be about once a month, once every two weeks, once a week, or once every other day. In another embodiment a compound of the invention and another agent are administered together about once per day to about 6 times per day. In another embodiment the administration of a compound of the invention and an agent continues for less than about 7 days. In yet another embodiment the administration continues for more than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, continuous dosing is achieved and maintained as long as necessary. [00291] Administration of the compounds of the invention may continue as long as necessary. In some embodiments, a compound of the invention is administered for more than
1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, a compound of the invention is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, a compound of the invention is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects. [00292] An effective amount of a compound of the invention may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intra- arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant. [00293] The compositions of the invention may also be delivered via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer. Such a method of administration may, for example, aid in the prevention or amelioration of restenosis following procedures such as balloon angioplasty. Without being bound by theory, compounds of the invention may slow or inhibit the migration and proliferation of smooth muscle cells in the arterial wall which contribute to restenosis. A compound of the invention may be administered, for example, by local delivery from the struts of a stent, from a stent graft, from grafts, or from the cover or sheath of a stent. In some embodiments, a compound of the invention is admixed with a matrix. Such a matrix may be a polymeric matrix, and may serve to bond the compound to the stent. Polymeric matrices suitable for such use, include, for example, lactone-based polyesters or copolyesters such as polylactide, polycaprolactonglycolide, polyorthoesters, polyanhydrides, polyaminoacids, polysaccharides, polyphosphazenes, poly (ether-ester) copolymers (e.g. PEO-PLLA); polydimethylsiloxane, poly(ethylene-vinylacetate), acrylate-based polymers or copolymers (e.g. polyhydroxyethyl methylmethacrylate, polyvinyl pyrrolidinone), fluorinated polymers such as polytetrafluoroethylene and cellulose esters. Suitable matrices may be nondegrading or may degrade with time, releasing the compound or compounds. Compounds of the invention may be applied to the surface of the stent by various methods such as dip/spin coating, spray coating, dip-coating, and/or brush-coating. The compounds may be applied in a solvent and the solvent may be allowed to evaporate, thus forming a layer of compound onto the stent. Alternatively, the compound may be located in the body of the stent or graft, for example in microchannels or micropores. When implanted, the compound diffuses out of the body of the stent to contact the arterial wall. Such stents may be prepared by dipping a
stent manufactured to contain such micropores or microchannels into a solution of the compound of the invention in a suitable solvent, followed by evaporation of the solvent. Excess drug on the surface of the stent may be removed via an additional brief solvent wash. In yet other embodiments, compounds of the invention may be covalently linked to a stent or graft. A covalent linker may be used which degrades in vivo, leading to the release of the compound of the invention. Any bio-labile linkage may be used for such a purpose, such as ester, amide or anhydride linkages. Compounds of the invention may additionally be administered intravascularly from a balloon used during angioplasty. Extravascular administration of the compounds via the pericard or via advential application of formulations of the invention may also be performed to decrease restenosis. [00294] A variety of stent devices which may be used as described are disclosed, for example, in the following references, all of which are hereby incorporated by reference: U.S. Pat. No.5451233; U.S. Pat. No.5040548; U.S. Pat. No.5061273; U.S. Pat. No. 5496346; U.S. Pat. No.5292331; U.S. Pat. No.5674278; U.S. Pat. No.3657744; U.S. Pat. No.4739762; U.S. Pat. No.5195984; U.S. Pat. No.5292331 ; U.S. Pat. No.5674278; U.S. Pat. No.5879382; U.S. Pat. No.6344053. [00295] The compounds of the invention may be administered in dosages. It is known in the art that due to intersubject variability in compound pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy. Dosing for a compound of the invention may be found by routine experimentation in light of the instant disclosure. [00296] When a compound of the invention is administered in a composition that comprises one or more agents, and the agent has a shorter half- life than the compound of the invention unit dose forms of the agent and the compound of the invention may be adjusted accordingly. [00297] The subject pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention
as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc. [00298] Exemplary parenteral administration forms include solutions or suspensions of active compound in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired. Methods of Use [00299] The method typically comprises administering to a subject a therapeutically effective amount of a compound of the invention. The therapeutically effective amount of the subject combination of compounds may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target cells, e.g., reduction of proliferation or downregulation of activity of a target protein. The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried. [00300] The disclosure also relates to methods of using the compounds described herein to treat in a subject in need thereof, a disease or disorder in which PDGFR signaling is implicated. These methods are accomplished by administering to the subject a compound of the disclosure in an amount effective to treat the disease or disorder. [00301] In some aspects, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is pulmonary hypertension (PH). [00302] In some embodiments, the pulmonary hypertension is pulmonary arterial hypertension (PAH) (WHO PH Group 1); PH secondary to heart failure (WHO PH Group 2); PH secondary to lung diseases and/or hypoxia (WHO PH Group 3); PH due to pulmonary artery obstruction (WHO Group 4); or PH due to unknown or rare diseases (WHO PH Group 5). [00303] In some embodiments, the PAH (WHO PH Group 1) is idiopathic PAH, PAH with vasoreactivity, heritable PAH, drugs and toxins-induced PAH, PAH associated with connective tissue disease, PAH associated with HIV infection, PAH associated with
portal hypertension, PAH associated with congenital heart disease, PAH associated with schistosomiasis, PAH in long-term responders to calcium channel blockers, PAH with overt signs of venous/capillaries involvement; persistent PH of the Newborn syndrome; or systemic sclerosis-associated PAH (SSc-PAH). [00304] In some embodiments, the PAH secondary to heart failure (WHO PH Group 2) is PH due to heart failure with preserved ejection fraction, PH due to heart failure with reduced ejection fraction, valvular heart disease, or congenital post-capillary obstructive lesions. [00305] In some embodiments, the PH secondary to lung diseases and/or hypoxia (WHO PH Group 3) is PH due to obstructive lung disease, PH due to restrictive lung disease, PH due to other lung diseases with mixed restrictive/obstructive pattern, PH due to hypoxia without lung disease, PH due to developmental lung disorders. [00306] In some embodiments, the PH due to obstructive lung disease is PH due to chronic obstructive pulmonary disease (COPD). [00307] In some embodiments, the PH due to restrictive lung disease is PH due to interstitial lung diseases (ILDs). [00308] In some embodiments, the PH due to interstitial lung diseases (ILDs) is PH due to idiopathic pulmonary fibrosis (IPF). [00309] In some embodiments, the PH due to pulmonary artery obstruction (WHO Group 4) is chronic thromboembolic PH (CTEPH) or PH due to other pulmonaty artery obstructions. [00310] In some embodiments, the PH due to unknown or rare diseases (WHO PH Group 5) is PH due to hematologic disorders, PH due to systemic disorders, PH due to other disorders, or PH due to complex congenital heart disease. [00311] In some aspects, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is a respiratory disease. [00312] In some embodiments, the respiratory disease is asthma. [00313] In some aspects, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is a fibrotic disease.
[00314] In some embodiments, the fibrotic disease is pulmonary fibrosis, cardiac fibrosis or liver fibrosis. [00315] In some embodiments, the fibrotic disease is pulmonary fibrosis. [00316] In some embodiments, the pulmonary fibrosis is an interstitial lung disease. [00317] In some embodiments, the interstitial lung disease is idiopathic pulmonary fibrosis. [00318] In some embodiments, the interstitial lung disease is rheumatoid arthritis- associated interstitial lung disease. [00319] In some embodiments, the interstitial lung disease is systemic sclerosis- associated interstitial lung disease. [00320] In some embodiments, the interstitial lung disease is connective tissue disease-associated interstitial lung disease. [00321] In some embodiments, the interstitial lung disease is nonspecific interstitial pneumonia. [00322] In some embodiments, the interstitial lung disease is unclassifiable interstitial lung disease. [00323] In some embodiments, the interstitial lung disease is hypersensitivity pneumonitis. [00324] In some embodiments, the interstitial lung disease is sarcoidosis. [00325] In some embodiments, the interstitial lung disease is non-idiopathic pulmonary fibrosis interstitial lung disease. [00326] In some aspects, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is a dermatological disease. [00327] In some embodiments, the dermatological disease or disorder is atopic dermatitis, scleroderma, or urticaria. [00328] In some aspects, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is an inflammatory disease or disorder. [00329] In some embodiments, the inflammatory disease or disorder is allergic rhinitis, irritable bowel syndrome (IBS); or inflammatory bowel disease (IBD).
[00330] In some aspects, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is an autoimmune disorder. [00331] In some aspects, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is a metabolic disease. [00332] In some aspects, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is vascular restenosis; age-related macular degeneration (AMD); irritable bowel syndrome (IBS); inflammatory bowel disease (IBD); obesity-cell related diseases; type I diabetes or type II diabetes. [00333] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is pulmonary arterial hypertension (PAH). [00334] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH secondary to heart failure (WHO PH Group 2). [00335] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH due to heart failure with preserved ejection fraction. [00336] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH due to heart failure with reduced ejection fraction. [00337] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is valvular heart disease. [00338] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is congenital post-capillary obstructive lesions. [00339] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof,
wherein the disease or disorder is PH secondary to lung diseases and/or hypoxia (WHO PH Group 3). [00340] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH due to pulmonary artery obstruction (WHO Group 4). [00341] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is chronic thromboembolic PH (CTEPH). [00342] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH due to unknown or rare diseases (WHO PH Group 5). [00343] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is idiopathic PAH. [00344] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PAH associated with connective tissue disease. [00345] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is systemic sclerosis-associated PAH (SSc-PAH). [00346] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH secondary to interstitial lung diseases (ILDs). [00347] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH secondary to chronic obstructive pulmonary disease (COPD). [00348] In other embodiments, the disclosure is directed to methods of using the compounds described herein to treat a disease or disorder in a subject in need thereof, wherein the disease or disorder is PH secondary to idiopathic pulmonary fibrosis (IPF). [00349] In treatment methods according to the disclosure, an effective amount of a pharmaceutical agent according to the disclosure is administered to a subject suffering from
or diagnosed as having such a disease or disorder. An "effective amount" means an amount or dose sufficient to generally bring about the desired therapeutic benefit in patients in need of such treatment for the designated disease or disorder. Effective amounts or doses of the compounds of the present disclosure may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease or disorder, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. An example of a dose is in the range of from about 0.001 to about 200 mg of compound per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day. [00350] In addition, the compounds of the disclosure may be used in combination with additional active ingredients in the treatment of the above diseases or disorders. The additional active ingredients may be coadministered separately with a compound of the disclosure or included with such an agent in a pharmaceutical composition according to the disclosure. The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an active agent according to the disclosure), decrease one or more side effects, or decrease the required dose of the active agent according to the disclosure. [00351] It should be understood that references herein to methods of treatment using one or more compounds or formulations thereof should also be interpreted as references to: (i) one or more compounds or formulations thereof for use in methods of treatment; and/or (ii) the use of one or more compounds or formulations thereof in the manufacture of a medicament for treating a pathological condition. Examples [00352] Compounds of Formula (I) in the present invention can be synthesized in accordance with general synthetic methods to those who are skilled in the art. The following reaction schemes are only meant to represent examples of the invention and are in no way meant to be a limit of the invention. Scheme 1
[00353] Scheme 1 illustrated the synthesis of key intermediate 1.4-Bromo-2- fluoropyridine (1-1) treated with hydrazine to give 4-bromo-2-hydrazineylpyridine (1-2), 4- bromo-2-hydrazineylpyridine (1-2) reacted with ethyl 2-oxoacetate (1-3) in a solvent such as methanol followed by the treatment with (diacetoxyiodo)benzene in a solvent such as dichloromethylene to produce ethyl 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate (1- 4) which then treated with base such as LiOH in a solvent such as THF-water to give key intermediate acid (1). Scheme 2
[00354] Scheme 2 illustrated the synthesis of key intermediate 2. Methyl 2-(5- bromopyridin-2-yl)acetate (2-1) reacted with 4-acetamidobenzenesulfonyl azide (2-2) and a base such as 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (2-3) in a solvent such as acetylnitrile to yield methyl 6-bromo-[1,2,3]triazolo[1,5-a]pyridine-3-carboxylate (2-4)
which then hydrolyzed with a base such as LiOH in a solvent such as THF-water to give the key intermediate acid (2). Scheme 3
[00355] Scheme 3 illustrated the synthesis of Formula I while L = NHCO. The key intermediate acid (1 or 2 or available commercially) coupled with pyridinylamine (I-1) in an appropriate coupling agent such as PyBop, a base such as DIEA in a solvent such as DMF to give an amide compound (I-2) which then coupled with boronated agent (I-3), a catalyst such as PdCl2(dppf).CH2Cl2, a base such as Cs2CO3 and a solvent such as dioxane-water to give compound (I-6). Alternatively, a bromotriazoleester (1-4 or 2-4) coupled with boronated agent (I-3), a catalyst such as PdCl2(dppf).CH2Cl2, a base such as Cs2CO3 and a solvent such as dioxane-water to yield ester compound (I-4) which then hydrolyzed with a base such as LiOH in a solvent such as THF-water to give acid (I-5). The acid (I-5) treated with pyridinylamine (I-1) in an appropriate coupling agent such as PyBop, a base such as DIEA in
a solvent such as DMF to give compound (I-6). The protecting Boc group was deprotected with an acid such HCl in a solvent such as dioxane to give amine (I-7). The amine (I-7) was then treated with acid chloride (I-8), a base such as NaHCO3 in a solvent such as DMF to produce a chloride compound (I-9). Treated compound (I-9) with amine (I-10), a base such as K2CO3 and in a solvent such as DMF to yield Formula I. Alternatively the amine (I-7) was coupled with an acid (I-11) with an appropriate coupling reagent such as T3P, a base such as TEA and a solvent such as DMF to produce Formula I. Scheme 4
[00356] Scheme 4 illustrated the alternate synthesis of Formula I while L = NHCO. The nitropyridinylamine (I-12) was reacted with an acid chloride (I-8) and base such as TEA in a solvent such as DCM to give a compound (I-13) which then treated with an amine (I-10), a base such as K2CO3 and in a solvent such as DMF to give nitro compound (I-14). The nitro compound (I-14) was reduced to an amine (I-15) under H2 with a catalyst such as Pd/C. The amine (I-15) was treated with an acid (I-5) to produce Formula I. Alternately the amine ((I- 15) coupled with key intermediate (1 or 2) in an appropriate coupling agent such as PyBop, a base such as DIEA in a solvent such as DMF to give a bromo compound (I-16). The bromo compound (I-16) coupled with boronated agent (I-3), a catalyst such as PdCl2(dppf).CH2Cl2, a base such as Cs2CO3 and a solvent such as dioxane-water to give Formula I. Alternately the
bromo compound (I-16) converted to a boronated compound (I-18) with 4,4,4',4',5,5,5',5'- octamethyl-2,2'-bi(1,3,2-dioxaborolane) (I-17), a catalyst such as Pd2(dba)3, a ligand such as PCy3, a base such as AcOK and in a solvent such as dioxane. The boronated compound (I-18) was then couple with a halide compound (I-19), a catalyst such as Pd-118, a base such as K3PO4 and a solvent such as dioxane-water to give Formula I. Scheme 5.
[00357] Scheme 5 illustrated the alternate synthesis of Formula I while L = NHCO and R2 = R2’. The bromo compound (I-16) was treated with an amine or alcohol (I-20), a catalyst such as Pd2(dba)3, a ligand such as Xantphos and a base such as Cs2CO3 to give Formula I. Scheme 6.
[00358] Scheme 6 illustrated the synthesis of Formula I while L = CONH. The key intermediate acid (1 or 2 or available commercially) coupled with pyridinylamine ester (I- 21) in an appropriate coupling agent such as PyBop, a base such as DIEA in a solvent such as DMF to give an ester compound (I-22). The ester compound (I-22) coupled with boronated agent (I-3), a catalyst such as PdCl2(dppf).CH2Cl2, a base such as Cs2CO3 and a solvent such as dioxane-water to give compound (I-23). Compound (I-23) was then hydrolyzed with a
base such as LiOH in a solvent such as THF-water to give an acid (I-24). The acid (I-24) was then couple with amine (I-25), an appropriate coupling reagent such as HATU, a base such as DIEA and a solvent such as DMF to yield Formula I. Scheme 7
[00359] Scheme 7 illustrated the alternative synthesis of Formula I while L = CONH. The ester compound (I-22) was first hydrolyzed with base such as LiOH in a solvent such as THF-water to give acid (I-26). The acid (I-26) was then couple with amine (I-25), an appropriate coupling reagent such as HATU, a base such as DIEA and a solvent such as DMF to produce a bromo containing compound (I-27). The bromo containing compound (I-27) coupled with boronated agent (I-3), a catalyst such as PdCl2(dppf).CH2Cl2, a base such as Cs2CO3 and a solvent such as dioxane-water to give Formula I. Alternatively, the bromo containing compound (I-27) converted to a boronated compound (I-28) with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (I-17), a catalyst such as Pd2(dba)3 and PCy3, a base such as AcOK and in a solvent such as dioxane. The boronated compound
(I-28) was then couple with a halide compound (I-19), a catalyst such as Pd-118, a base such as K3PO4 and a solvent such as dioxane-water to give Formula I. Scheme 8.
[00360] Scheme 8 illustrated the synthesis of Formula I while L = NHCONH. The amine (I-25) first treated with phenyl carbonochloridate (I-29) in a solvent such as DCM to give compound (I-30). compound (I-30) was reacted with compound (I-12), a base such as DMAP and in a solvent such as acetylnitrile to yield nitro containing compound (I-31) which then reduced under H2 with a catalyst such as Pd/C in a solvent such as methanol to give amine compound (I-32). The amine compound (I-32) coupled with key intermediate 1, an appropriate coupling agent such as PyBop, a base such as DIEA in a solvent such as DMF to give compound (I-33). Compound (I-33) coupled with boronated agent (I-3), a catalyst such as PdCl2(dppf).CH2Cl2, a base such as Cs2CO3 and a solvent such as dioxane-water to give Formula I. Intermediate 1 Ethyl 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate
Step a: 4-Bromo-2-hydrazinylpyridine
[00361] A mixture of 4-bromo-2-fluoropyridine (100 g, 568 mmol) in hydrazine (500 mL) was stirred at room temperature for 16 h. The mixture was concentrated and washed with petroleum ether (50 mL x 3) to give the crude product 4-bromo-2- hydrazinylpyridine (100 g, 93%) as a white solid. LCMS (ESI): mass calcd. for C5H6BrN3, 187.0; m/z found, 187.7 [M+H]+. Step b: Ethyl 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate
[00362] To a solution of 4-bromo-2-hydrazinylpyridine (25 g, 133 mmol) in CH3OH (400 mL) was added ethyl 2-oxoacetate (33 g, 160 mmol). The mixture was stirred at 60°C for 2 h. The reaction mixture cooled down to room temperature and concentrated in vacuo. DCM (400 mL) was added to the residue and the mixture was cooled to 0°C. (Diacetoxyiodo)benzene (56 g, 173 mmol) was added in portions. After addition, the mixture was allowed to warm to room temperature and stirred for 15 h. The mixture was diluted with DCM (1000 mL), and the resulting mixture was washed with water (500 mL x 2). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give the crude product, which was purified by column chromatography over silica gel (gradient elution: 0~60% ethyl acetate in petroleum ether) to give ethyl 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate (23 g, 55%) as a yellow solid. LCMS (ESI): mass calcd. for C9H8BrN3O2, 269.0; m/z found, 269.8 [M+H]+. Intermediate 2 Ethyl 6-bromo-[1,2,3]triazolo[1,5-a]pyridine-3-carboxylate
[00363] To a solution of ethyl 2-(5-bromopyridin-2-yl)acetate (8 g, 32.78 mmol, 1.0 equiv.) and DBU (5.99 g, 36.05 mmol, 1.1 equiv.) in CH3CN (120 mL) was added p-ABSA (9.45 g, 39.33 mmol, 1.2 equiv.) in portions while cooled by an ice bath. The ice bath remained for cooling overnight. When the reaction was completed, the mixture was diluted with water and extracted with EA (150 mL x 3). The organic layers were combined, washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column (EA/PE, 0 % ~ 80%) to afford ethyl 6-bromo-[1,2,3]triazolo[1,5-a]pyridine-3-carboxylate (6.70 g, 89.5 % yield) as an off-white solid. LC/MS: mass calcd. for C9H8BrN3O2: 268.98, found: 270.00 [M+H+2]+. 1H NMR (300 MHz, DMSO-d6) δ 9.76 (dd, J = 1.6, 0.9 Hz, 1H), 8.10 (dd, J = 9.3, 1.0 Hz, 1H), 7.87 (dd, J = 9.3, 1.6 Hz, 1H), 4.41 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H). Intermediate 3 N-(5-Amino-6-methylpyridin-3-yl)-2-(2,2-dimethylpyrrolidin-1-yl)acetamide
[00364] Step a: A 1 L flask was charged with tert-butyl (5-amino-2-methylpyridin- 3-yl)carbamate (30.0 g, 134.4 mmol), pyridine (21.2 g, 268.0 mmol) in DCM (250 mL) and a stir bar. Chloroacetyl chloride (16.7 g, 147.9 mmol) in DCM (50 mL) was added at 0 °C under nitrogen. The resulting mixture was maintained under nitrogen and stirred at room temperature for 1 h. The reaction was quenched with H2O (200 mL) and extracted with DCM (500 mL × 3). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue obtained was purified by silica gel chromatography (0-66% ethyl acetate/petroleum ether) to afford the tert-butyl (5-(2-chloroacetamido)-2-methylpyridin-3- yl)carbamate as a yellow solid (53.3 g). MS (ESI) calcd. for C13H18ClN3O3: 299.10 m/z, found: 300.25 [M+H]+. [00365] Step b: A 250 mL flask was charged with 2,2-dimethylpyrrolidine hydrochloride (5.0 g, 36.9 mmol), K2CO3 (9.2 g, 66.6 mmol) in acetonitrile (100 mL) and a stir bar. After stirring for 20 min, tert-butyl (5-(2-chloroacetamido)-2-methylpyridin-3-
yl)carbamate (10.0 g, 33.4 mmol) was added. The resulting mixture was stirred at room temperature overnight. The mixture was concentrated. The residue was purified by silica gel chromatography (0-10% MeOH/DCM) to afford tert-butyl (5-(2-(2,2-dimethylpyrrolidin-1- yl)acetamido)-2-methylpyridin-3-yl)carbamate as an off-white solid (8.6 g, 71.1% yield). MS (ESI) calcd. for C19H30N4O3: 362.23 m/z, found: 363.15 [M+H]+. [00366] Step c: Into a 250 mL flask was placed tert-butyl (5-(2-(2,2- dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)carbamate (11.0 g, 30.3 mmol), a stir bar and HCl (80 mL, 4 M in 1,4-dioxane). The resulting mixture was stirred at room temperature for 1 h and yellow precipitate was formed. Solvent was removed under reduced pressure. Et2O (300 mL) was added to the residue and the mixture was stirred for 10 min. The mixture was filtered and washed with Et2O (50 mL × 3). The filter cake was dried under vacuum to afford N-(5-amino-6-methylpyridin-3-yl)-2-(2,2-dimethylpyrrolidin-1- yl)acetamide as yellow solid ( 7935.9 mg, 97.8% yield). MS (ESI) calcd. for C13H20N4O: 262.18 m/z, found: 263.10 [M+H]+. Intermediate 4 (S)-N-(5-Amino-6-methylpyridin-3-yl)-2-(2-methylpyrrolidin-1-yl)acetamide
[00367] Step a: A 250 mL flask was charged with (S)-2-methylpyrrolidine hydrochloride (4.5 g, 37.00 mmol), K2CO3 (9.2 g, 66.57 mmol), acetonitrile (100 mL) and a stir bar. After stirring for 20 min, tert-butyl (5-(2-chloroacetamido)-2-methylpyridin-3- yl)carbamate (10.0 g, 33.4 mmol) was added. The resulting mixture was stirred at room temperature overnight. The mixture was concentrated and the residue obtained was purified by silica gel chromatography (0-85% EtOAc/petroleum ether) to afford the tert-butyl (S)-(2- methyl-5-(2-(2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)carbamate as a white solid (10.8 g, 92.9% yield). MS (ESI) calcd. for C18H28N4O3: 348.22 m/z, found: 349.10 [M+H]+. [00368] Step b: Into a 250 mL flask was placed tert-butyl (S)-(2-methyl-5-(2-(2- methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)carbamate (13.0 g, 37.309 mmol), a stir bar and HCl (80 mL, 4 M in 1,4-dioxane). The resulting mixture was stirred at room temperature for 1 h and yellow precipitate formed. The mixture was removed under reduced pressure. The residue obtained was added to Et2O (300 mL) with stirring for 10 min. The mixture was filtered,
washed with Et2O (50 mL×3). The filter cake was dried under vacuum to afford the (S)-N-(5- amino-6-methylpyridin-3-yl)-2-(2-methylpyrrolidin-1-yl)acetamide as a yellow solid ( 8924.9 mg, 91.6 % yield). MS (ESI) calcd. for C13H20N4O: 248.16 m/z, found: 249.10 [M+H]+. Intermediate 5 (R)-N-(5-Amino-6-methylpyridin-3-yl)-2-(2-methylpyrrolidin-1-yl)acetamide
[00369] Step a: A 250 mL flask was charged with (R)-2-methylpyrrolidine hydrochloride (4.5 g, 37.0 mmol), K2CO3 (9.2 g, 66.6 mmol), acetonitrile (100 mL) and a stir bar. After stirring for 20 min, tert-butyl (5-(2-chloroacetamido)-2-methylpyridin-3- yl)carbamate (10.0 g, 33.36 mmol) was added. The resulting mixture was stirred at room temperature overnight. The resulting mixture was concentrated and the residue was purified by silica gel chromatography (0-80% EtOAc/petroleum) to afford the tert-butyl (R)-(2-methyl-5- (2-(2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)carbamate as an off-white solid (11.2 g, 96.4% yield). MS (ESI) calcd. for C18H28N4O3: 348.22 m/z, found: 349.15 [M+H]+. [00370] Step b: Into a 250 mL flask was placed tert-butyl (R)-(2-methyl-5-(2-(2- methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)carbamate (12.0 g, 34.4 mmol), a stir bar and HCl (80 mL, 4 M in 1,4-dioxane). The resulting mixture was stirred at room temperature for 1 h and a yellow precipitate formed. The mixture was concentrated under reduced pressure. The residue was added to DCM (300 mL) with stirring for 10 min. The mixture was filtered and washed with DCM (50 mL×3). The filter cake was dried under vacuum to afford the (R)-N-(5- amino-6-methylpyridin-3-yl)-2-(2-methylpyrrolidin-1-yl)acetamide as yellow solid (8717.9 mg, 95.1 % yield). MS (ESI) calcd. for C13H20N4O: 248.16 m/z, found: 249.10 [M+H]+. Intermediate 6 Ethyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxylate
[00371] A 10-20 mL microwave vial, equipped with a stir bar, was charged with ethyl 6-bromo-[1,2,3]triazolo[1,5-a]pyridine-3-carboxylate (314 mg, 1.16 mmol), 1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (87.6 mg, 0.120 mmol), KOAc (352 mg, 3.55 mmol), bis(pinacolato)diboron (457 mg, 1.76 mmol), and 1,4-dioxane (10 mL). The vial was sealed with a cap. The contents were sparged with nitrogen. The mixture was heated at 98 °C for 6 h and allowed to cool to room temperature. The mixture was filtered through a pad of celite, and pad was washed with DCM. Filtrate was concentrated under reduced pressure to give crude material. The crude residue was purified using silica gel column chromatography with EtOAc and Heptane to give ethyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- [1,2,3]triazolo[1,5-a]pyridine-3-carboxylate (293 mg, 80%) as a yellowish brown solid. LCMS (ESI): mass calcd. for C15H20BN3O4, 317.2; m/z found, 236.1 [M+H]+ (boronic acid).1H NMR (CHLOROFORM-d, 400 MHz) δ 9.14 (t, 1H, J=1.1 Hz), 8.20 (dd, 1H, J=1.0, 8.8 Hz), 7.78 (dd, 1H, J=1.0, 8.8 Hz), 4.51 (q, 2H, J=7.1 Hz), 1.47 (t, 3H, J=7.2 Hz), 1.37 (s, 12H). Intermediate 7 6-Bromo-N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)- [1,2,3]triazolo[1,5-a]pyridine-3-carboxamide
Step a: 6-Bromo-[1,2,3]triazolo[1,5-a]pyridine-3-carboxylic acid
[00372] To a solution of ethyl 6-bromo-[1,2,3]triazolo[1,5-a]pyridine-3-carboxylate (10.0 g, 37.0 mmol) in THF (100 mL) was added a solution of LiOH (1.33 g, 55.5 mmol) in water (50 mL). The reaction was heated at 50 °C for 2.5 h and allowed to cool to room temperature. The mixture was concentrated in vacuo. Additional water (50 mL) was added to the residue. The mixture was acidified to pH = 1 with 6 M HCl (aq). The precipitate was collected by filtration, air-dried, and dried under high vacuum to afford 6-bromo- [1,2,3]triazolo[1,5-a]pyridine-3-carboxylic acid (8.90 g, 99%) as a light yellow solid. LCMS (ESI): mass calcd. for C7H4BrN3O2, 240.9; m/z found, 241.9 [M+H]+. 1H NMR (400 MHz,
DMSO-d6) δ 13.44 (br s, 1H), 9.73 (t, J=1.00 Hz, 1H), 8.11 (dd, J=1.00 Hz, 1H), 7.83 (dd, J=1.00 Hz, 1H). Step b: tert-Butyl (5-(6-bromo-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamido)-6- methylpyridin-3-yl)carbamate
[00373] EDCI (9.87 g, 51.5 mmol) was added to a solution of 6-bromo- [1,2,3]triazolo[1,5-a]pyridine-3-carboxylic acid (8.90 g, 36.8 mmol) and tert-butyl (5-amino- 6-methylpyridin-3-yl)carbamate (7.39 g, 33.1 mmol) in pyridine (100 mL). The reaction proceeded at 25 °C under argon for 18 h. Solvent was removed in vacuo. The residue was taken up in MeOH (100 mL) and stirred for 30 min. The slurry was filtered. The precipitate was collected and washed with MeOH. The solid was air-dried and dried under high vacuum to give tert-butyl (5-(6-bromo-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamido)-6-methylpyridin- 3-yl)carbamate (14.0 g, 85%) as an off-white solid. LCMS (ESI): mass calcd. for C18H19BrN6O3, 446.1; m/z found, 447.1 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 9.77 (s, 1H), 9.55 (br s, 1H), 8.38 (d, J=1.00 Hz, 1H), 8.22 (d, J=1.00 Hz, 1H), 8.08 (br s, 1H), 7.83 (dd, J=1.00 Hz, 1H), 2.39 (s, 3H), 1.50 (s, 9H). Step c: N-(5-Amino-2-methylpyridin-3-yl)-6-bromo-[1,2,3]triazolo[1,5- a]pyridine-3-carboxamide
[00374] To a solution of tert-butyl (5-(6-bromo-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamido)-6-methylpyridin-3-yl)carbamate (320 mg, 0.72 mmol) in DCM (6 mL) was added TFA (3.0 mL, 39 mmol) dropwise. The reaction proceeded for 1 h at room temperature. Excess solvent was removed, and the residue was dried in vacuo to afford N-(5-amino-2- methylpyridin-3-yl)-6-bromo-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide (320 mg, 97%) a yellow solid. LCMS (ESI): mass calcd. for C13H11BrN6O, 346.0; m/z found, 347.0 [M+H]+. Step d: 6-Bromo-N-(5-(2-chloroacetamido)-2-methylpyridin-3-yl)- [1,2,3]triazolo[1,5-a]pyridine-3-carboxamide
[00375] To a solution of N-(5-amino-2-methylpyridin-3-yl)-6-bromo- [1,2,3]triazolo[1,5-a]pyridine-3-carboxamide (7.90 g, 20.6 mmol) in DCM (200 mL) was added TEA (8.6 mL, 62 mmol) followed by the addition of 2-chloroacetyl chloride (2.0 mL, 35 mmol) dropwise. The mixture was stirred at 25 °C under argon for 23 h. Silica gel (5 g) was added, and all solvents were removed in vacuo. The silica gel mesh was loaded on a Redi Sep Rf silica gel cartridge (40 g). The desired product was eluted with EtOAc over 5 min then MeOH/EtOAc (0 - 30%) over 15 min to provide 6-bromo-N-(5-(2-chloroacetamido)-2- methylpyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide (4.2 g, 48%) as a tan solid. LCMS (ESI): mass calcd. for C15H12BrClN6O2, 422.0; m/z found, 423.0 [M+H]+. Step e: 6-Bromo-N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin- 3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide
[00376] To a mixture of 6-bromo-N-(5-(2-chloroacetamido)-2-methylpyridin-3-yl)- [1,2,3]triazolo[1,5-a]pyridine-3-carboxamide (7.00 g, 16.5 mmol) and 3,3-dimethylazetidine hydrochloride (2.41 g, 19.8 mmol) in DMF (100 mL) was added K2CO3 (6.85 g, 49.6 mmol). The mixture was heated at 50 °C under argon for 4.25 h and allowed to cool to room temperature. The mixture was poured into water (150 mL) and stirred for 15 min. Precipitate was collected via filtration, washed with excess water, and air-dried. The collected solid was recrystallized from EtOAc to give 6-bromo-N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2- methylpyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide (2.62 g, 34%) as a tan solid. LCMS (ESI): mass calcd. for C20H22BrN7O2, 471.1; m/z found, 472.2 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 10.31 (s, 1H), 9.80 (s, 1H), 9.7-9.7 (m, 1H), 8.52 (d, 1H, J=2.4 Hz), 8.20 (d, 1H, J=2.4 Hz), 8.16 (dd, 1H, J=0.9, 9.4 Hz), 7.80 (dd, 1H, J=1.5, 9.3 Hz), 3.20 (s, 2H), 3.02 (s, 4H), 2.39 (s, 3H), 1.16 (s, 6H). Intermediate 8 (S)-6-Bromo-N-(2-methyl-5-(2-(2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)- [1,2,3]triazolo[1,5-a]pyridine-3-carboxamide
[00377] A 250 mL round bottom flask, equipped with a stir bar, was charged with 6- bromo-[1,2,3]triazolo[1,5-a]pyridine-3-carboxylic acid (5.29 g, 21.9 mmol), N-(5-amino-6- methyl-3-pyridyl)-2-[(2S)-2-methylpyrrolidin-1-yl]acetamide (5.80 g, 22.8 mmol), EDCI (6.37 g, 33.2 mmol), and pyridine (90 mL). A nitrogen atmosphere was established. The reaction was heated at 60 °C under an argon inlet. After 2 h, the reaction was allowed to cool to room temperature. Pyridine was removed under reduced pressure. The residue was purified using silica gel column chromatography using 2% NH4OH in MeOH and EtOAc. The resulting solid from the purification was washed with water and allowed to air-dry under vacuum to afford (S)-6-bromo-N-(2-methyl-5-(2-(2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)- [1,2,3]triazolo[1,5-a]pyridine-3-carboxamide (6.13 g, 59%) as an off-white solid. LCMS (ESI): mass calcd. for C20H22BrN7O2, 471.1; m/z found, 472.1 [M+H]+. 1H NMR (CHLOROFORM-d, 400 MHz) δ 9.22 (s, 1H), 9.0-9.0 (m, 2H), 8.76 (d, 1H, J=2.4 Hz), 8.69 (d, 1H, J=2.4 Hz), 8.34 (dd, 1H, J=1.0, 9.3 Hz), 7.62 (dd, 1H, J=1.5, 9.3 Hz), 3.45 (d, 1H, J=17.1 Hz), 3.21 (ddd, 1H, J=3.4, 7.9, 9.2 Hz), 3.11 (d, 1H, J=17.1 Hz), 2.6-2.7 (m, 4H), 2.4- 2.5 (m, 1H), 2.0-2.1 (m, 1H), 1.8-1.9 (m, 2H), 1.5-1.6 (m, 1H), 1.15 (d, 3H, J=6.4 Hz). Intermediate 9 6-Bromo-N-(5-(2-((cis-2,6-dimethylmorpholino)acetamido)-2-methylpyridin-3-yl)- [1,2,3]triazolo[1,5-a]pyridine-3-carboxamide
[00378] To a mixture of N-(5-amino-2-methylpyridin-3-yl)-6-bromo- [1,2,3]triazolo[1,5-a]pyridine-3-carboxamide TFA salt (336 mg, 0.730 mmol) and 2-((cis-2,6- dimethylmorpholino)acetic acid (133 mg, 0.770 mmol) was added EDCI (196 mg, 1.02 mmol) and pyridine (4.0 mL). The suspension was stirred at room temperature for 1 h. The mixture was heated at 60 °C for 16 h. Pyridine was removed under reduced pressure. The residue was dissolved in 2 mL of DCM, loaded to a 12 g silica gel column, and purified by silica gel column
chromatography using (MeOH/DCM, 0% => 15%) to afford 6-bromo-N-(5-(2-((cis-2,6- dimethylmorpholino)acetamido)-2-methylpyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide as a yellow solid (103 mg, 28%). LCMS (ESI): mass calcd. for C21H24BrN7O3, 501.1; m/z found, 502.1 [M+H]+. Intermediate 10 (R)-6-Bromo-N-(2-methyl-5-((2-(2-methylpyrrolidin-1-yl)ethyl)carbamoyl)pyridin-3-yl)- [1,2,3]triazolo[1,5-a]pyridine-3-carboxamide
[00379] To a solution of N-(5-amino-2-methylpyridin-3-yl)-6-bromo- [1,2,3]triazolo[1,5-a]pyridine-3-carboxamide (320 mg, 0.7 mmol) in DCM (8 mL) was added DIEA (1.2 mL, 6.9 mmol) followed by 3-chloropropionyl chloride dropwise at 0 °C. The mixture was stirred at room temperature for 2 h and concentrated under reduced pressure. The residue was washed with MeOH to yield a white solid. The white solid was dissolved in DMF. K2CO3 (480 mg, 3.50 mmol) and R-2-methylpyrroline were added. The mixture was heated at 75 °C for 2 h and allowed to cool to room temperature. Solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography using (4 g column, MeOH/DCM 0% => 15%) to yield (R)-6-bromo-N-(2-methyl-5-((2-(2-methylpyrrolidin-1- yl)ethyl)carbamoyl)pyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide (150 mg, 44%) as an orange solid. LCMS (ESI): mass calcd. for C21H24BrN7O2, 485.1; m/z found, 486.1 [M+H]+. Intermediate 11 N-(5-(2-(2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2-methylpyridin-3-yl)-6-bromo- [1,2,3]triazolo[1,5-a]pyridine-3-carboxamide
[00380] To a mixture of N-(5-amino-2-methylpyridin-3-yl)-6-bromo- [1,2,3]triazolo[1,5-a]pyridine-3-carboxamide TFA salt (309 mg, 0.670 mmol) and 2-(2-
azabicyclo[2.2.1]heptan-2-yl)acetic acid (109.2 mg, 0.70 mmol) was added EDCI (180 mg, 0.940 mmol) and pyridine (93.0 mL). The suspension was stirred at room temperature for 1 h. The mixture was heated at 60 °C for 16 h. Pyridine was removed under reduced pressure. The residue was dissolved in 2 mL of DCM, loaded to a 12 g silica gel column, and purified by silica gel column chromatography using (MeOH/DCM, 0% => 15%) to give N-(5-(2-(2- azabicyclo[2.2.1]heptan-2-yl)acetamido)-2-methylpyridin-3-yl)-6-bromo-[1,2,3]triazolo[1,5- a]pyridine-3-carboxamide (170 mg, 48%) as a yellow solid. LCMS (ESI): mass calcd. for C21H22BrN7O2, 483.1; m/z found, 484.0 [M+H]+. Example 1. 7-(1-Methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2-methylpiperidin-1- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
Step a: tert-Butyl (6-methyl-5-nitropyridin-3-yl)carbamate
[00381] To a mixture of 5-bromo-2-methyl-3-nitropyridine (15 g, 69 mmol), tert- butyl carbamate (9.7 g, 83 mmol), XPhos (30 g, 62 mmol) and Cs2CO3 (32 g, 97 mmol) in dioxane (300 mL) was added Pd2(dba)3 (9.5 g, 10 mmol) at room temperature under an atmosphere of nitrogen. The reaction mixture was stirred at 100°C overnight. The reaction was followed by addition of water (200 mL), which was extracted with EtOAc (200 mL x 3). The organic layer was washed with brine (200 mL) and dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give the crude product, which was purified by column chromatography over silica gel (gradient elution: 0~60% ethyl acetate in petroleum ether). The pure fractions were collected and concentrated to dryness in vacuum to give tert-butyl (6- methyl-5-nitropyridin-3-yl)carbamate (10 g, 55%) as a yellow solid. LCMS (ESI): mass calcd. for C11H15N3O4, 253.1; m/z found, 254.1 [M+H]+. Step b: tert-Butyl (5-amino-6-methylpyridin-3-yl)carbamate
To a solution of tert-butyl (6-methyl-5-nitropyridin-3-yl)carbamate (3.0 g, 12 mmol) in MeOH (30 mL) was added Pd/C (1.0 g, 10%). The resulting mixture was stirred at room temperature under hydrogen for 16 h. The reaction mixture was filtered. The filtrate was concentrated to dryness to give crude tert-butyl (5-amino-6-methylpyridin-3-yl)carbamate (2.6 g, 98%) as a yellow solid.1H NMR (400 MHz, DMSO-d4) δ 9.14 (br s, 1H), 7.68 (d, J=2.15 Hz, 1H), 7.19 (br s, 1H), 4.99 (s, 2H), 2.17 (s, 3H), 1.46 (s, 9H). Step c: Lithium 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate
[00382] To a solution of 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate (3.0 g, 9.5 mmol) in THF (90 mL) was added a solution of LiOH (399 mg, 9.5 mmol) in H2O (30 mL). The reaction was stirred at room temperature for 1 hr. The mixture was concentrated in vacuo to give crude product, lithium 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate (3.1 g, crude), as a red solid. LCMS (ESI): mass calcd. for C7H3BrN3O2H, 242.0; m/z found, 243.9 [M+2]+. Step d: tert-Butyl (5-(7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamido)-6- methylpyridin-3-yl)carbamate
[00383] To a mixture of lithium 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3- carboxylate (4.0 g, 16 mmol) in DMF (150 mL) was added tert-butyl (5-amino-6- methylpyridin-3-yl)carbamate (2.5 g, 9.6 mmol) and DIPEA (8.9 mL, 48 mmol). The mixture was stirred at room temperature for 10 min. PyBop (11 g, 24 mmol) was added slowly at 0°C and the mixture was stirred at room temperature overnight. The reaction was followed by addition of water (20 mL), which was extracted with DCM (30 mL x 3). The organic layer was washed with brine (30 mL) and dried over anhydrous Na2SO4 and concentrated in vacuo to give the crude product as pink solid. The product was purified by column chromatography over
silica gel (gradient elution: 0~60% ethyl acetate in petroleum ether) to give the desired product tert-butyl (5-(7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamido)-6-methylpyridin-3- yl)carbamate as a pink solid. LCMS (ESI): mass calcd. for C18H19BrN6O3, 446.1; m/z found, 447.0 [M+H]+. Step e: tert-Butyl (6-methyl-5-(7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3- a]pyridine-3-carboxamido)pyridin-3-yl)carbamate
[00384] To a mixture of tert-butyl (5-(7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamido)-6-methylpyridin-3-yl)carbamate (3.3 g, 5.9 mmol), 1-methyl-4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.2 g, 5.9 mmol) and Cs2CO3 (5.7 g, 18 mmol) in a mixture of 1,4-dioxane/H2O (150 mL, 4:1) was added PdCl2(dppf)·CH2Cl2 (720 mg, 0.88 mmol) under a nitrogen atmosphere. The mixture was stirred at 100°C for 15 h. The reaction mixture was concentrated under vacuum to give a black solid which was washed with ethyl acetate/water (250 mL, 1:1) to give tert-butyl (6-methyl-5-(7-(1-methyl-1H-pyrazol-4- yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamido)pyridin-3-yl)carbamate (2.9 g, 99%) as a gray solid. LCMS (ESI): mass calcd. for C22H24N8O3, 448.2; m/z found, 449.1 [M+H]+. Step f: N-(5-amino-2-methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00385] A solution of tert-butyl (6-methyl-5-(7-(1-methyl-1H-pyrazol-4-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamido)pyridin-3-yl)carbamate (2.9 g, 5.9 mmol) in HCl/dioxane (44 mL, 4M) was stirred at room temperature for 1 h. The mixture was concentrated under vacuum to give crude N-(5-amino-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (2.5 g, 67%) as gray solid. LCMS (ESI): mass calcd. for C17H16N8O, 348.1; m/z found, 349.1[M+H]+. Step g: N-(5-(2-Chloroacetamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00386] To a mixture of N-(5-amino-2-methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol- 4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (0.8 g, 1.9 mmol) and NaHCO3 (319 mg, 3.8 mmol) in DMF (10 mL) was added 2-chloroacetyl chloride (0.23 mL, 0.8 mmol) dropwise at 0°C. The mixture was stirred at room temperature for 2 h. Saturated NaHCO3 (15 mL) was added slowly. The mixture was extracted with DCM/MeOH (5/1, 20 mL x 3). The organic layer was dried over anhydrous MgSO4, filtered and evaporated to afford crude of N-(5-(2- chloroacetamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3- a]pyridine-3-carboxamide (0.3 g, 34%) as yellow solid. LCMS (ESI): mass calcd. for C19H17ClN8O2, 424.1; m/z found, 425.0 [M+H]+. Step h: N-(5-(2-chloroacetamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00387] To a solution of N-(5-(2-chloroacetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (80 mg, 0.16 mmol) and 2-methylpiperidine (20 mg, 0.20 mmol) in DMF (2 mL) was added K2CO3 (68 mg, 0.49 mmol). The reaction mixture was stirred at 50°C for 5 h. The reaction mixture was purified by preparative high-performance liquid chromatography over column: Boston Prime C18150 x 30mm,5µm to give the title compound N-(5-(2-chloroacetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (20 mg, 24%) as a white solid. LCMS (ESI): mass calcd. for C25H29N9O2, 487.2; m/z found, 488.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.73 (s, 1H), 9.89 (s, 1H), 9.13 (d, J=7.15 Hz, 1H), 8.62 (d, J=2.03 Hz, 1H), 8.48 (s, 1H), 8.28 (d, J=1.91 Hz, 1H), 8.20 (d, J=5.36 Hz, 2H), 7.54 (d, J=7.51 Hz, 1H), 3.92 (s, 3H), 3.26 - 3.32 (m, 2H), 3.09 (d, J=16.21 Hz, 1H), 2.78 - 2.85 (m, 1H), 2.46 - 2.47 (m, 3H), 2.31 - 2.40 (m, 1H), 1.50 - 1.64 (m, 4H), 1.26 - 1.37 (m, 2H), 1.04 (d, J=6.32 Hz, 3H).
[00388] The following tabulated examples were prepared by a similar method of Example 1 from the appropriate starting materials.
Example 71.
N-(5-(2-(4,4-Dimethylpiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
Step a: 2-Chloro-N-(6-methyl-5-nitropyridin-3-yl)acetamide
[00389] To a solution of 6-methyl-5-nitropyridin-3-amine (300 mg, 1.876 mmol) and Et3N (0.5mL, 3.751mmol) in DCM (3 mL) was added 2-chloroacetyl chloride (0.22 mL, 0.224mmol) at 0 °C. The mixture was allowed to warm to 25 °C for 1 h. The reaction mixture was washed with water (2 mL x 2). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated in vacuo to afford crude product as a black oil. LCMS (ESI): mass calcd. for C8H8ClN3O3, 229.0; m/z found, 229.8 [M+H]+. Step e: 2-(4,4-Dimethylpiperidin-1-yl)-N-(6-methyl-5-nitropyridin-3- yl)acetamide
[00390] To a mixture of 2-chloro-N-(6-methyl-5-nitropyridin-3-yl)acetamide (300 mg, 1.0 mmol) and K2CO3 (430 mg, 3.1 mmoL) in DMF (5 mL) was added 4,4- dimethylpiperidine (186 mg, 1.2 mmol). The reaction mixture was stirred at 25°C for 16 h. The reaction mixture was filtered and the filtrate was concentrated under vacuum to give crude product, which was purified by silica gel chromatography (petroleum ether/ethyl acetate from 100/0 to 0/100). The product fractions were collected and the solvent was evaporated to give 2-(4,4-dimethylpiperidin-1-yl)-N-(6-methyl-5-nitropyridin-3-yl)acetamide (245 mg, 67%) as yellow solid. LCMS (ESI): mass calcd. for C15H22N4O3, 306.2; m/z found, 307.0 [M+H]+. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 9.52 (br s, 1H), 8.70 - 8.79 (m, 2H), 3.15 (s, 2H), 2.79 (s, 3H), 2.52 - 2.59 (m, 4H), 1.42 - 1.50 (m, 4H), 0.97 (s, 6H). Step f: N-(5-amino-6-methylpyridin-3-yl)-2-(4,4-dimethylpiperidin-1- yl)acetamide
[00391] To a solution of 2-(4,4-dimethylpiperidin-1-yl)-N-(6-methyl-5-nitropyridin- 3-yl)acetamide (188 mg, 0.56 mmol) in EtOH (5 mL) and H2O (1 mL) was added Fe (155 mg, 2.8 mmol) and NH4Cl (149 mg, 2.8 mmol). The mixture was stirred at 80°C for 2.5 h. The reaction mixture was cooled down to room temperature, ethyl acetate (4 mL) was added. The mixture was filtered through Celite, rinsed with DCM (5 mL). Solvent from the filtrate was removed under reduced pressure to give crude compound. Ethyl acetate (5 mL) were added to the compound, the mixture was washed with water (3 mL x 2). The organic layer was dried over MgSO4 and concentrated in vacuo to give N-(5-amino-6-methylpyridin-3-yl)-2-(4,4- dimethylpiperidin-1-yl)acetamide (132 mg, 77%) as white solid. LCMS (ESI): mass calcd. for C15H24N4O, 276.2; m/z found, 277.1 [M+H]+. Step g: 7-bromo-N-(5-(2-(4,4-dimethylpiperidin-1-yl)acetamido)-2- methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00392] To a solution of 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid (110 mg, 0.40 mmol), N-(5-amino-6-methylpyridin-3-yl)-2-(4,4-dimethylpiperidin-1- yl)acetamide (121 mg, 0.44 mmol), DIEA (0.21mL,1.2 mmol) in DMF (2 mL) was added PhI(OAC)2 (278 mg, 0.60 mmol) at 0°C. The mixture stirred at 25°C for 12 h. Water (1 mL) was added. Extract was obtained with DCM (1 mL x 3). The organic layer was washed with brine (2 mL), dried over Na2SO4 and concentrated in vacuo to give a crude product as yellow oil. The product was purified by silica gel chromatography (dichloromethane/methanol from 100/0 to 90/10). Product fractions were collected and the solvent was evaporated to give 7- bromo-N-(5-(2-(4,4-dimethylpiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (194 mg, 98%) as a yellow oil. LCMS (ESI): mass calcd. for C22H26BrN7O2, 501.1; m/z found, 501.8 [M+H]+. Step h: N-(5-(2-(4,4-dimethylpiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00393] To a mixture of 7-bromo-N-(5-(2-(4,4-dimethylpiperidin-1-yl)acetamido)-2- methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (150 mg,0.3 mmol), 1- methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (75 mg, 0.36 mmol) and Cs2CO3 (293 mg, 0.90 mmol) in 1,4-dioxane:H2O (4:1) (10 mL) was added Pd(dppf)Cl2·CH2Cl2 (12 mg,0.02 mmol) at room temperature. The reaction mixture was purged with N2 for 2 min. The mixture was stirred at 90°C for 16 h under nitrogen. The mixture was allowed to cool to room temperature. The reaction mixture was filtered and the filtrate was concentrated under vacuum to give crude product, which was purified by preparative high- performance liquid chromatography over column: Xtimate C18100 x 30 mm, 3 µm to give the title compound N-(5-(2-(4,4-dimethylpiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (43 mg, 28%) as a white solid. LCMS (ESI): mass calcd. for C26H31N9O2, 501.3; m/z found, 502.2 [M+H]+. 1H NMR (400 MHz, METHANOL-d4) δ 9.23 (d, J=7.06 Hz, 1H), 8.60 (d, J=1.98 Hz, 1H), 8.50 (s, 1H), 8.28 (s, 1H), 7.98 - 8.11 (m, 2H), 7.48 (br d, J=7.50 Hz, 1H), 3.96 (s, 3H), 3.47 (br s, 2H), 2.80 (br s, 4H), 2.56 (s, 3H), 1.55 (br t, J=5.29 Hz, 4H), 0.99 (s, 6H). [00394] Example 72 was prepared by a similar method of example 71 from the appropriate starting materials.
Example 73. N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-(2-
hydroxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
Step a: N-(5-amino-2-methylpyridin-3-yl)-7-bromo-[1,2,4]triazolo[4,3- a]pyridine-3-carboxamide
[00395] To a mixture of tert-butyl (5-(7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamido)-6-methylpyridin-3-yl)carbamate (4 g, 6.6 mmol) in HCl/dioxane (49 mL, 4 M, 197 mmol) was stirred at 25°C for 16 h. The desired fractions were concentrated to dryness under vacuum to give N-(5-amino-2-methylpyridin-3-yl)-7-bromo-[1,2,4]triazolo[4,3- a]pyridine-3-carboxamide (4 g, crude) as a white solid. LCMS (ESI): mass calcd. for C13H11BrN6O, 346.0; m/z found, 347.0 [M+H]+. Step b: 7-Bromo-N-(5-(2-chloroacetamido)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00396] To a mixture of N-(5-amino-2-methylpyridin-3-yl)-7-bromo- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (4 g, 8.3 mmol) and NaHCO3 (1.4 g, 17 mmoL) in DMF (100 mL) was added 2-chloroacetyl chloride (0.99 mL, 12 mmol) dropwise at 0°C. The reaction was allowed to warm to room temperature with stirring. After 2 h, the reaction mixture was filtered. The filtrate was concentrated in vacuo to give a yellow solid. Saturated aqueous NaHCO3 (20 mL) was added to the yellow solid slowly to obtain pH~7 while cooled with an ice bath. The mixture was triturated with water and the filter cake was dried in vacuum to give 7-bromo-N-(5-(2-chloroacetamido)-2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3- a]pyridine-3-carboxamide (4.1 g, crude) as a yellow solid. LCMS (ESI): mass calcd. for C15H12BrClN6O2, 423.6; m/z found, 422.9 [M+H]+.
Step c: N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7- bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00397] To a mixture of 7-bromo-N-(5-(2-chloroacetamido)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (3.0 g, 6.7 mmol), K2CO3 (2.8 g, 20 mmoL) and NaI (0.6 g, 4.0 mmol) in DMF (100 mL) was added 7-azaspiro[3.5]nonane (1.3 g, 8.0 mmol). The reaction mixture was stirred at 50°C for 2 h before cooling to room-temperature. The reaction mixture was filtered and the filtrate was concentrated under vacuum to give crude product, which was triturated with MTBE (10 mL) and the filter cake was dried in vacuum to give N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-bromo- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (2.4 g, 65%) as yellow solid. LCMS (ESI): mass calcd. for C23H26BrN7O2, 511.1; m/z found, 512.1 [M+H]+. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 9.32 (br s, 1H), 9.21 (d, J=7.50 Hz, 1H), 9.15 (br s, 1H), 8.89 (d, J=2.43 Hz, 1H), 8.45 (d, J=2.21 Hz, 1H), 8.12 (s, 1H), 7.18 (dd, J=7.39, 1.65 Hz, 1H), 3.08 (s, 2H), 2.63 (s, 3H), 2.47 (br s, 4H), 1.83 - 1.94 (m, 2H), 1.72 - 1.81 (m, 4H), 1.67 (br t, J=5.40 Hz, 4H). Step d: N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7- (1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide O
[00398] To a mixture of N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2- methylpyridin-3-yl)-7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (100 mg, 0.18 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (130 mg, 0.55 mmol) and Cs2CO3 (178 mg, 0.55 mmol) in 1,4-dioxane:H2O (4:1) (5 mL) was added Pd(dppf)Cl2·CH2Cl2 (22 mg,0.03 mmol) at room temperature. The reaction mixture was purged with N2 for 2 min. The reaction mixture was stirred at 100°C for 16 h under nitrogen. The reaction mixture was allowed to cool to room temperature. The mixture was filtered and
the filtrate was concentrated under vacuum to give crude product, which was purified by preparative high-performance liquid chromatography over column: Welch Xtimate C18150 x 25 mm, 5 µm to give the title compound N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2- methylpyridin-3-yl)-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide (49 mg, 50%) as a yellow solid. LCMS (ESI): mass calcd. for C28H33N9O3, 543.3; m/z found, 544.2 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 10.69 (s, 1H), 9.89 (s, 1H), 9.08 (d, J=7.28 Hz, 1H), 8.57 (d, J=2.21 Hz, 1H), 8.46 (s, 1H), 8.23 (d, J=1.98 Hz, 1H), 8.17 - 8.21 (m, 2H), 7.52 (d, J=7.28 Hz, 1H), 4.95 (br s, 1H), 4.16 (t, J=5.51 Hz, 2H), 3.75 (t, J=5.40 Hz, 2H), 3.05 (s, 2H), 2.42 (s, 3H), 2.36 (br s, 4H), 1.75 - 1.84 (m, 2H), 1.64 - 1.71 (m, 4H), 1.57 (br t, J=5.29 Hz, 4H). [00399] The following tabulated examples were prepared by a similar method of Example 73 from the appropriate starting materials.
Example 93 (R)-7-(6-(3-hydroxyoxetan-3-yl)pyridin-3-yl)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
Step a: (R)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)- 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide
[00400] To a mixture of (R)-7-bromo-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (200 mg, 0.42 mmol) in 1,4-dioxane (12 mL) was added 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2- dioxaborolane) (660 mg, 2.6 mmol), potassium acetate (249 mg, 2.5 mmol), Pd2(dba)3 (155 mg, 0.17 mmol) and PCy3 (134 mg, 0.33 mmol). The resulting mixture was heated at 100 °C and stirred for 15 hours under nitrogen. The mixture was concentrated under vacuum to afford (R)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-7-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (200 mg, 50%) as a black solid. The black solid was used for the next step. LCMS (ESI): mass calcd. For C26H34BN7O4, 519.3; m/z found, 520.4 [M+H]+. Step b: (R)-7-(6-(3-hydroxyoxetan-3-yl)pyridin-3-yl)-N-(2-methyl-5-(2-(2- methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide
[00401] To a mixture of (R)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (200 mg, 0.39 mmol) in 1,4-dioxane:H2O (4:1) (10 mL) was added 3-(5-bromopyridin-2-yl)oxetan-3-ol (98 mg, 0.43 mmol), potassium phosphate (245 mg, 1.2 mmol) and Pd-118 (51 mg, 0.08 mmol). The resulting mixture was heated at 80 °C and stirred for 2 h under nitrogen. The reaction solution was concentrated in vacuo to give a brown solid. The brown solid was subjected to column chromatography over silica gel (gradient: DCM:MeOH from 100:0 to 80:20). The pure fractions were collected and concentrated to dryness in vacuo to give (R)-7-(6-(3-hydroxyoxetan-3-yl)pyridin-3-yl)-N-(2- methyl-5-(2-(2-methylpyrrolidin-1-yl)acetamido) pyridine -3-yl)-[1,2,4]triazolo[4,3- a]pyridine-3-carboxamide (32 mg, 14%) as a white solid. LCMS (ESI): mass calcd. for C28H30N8O4, 542.2; m/z found, 543.2 [M+H]+. 1H NMR (400MHz, METHANOL- d4) δ 9.41 (d, J=7.5 Hz, 1H), 9.06 (d, J=1.8 Hz, 1H), 8.68 - 8.61 (m, 2H), 8.54 (d, J=2.0 Hz, 1 H), 8.31 - 8.18 (m,2H), 8.05 (dd, J=1.5, 7.5 Hz, 1H), 4.99 (d, J=7.0 Hz, 2H), 3.62 (d, J=15.8 Hz, 1H), 3.32 - 3.32 (m, 2H), 3.32 - 3.29 (m, 1H), 3.17 (d, J=15.8 Hz, 1H),2.66 (br d, J=7.3 H z, 1H), 2.61 (s, 3H), 2.46 (q, J=8.6 Hz, 1H), 2.11 - 1.99 (m, 1H), 1.96 - 1.76 (m, 2H), 1.63 - 1 .50 (m, 1H), 1.20 (d, J=6.0 Hz, 3H). [00402] The following tabulated examples were prepared by a similar method of Example 93 from the appropriate starting compounds.
Example 100 N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(oxetan-3- ylamino)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00403] To a mixture of N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2- methylpyridin-3-yl)-7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (200 mg, 0.38 mmol), oxetan-3-amine (42 mg 0.58 mmol) and Cs2CO3 (375 mg, 1.2 mmol) in DMF (10 mL) was added Pd2(dba)3 (70 mg, 0.08 mmol) and Xantphos (44 mg, 0.08 mmol) at room temperature. The reaction mixture was purged with nitrogen for 2 min. The reaction mixture was stirred at 80 °C for 2 h under nitrogen. The mixture was allowed to cool to room temperature and filtered. The filtrate was concentrated under vacuum to give crude product, which was purified by preparative high-performance liquid chromatography over column: Xtimate C18150 x 40 mm, 5 µm to give N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2- methylpyridin-3-yl)-7-(oxetan-3-ylamino)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (37 mg, 17%) as a white solid. LCMS (ESI): mass calcd. for C26H32N8O3, 504.3; m/z found, 505.1
[M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.47 (s, 1H), 9.90 (s, 1H), 8.87 (d, J=7.51 Hz, 1H), 8.59 (d, J=2.27 Hz, 1H), 8.26 (d, J=2.26 Hz, 1H), 7.69 (d, J=6.08 Hz, 1H), 6.75 (dd, J=7.57, 2.21 Hz, 1H), 6.39 (d, J=1.91 Hz, 1H), 4.94 (t, J=6.62 Hz, 2H), 4.69 (br d, J=6.32 Hz, 1H), 4.48 (t, J=6.08 Hz, 2H), 3.01 - 3.18 (m, 2H), 2.37 - 2.46 (m, 7H), 1.79 - 1.87 (m, 2H), 1.69 - 1.75 (m, 4H), 1.61 (t, J=5.36 Hz, 4H). [00404] The following tabulated examples were prepared by a similar method of Example 100 from the appropriate starting materials.
Example 104 N-(5-((2-(3,3-dimethylmorpholino)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
Step a: Ethyl 5-(7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamido)-6- methylnicotinate
[00405] To a solution of 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid (5.3 g, 19.9 mmol), ethyl 5-amino-6-methylnicotinate (4.0 g, 21.9 mmol) and DIEA (10.5 mL, 59.8 mmol) in DMF (160 mL) was added Pybrop (11.2 g, 23.9 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction was followed by addition of water (150 mL), which was extracted with EtOAc (200 mL x 3). The organic layer was washed with brine (200 mL), dried over anhydrous Na2SO4 and concentrated in vacuo to give crude product as yellow oil. The product was purified by silica gel chromatography (petroleum ether/ethyl acetate from 100/0 to 0/100). The product fractions were collected, and the solvent was evaporated to give ethyl 5-(7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamido)-6-methylnicotinate (2.6 g, 6.1 mmol, 31% yield) as white a solid. LCMS (ESI): mass calcd. for C16H14BrN5O3: 403.0; m/z found: 405.0 [M+H]+. Step b: Ethyl 6-methyl-5-(7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3- a]pyridine-3-carboxamido)nicotinate
[00406] To a solution of ethyl 5-(7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamido)-6-methylnicotinate (2.6 g, 6.6 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H-pyrazole (1.5 g, 7.3 mmol) and K2CO3 (2.5 mL, 18.2 mmol) in 1,4- dioxane (128 mL) and H2O (32 mL) was added [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (247.8 mg, 0.3 mmol) at room temperature. The resulting mixture was stirred at 90 °C overnight. Water (100 mL) was added to the mixture, and the mixture was extracted with ethyl acetate (150 mL x 3). The combined organic layers were washed with saturated NaCl (100 mL x 3) and concentrated under reduced pressure to give the crude product as a yellow solid, which was purified by column on silica gel (eluent: DCM/MeOH =0/100 to 10/90). The pure fractions were collected, and the solvent was removed to give the product as a white solid which was purified by preparative high- performance liquid chromatography over column: YMC-Triart Prep C18150 x 40 mm, 7 µm to give ethyl 6-methyl-5-(7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamido)nicotinate (1.8 g, 4.4 mmol, 73% yield) as a white solid. LCMS (ESI): mass for C20H19N7O3: 405.2; m/z found: 406.1 [M+H]+. Step c: 6-Methyl-5-(7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine- 3-carboxamido)nicotinic acid
[00407] To a solution of ethyl 6-methyl-5-(7-(1-methyl-1H-pyrazol-4-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamido)nicotinate (1.0 g, 2.5 mmol) in mixture of THF:H2O (3:1) (20 mL) was added LiOH (155.3 mg, 3.7 mmol). The mixture was stirred at room temperature for 1 h. The mixture was evaporated under vacuum and purified by preparative high-performance liquid chromatography over column: YMC Exphere C18250 x 50 mm, 10 µm to give 6-methyl-5-(7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3- a]pyridine-3-carboxamido)nicotinic acid (970 g, 2.6 mmol, 97% yield) as a white solid. LCMS (ESI): mass for C18H15N7O3: 377.1; m/z found: 378.1 [M+H]+. Step d: N-(5-((2-(3,3-dimethylmorpholino)ethyl)carbamoyl)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00408] To a mixture of 6-methyl-5-(7-(1-methyl-1H-pyrazol-4-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamido)nicotinic acid (100 mg, 0.3 mmol), 2-(3,3- dimethylmorpholino)ethanamine (54.2 mg, 0.4 mmol) and DIEA (174 µL, 1.1 mmol) in DMF (1.5 mL) was added HATU (150.3 mg, 0.4 mmol) at room temperature. The resulting mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo to give the crude product as a yellow solid, which was purified by preparative high-performance liquid chromatography over column: Phenomenex Gemini-NX 80 x 30 mm, 3 µm to give N- (5-((2-(3,3-dimethylmorpholino)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (45.5 mg, 0.1 mmol, 16% yield) as a white solid. LCMS (ESI): mass calcd. for C26H31 N9O3: 517.3; m/z found: 518.3 [M+H]+.1H NMR (400 MHz, METHANOL-d4) δ 9.28 (d, J=7.28 Hz, 1H), 8.80 - 8.83 (m, 1H), 8.58 - 8.61 (m, 1H), 8.32 (s, 1H), 8.27 - 8.31 (m, 1H), 8.12 -8.14 (m, 1H), 8.07 (s, 1H), 7.54 (d, J=7.70 Hz, 1H), 4.00 (s, 3H), 3.79 - 3.85 (m, 2H), 3.57 (t, J=6.53 Hz, 2H), 3.45 (s, 2H), 2.82 - 2.95 (m, 4H), 2.71(s, 3H), 1.14 (s, 6H). [00409] The following tabulated examples were prepared by a similar method of Example 104 from the appropriate starting materials.
Example 142 N-(5-((2-(8-oxa-1-azaspiro[4.5]decan-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
Step a: N-(5-((2-(8-oxa-1-azaspiro[4.5]decan-1-yl)ethyl)carbamoyl)-2- methylpyridin-3-yl)-7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00411] To a solution of lithium 5-(7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamido)-6-methylnicotinate (180 mg, 0.22 mmol), 2-(8-oxa-1-azaspiro[4.5]decan-1- yl)ethanamine (40 mg, 0.22 mmol) and DIEA (0.14 mL, 0.86 mmol) in DMF (6 mL) was added PyBrOP (200 mg, 0.43 mmol). The resulting mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated to dryness in vacuum give a yellow oil. The yellow oil was subjected to column chromatography over silica gel (gradient elution: 0~50% methanol in dichloromethane). The pure fractions were collected and concentrated to dryness in vacuum to give N-(5-((2-(8-oxa-1-azaspiro[4.5]decan-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7- bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (140 mg, 99% yield) as a yellow solid. LCMS (ESI): mass calcd. for C24H28BrN7O3: 542.428; m/z found, 543.9 [M+H]+. Step b: N-(5-((2-(8-oxa-1-azaspiro[4.5]decan-1-yl)ethyl)carbamoyl)-2- methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide
[00412] To a solution of N-(5-((2-(8-oxa-1-azaspiro[4.5]decan-1- yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide (130 mg, 0.20 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 1H-pyrazole (50 mg, 0.24 mmol) and K2CO3 (82 mg, 0.60 mmol) in 1,4-dioxane/H2O (5 mL,
4:1) was added PdCl2(dppf).CH2Cl2 (8.1 mg, 0.01 mmol) at room-temperature under an atmosphere of nitrogen. The resulting mixture was stirred at 90 °C for 2 h. Water (10 mL) was added to the mixture, and the mixture was extracted with DCM (10 mL × 3). The combined organic layers were concentrated under reduced pressure to give a yellow oil. The crude product was purified by preparative high-performance liquid chromatography over column: DAICEL CHIRALCEL OJ-H (250 x 30 mm, 5 µm) to give N-(5-((2-(8-oxa-1- azaspiro[4.5]decan-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol-4- yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (12 mg, 65%) as a white solid. LCMS (ESI): mass calcd. for C28H33N9O3: 543.3; m/z found, 544.2 [M+H]+. 1H NMR (400 MHz, METHANOL-d4) δ 9.25 (d, J=7.28 Hz, 1H), 8.77 (d, J=1.98 Hz, 1H), 8.54 (d, J=1.76 Hz, 1H), 8.30 (s, 1H), 8.10 (s, 1H), 8.05 (s, 1H), 7.52 (dd, J=7.28, 1.54 Hz, 1H), 3.98 (s, 3H), 3.91 (br dd, J=11.47, 4.63 Hz, 2H), 3.57 - 3.44 (m, 4H), 3.00 - 2.88 (m, 2H), 2.76 (t, J=6.84 Hz, 2H), 2.68 (s, 3H), 1.94 - 1.83 (m, 4H), 1.77 (td, J=12.90, 5.07 Hz, 2H), 1.33 - 1.21 (m, 4H). [00413] The following tabulated examples were prepared by a similar method of Example 142 from the appropriate starting materials.
Example 145 2-(4-(3-((5-((2-(2,2-Dimethylpyrrolidin-1- yl)ethyl)carbamoyl)-2-methylpyridin-3- yl)carbamoyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl)acetic acid
Step a: 5-(7-Bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamido)-6- methylnicotinic acid
[00414] To a solution of ethyl 5-(7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamido)-6-methylnicotinate (300 mg, 0.62 mmol) in THF (3 mL) and H2O (1 mL) was added LiOH·H2O (26 mg, 0.62 mmol) at room temperature. The mixture was stirred at room temperature for 4 h. The reaction mixture was poured into 10 mL of ice-water carefully and acidified with 1N HCl to pH = 5. The mixture was filtered, and the filter cake was rinsed with H2O (10 mL). The filter cake was dried in vacuo to afford 5-(7-bromo-[1,2,4]triazolo[4,3- a]pyridine-3-carboxamido)-6-methylnicotinic acid (280 mg, 107%) as a white solid. Step b: 7-Bromo-N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2- methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00415] To a solution of 5-(7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamido)- 6-methylnicotinic acid (227 mg, 0.54 mmol), 2-(2,2-dimethylpyrrolidin-1-yl)ethanamine (84 mg, 0.59 mmol) and DIEA (0.28 mL, 1.6 mmol) in DMF (4 mL) was added PyBrOP (376 mg, 0.8 mmol) at room temperature. The mixture stirred at room temperature for 12 h and concentrated under vacuum to give the crude product, which was purified by column
chromatography over silica gel (eluent: dichloromethane/methanol from 100:0 to 80:20) to give 7-bromo-N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (240 mg, 86%) as a yellow solid. Step c: 2-(4-(3-((5-((2-(2,2-Dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2- methylpyridin-3-yl)carbamoyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1- yl)acetic acid
[00416] To a solution of 7-bromo-N-(5-((2-(2,2-dimethylpyrrolidin-1- yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (190 mg, 0.37 mmol), 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetic acid (117 mg, 0.44 mmol) and NaHCO3 (92 mg, 1.1 mmol) in H2O/1,4-dioxane (10 mL, 1:4) was added PdCl2(dppf).CH2Cl2 (30 mg, 0.037 mmol). The mixture stirred at 90 °C for 15 h and concentrated under vacuum to give the crude product, which was purified by preparative high- performance liquid chromatography over column: Welch Xtimate C18150 x 30 mm, 5 µm to give 2-(4-(3-((5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3- yl)carbamoyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl)acetic acid (37.6 mg, 18%) as a white solid. LCMS (ESI): mass calcd. for C27H31N9O4: 545.2; m/z found, 546.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.86 (s, 1H) 9.08 (br d,J=7.03 Hz, 1H) 8.88 (br d, J=4.17 Hz, 1H) 8.82 (d, J=1.91 Hz, 1H) 8.37 (br s, 1H) 8.30 (d, J=1.43 Hz, 1H) 8.10 - 8.18 (m, 2H) 7.47(br d, J=5.36 Hz, 1H) 7.47(br d, J=5.36 Hz, 1H) 4.84 (br s, 2H) 3.05 - 3.16 (m, 1H) 2.77 - 2.88 (m, 2H) 2.57 (s, 4H) 1.65 - 1.88 (m, 5H) 1.09 (br s, 6H). [00417] The following tabulated examples were prepared by a similar method of Example 145 from the appropriate starting materials.
Example 148 N-(5-(3-(6-azaspiro[2.5]octan-6-yl)propanamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
Step a: N-(5-acrylamido-2-methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00418] To a solution of N-(5-amino-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (300 mg, 0.71 mmol) and 3- chloropropanoyl chloride (68 uL, 0.71 mmol) in DCM (2 mL) cooled to 0 °C was added TEA (477 uL, 3.6 mmol) dropwise. The reaction was allowed to warm to 25 °C; the reaction
proceeded for 12 h. The mixture was dried in vacuo to afford N-(5-acrylamido-2- methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide (300 mg, 8.4%) as a solid. Step b: N-(5-(3-(6-azaspiro[2.5]octan-6-yl)propanamido)-2-methylpyridin-3-yl)- 7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00419] To a solution of N-(5-acrylamido-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (100 mg, 0.12 mmol) and 6- azaspiro[2.5]octane (38.6 mg, 0.26 mmol) in CH3CN (2 mL) was added DBU (106 uL, 0.71 mmol) (dropwise). The mixture stirred at 80 °C for 12 h and concentrated under vacuum to give the crude product, which was purified by preparative high-performance liquid chromatography over column: Phenomenex Gemini-NX 80 x 40 mm, 3 µm to give N-(5-(3-(6- azaspiro[2.5]octan-6-yl)propanamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (35 mg, 57%) as a white solid. LCMS (ESI): mass calcd. for C27H31N9O2: 513.3; m/z found, 514.1 [M+H]+.1H NMR (400 MHz, DMSO- d6) δ 10.43 (s, 1H) 10.15 (s, 1H) 8.84 (d, J=7.50 Hz, 1H) 8.27 (d, J=2.20 Hz, 1H) 8.20 (s, 1H) 7.96 (d, J=1.98 Hz, 1H) 7.92 (d, J=5.29 Hz, 2H) 7.26 (dd, J=7.28, 1.54 Hz, 1H) 2.25 - 2.64 (m, 8H) 3.64 (s, 3H) 2.18 (s, 3H) 0.91 - 1.22 (m, 4H) 0.00 (s, 4H). [00420] The following tabulated examples were prepared by a similar method of Example 148 from the appropriate starting materials.
Example 162 N-(5-(3-(cyclobutyl(cyclopentyl)amino)propanamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00421] N-(5-amino-2-methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (120 mg, 0.3 mmol), 3- (cyclobutyl(cyclopentyl)amino)propanoic (61.6 mg, 0.3 mmol) and TEA (198 μL, 1.4 mmol) were dissolved in DMSO (3 mL). The mixture was stirred at room temperature for 30 min. T3P (543.7 mg, 0.85 mmol) was added slowly. The mixture was stirred at 50 °C overnight. The filtrate was concentrated to afford crude product. The crude product was purified by preparative high-performance liquid chromatography over column: Phenomenex Gemini-NX C1875 x 30 mm, 3 µm to give N-(5-(3-(cyclobutyl(cyclopentyl)amino)propanamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (11.7 mg, 7.4%) as a white solid. LCMS (ESI): mass calcd. for C29H35N9O2: 541.3; m/z found, 542.4 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 10.65 (s, 1H), 10.23 (br s, 1H), 9.08 (d, J=7.28 Hz, 1H) , 8.43 (s, 2H), 8.11 - 8.20 (m, 3H), 7.50 (d, J=7.28 Hz, 1H), 3.88 (s, 3H) , 3.08 - 3.22 (m, 2H), 2.96 (br s, 1H), 2.80 (br s, 1H), 2.41 - 2.43 (m, 3H), 1.77 - 2.01 (m, 4H), 1.61 - 1.74 (m, 2H) 1.15 - 1.60 (m, 10H). [00422] The compounds of the following tabulated examples were prepared by a similar method of Example 162 from the appropriate starting materials.
Example 177 (S)-N-(2-methyl-5-(2-(1-methylpyrrolidin-2-yl)acetamido)pyridin-3-yl)-7-(thiophen-3- yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
Step a: tert-Butyl (S)-2-(2-((5-(7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamido)-6-methylpyridin-3-yl)amino)-2-oxoethyl)pyrrolidine-1-carboxylate
[00423] To a solution of N-(5-amino-2-methylpyridin-3-yl)-7-bromo- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide(1.6 g, 3.8 mmol, 2HCl), (S)-2-(1-(tert- butoxycarbonyl)pyrrolidin-2-yl)acetic acid (1.7 g, 7.6 mmol) in DMF (50 mL) was added TCFH (4.3 g, 7.7 mmol) and NMI (2.2 g, 27.3 mmol) in DMF (50 mL). The resultant mixture was stirred at 50 °C for 12 h. The reaction mixture was diluted with ethyl acetate (10 mL) and filtered over celite. The filtrate was concentrated. The residue was purified by column chromatography over silica gel (eluent: petroleum ether: ethyl acetate (1:0) to give tert-butyl (S)-2-(2-((5-(7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamido)-6-methylpyridin-3- yl)amino)-2-oxoethyl)pyrrolidine-1-carboxylate (3 g) as a yellow solid. LCMS (ESI): mass calcd. for C24H28BrN7O4: 558.428; m/z found, 559.9 [M+H]+. Step b: (S)-7-bromo-N-(2-methyl-5-(2-(1-methylpyrrolidin-2- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00424] To a solution of (S)-tert-butyl 2-(2-((5-(7-bromo-[1,2,4]triazolo[4,3- a]pyridine-3-carboxamido)-6-methylpyridin-3-yl)amino)-2-oxoethyl)pyrrolidine-1- carboxylate (500 mg, 0.90 mmol) in HCOOH (4 mL) was added paraformaldehyde (161 mg, 1.8 mmol) under nitrogen. The proceeded at 80 °C for 16 h. The mixture was concentrated under reduced pressure to give crude product, which was purified by preparative high- performance liquid chromatography over column: Xtimate C18100 x 30 mm, 10 µm to give (S)-7-bromo-N-(2-methyl-5-(2-(1-methylpyrrolidin-2-yl)acetamido)pyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (120 mg, 28%) as a yellow solid. LCMS (ESI): mass calcd. for C20H22BrN7O2, 471.1; m/z found, 472.1 [M+H]+. Step c: (S)-N-(2-methyl-5-(2-(1-methylpyrrolidin-2-yl)acetamido)pyridin-3-yl)-7- (thiophen-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00425] To a solution of (S)-7-bromo-N-(2-methyl-5-(2-(1-methylpyrrolidin-2- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (100 mg, 0.2 mmol), thiophen-3-ylboronic acid (35 mg, 0.27 mmol) and K3PO4 (140 mg, 0.66 mmol) in 1,4-dioxane (8 mL) and H2O (2 mL) was added Pd-118 (25 mg, 0.04 mmol) under nitrogen. The mixture stirred at 100 °C for 1 h and concentrated under vacuum to give the crude product, which was purified by preparative high-performance liquid chromatography over column: Phenomenex C18 75 x 30 mm, 3 µm to give (S)-N-(2-methyl-5-(2-(1-methylpyrrolidin-2- yl)acetamido)pyridin-3-yl)-7-(thiophen-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (26.7 mg, 97%) as a yellow solid. LCMS (ESI): mass calcd. for C24H25N7O2S: 475.2; m/z found, 476.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.33 (s, 1H), 9.16 (d, J=7.88 Hz, 1H), 8.54 (d, J=2.25 Hz, 1H), 8.42 (s, 1H) 8.31 - 8.36 (m, 1H), 8.24 (d, J=2.13 Hz, 1H), 7.89 (dd, J=5.00, 1.25 Hz, 1H), 7.78 (dd, J=5.00, 2.88 Hz, 1H), 7.74 (dd, J=7.38, 1.63 Hz, 1H), 2.92 - 3.01 (m, 1H), 2.63 (dd, J=13.88, 4.63 Hz, 1H), 2.47 - 2.48 (m, 1H), 2.46 (s, 3H), 2.28 -2.32 (m, 1H), 2.27 (s, 3H), 2.13 (q, J=8.71 Hz, 1H), 1.89 - 1.99 (m, 1H), 1.62 - 1.71 (m, 2H), 1.48 - 1.58 (m, 1H). [00426] The following tabulated examples were prepared by a similar method of example 177 from the appropriate starting materials.
Example 191 N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(6-(3- hydroxyoxetan-3-yl)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00427] To a solution of mixture of 7-chloro-N-(5-(3-(2,2-dimethylpyrrolidin-1- yl)propanamido)-2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide and 7- bromo-N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (100 mg, 0.1 mmol) in 1,4-dioxane (12.8 mL) was added methyl 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (160 mg, 0.63 mmol) , KOAc (63 mg, 0.64 mmol), S-phos (33 mg, 0.08 mmol) and (dba)3Pd2 (40 mg, 0.04 mmol) under N2. The resulting mixture was heated at 100 °C and stirred for 12 hours. The mixture was cooled to r.t. 3-(5-bromopyridin-2-yl)oxetan-3-ol (96 mg, 0.417 mmol), K3PO4 (135 mg, 0.636 mmol), Pd- 118 (30 mg, 0.046 mmol) and H2O (3.2 mL) were added to the 40 mL thread vials with magnetic stirrer. The mixture stirred at 70°C for 2 h and then concentrated under vacuum to give the crude product, which was purified by preparative high-performance liquid chromatography over column: Xtimate C18150*40mm*5um (18.4 mg, 28%) as a yellow solid. LCMS (ESI): mass calcd. for C30H34N8O4: 570.642; m/z found, 571.4 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 11.36 (br s, 1 H), 11.25 (s, 1 H), 10.35 (br s, 1 H), 9.24 (d, J=7.51 Hz, 1 H), 8.89 (dd, J=10.67, 1.85 Hz, 2 H), 8.77 (s, 1 H), 8.61 (s, 1 H), 8.31 (d, J=8.46
Hz, 1 H), 8.03 - 8.16 (m, 2 H), 4.12 (br d, J=11.44 Hz, 1 H), 3.99 (br d, J=11.44 Hz, 1 H), 3.05 - 3.29 (m,6 H), 2.86 - 3.04 (m, 2 H), 2.67 (s, 3 H), 1.74 - 2.10 (m, 5 H), 1.50 (s, 3 H), 1.22 (s, 3 H) [00428] Example 192 was prepared by a similar method of example 191 from the appropriate starting materials.
Example 193 N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
Step a: tert-Butyl (6-methyl-5-nitropyridin-3-yl)carbamate
[00429] To a solution of 5-bromo-2-methyl-3-nitropyridine (3.0 g, 13.8 mmol), tert- butyl carbamate (1.9 g, 16.6 mmol), XPhos (5.9 g, 12.4 mmol) and cesium carbonate (6.3 g, 19.4 mmol) in 1,4-dioxane (60 mL) was added tris(dibenzylideneacetone)dipalladium(0) (3.8 g, 4.2 mmol) under nitrogen. The resulting mixture was stirred at 100 °C for 12 h. The resulting
mixture was extracted with ethyl acetate (100 mL x 3). The organic extracts were concentrated under reduced pressure to give crude product, which was purified by column chromatography over silica gel (eluent: petroleum ether/ethyl acetate = 3:2) to give tert-butyl (6-methyl-5- nitropyridin-3-yl)carbamate (1.5 g, 43%) as a yellow solid. LCMS (ESI): mass calcd. for C11H15N3O4: 253.1; m/z found, 254.1 [M+H]+. Step b: 6-Methyl-5-nitropyridin-3-amine
[00430] The solution of tert-butyl (6-methyl-5-nitropyridin-3-yl)carbamate (1.3 g, 5.1 mmol) in TFA (6 mL) was stirred at 20 °C for 1 h. Then the reaction mixture was concentrated under reduced pressure to give 6-methyl-5-nitropyridin-3-amine (1.4 g, 95%) as a yellow oil. LCMS (ESI): mass calcd. for C6H7N3O2, 153.1; m/z found, 154.2 [M+H]+. Step c: N-(6-methyl-5-nitropyridin-3-yl)acrylamide
[00431] To a solution of 6-methyl-5-nitropyridin-3-amine (1.4 g, 5.2 mmol) and triethylamine (2.2 mL, 15.7 mmol) in DCM (20 mL) was added 3-chloropropanoyl chloride (0.97 mL, 7.86 mmol) at room temperature. The resultant mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated to yield crude product, which was purified by column chromatography over silica gel (eluent: petroleum ether: ethyl acetate = 0:1) to afford N-(6- methyl-5-nitropyridin-3-yl)acrylamide (1 g, 92%) as a yellow solid. LCMS (ESI): mass calcd. for C9H9N3O3: 207.1; m/z found, 208.1 [M+H]+. Step d: 3-(2,2-Dimethylpyrrolidin-1-yl)-N-(6-methyl-5-nitropyridin-3- yl)propanamid
e [00432] To a solution of N-(6-methyl-5-nitropyridin-3-yl)acrylamide (1 g, 4.8 mmol), potassium carbonate (4.0 g, 28.9 mmol) and potassium iodide (0.08 g, 0.48 mmol) in acetonitrile (10 mL) was added 2,2-dimethylpyrrolidine (0.72 g, 7.2 mmol) at room temperature. The resultant mixture was stirred at 75 °C for 12 h. The reaction mixture was concentrated and purified by column chromatography over silica gel (eluent: dichloromethane:
methanol = 90:10) to give 3-(2,2-dimethylpyrrolidin-1-yl)-N-(6-methyl-5-nitropyridin-3- yl)propanamide (680 mg, 46%) as a yellow solid. LCMS (ESI): mass calcd. for C15H22N4O3: 306.2; m/z found, 307.0 [M+H]+. Step e: N-(5-amino-6-methylpyridin-3-yl)-3-(2,2-dimethylpyrrolidin-1- yl)propanamide
[00433] To a solution of 3-(2,2-dimethylpyrrolidin-1-yl)-N-(6-methyl-5- nitropyridin-3-yl)propanamide (680 mg, 2.2 mmol) and ammonium chloride (594 mg, 11.0 mmol) in EtOH/H2O=5:1 (5 mL) was added iron (620 mg, 11.1 mmol) at room temperature. The resultant mixture was stirred at 75 °C for 1 h. The reaction mixture was filtered through a pad of celite. The celite pad was washed with DCM (30 mL). The filtrate was washed with 20 mL of saturated aqueous NaHCO3 and extracted with DCM (20 mL x 3). The organic layer was concentrated to give N-(5-amino-6-methylpyridin-3-yl)-3-(2,2-dimethylpyrrolidin-1- yl)propenamide (600 mg, 71%) as a yellow solid. LCMS (ESI): mass calcd. for C15H24N4O: 276.2; m/z found, 277.2 [M+H]+. Step f: 7-Bromo-N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2- methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00434] To a solution of lithium 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3- carboxylate (200 mg, 0.74 mmol) and N-5-(3-(2,2-dimethylpyrrolidin-1-yl)propyl)-2- methylpyridine-3,5-diamine (282 mg, 0.74 mmol) in DMF (5 mL) was added N-ethyl-N- isopropylpropan-2-amine (0.39 mL, 2.2 mmol) and bromotri(pyrrolidin-1-yl)phosphonium hexafluorophosphate(V) (411 mg, 0.88 mmol) at room temperature. The resultant mixture was stirred at 20 °C for 12 h. The reaction was followed by addition of water (10 mL), which was extracted with dichloromethane (10 mL x 3). The organic layer was concentrated to give crude product, which was purified by column chromatography over silica gel (eluent: dichloromethane: methanol = 9:1) to afford 7-bromo-N-(5-(3-(2,2-dimethylpyrrolidin-1-
yl)propanamido)-2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (150 mg, 41%) as a brown oil. LCMS (ESI): mass calcd. for C22H26BrN7O2: 501.1; m/z found, 502.2 [M+H]+. Step g: N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00435] To a solution of 7-bromo-N-(5-(3-(2,2-dimethylpyrrolidin-1- yl)propanamido)-2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (100 mg, 0.2 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (49.9 mg, 0.24 mmol) and K2CO3 (82.8 mg, 0.6 mmol) in 1,4-dioxane (4 mL) and H2O (1 mL) was added Pd(dppf)Cl2.DCM (16.3 mg, 0.02 mmol) under nitrogen. The mixture stirred at 100 °C for 12 h and then concentrated under vacuum to give the crude product, which was purified by preparative high-performance liquid chromatography over column: Boston Prime C18150 x 30 mm, 5 µm to give N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (31.5 mg, 30%) as a yellow solid. LCMS (ESI): mass calcd. for C26H31N9O2: 501.3; m/z found, 502.3 [M+H]+.1H NMR (400 MHz, METHANOL-d4) δ 9.26 (d, J=7.3 Hz, 1H), 8.59 (d, J=2.3 Hz, 1H), 8.51 (d, J=2.0 Hz, 1H), 8.31 (s, 1H), 8.12 (s, 1H), 8.05 (s,1H), 7.52 (d, J=7.3 Hz, 1H), 4.00 (s, 3H), 2.94 - 2.78 (m, 4H), 2.63 - 2.57 (m, 5H), 1.93 - 1.81 (m, 2H), 1.78 - 1.71 (m, 2H), 1.11 (s, 6H). Example 194 N-(5-(3-(2-(2,2-dimethylpyrrolidin-1-yl)ethyl)ureido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
Step a: Phenyl (2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamate
[00436] To a solution of 2-(2,2-dimethylpyrrolidin-1-yl)ethanamine (500 mg, 3.5 mmol) in DCM (20 mL) was added phenyl carbonochloridate (0.44 mL, 3.5 mmol). The resultant mixture was stirred at 0 °C for 1.5 h. The reaction mixture was concentrated to give phenyl (2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamate (510 mg, 28%) as a red oil. LCMS (ESI): mass calcd. for C15H22N2O2: 262.2; m/z found, 263.0 [M+H]+. Step b: 1-(2-(2,2-Dimethylpyrrolidin-1-yl)ethyl)-3-(6-methyl-5-nitropyridin-3-yl)urea
[00437] To a solution of phenyl (2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamate (510 mg, 0.99 mmol, 2HCl) and N-(5-amino-2-methylpyridin-3-yl)-N-oxohydroxylammonium (158 mg, 0.99 mmol) in acetonitrile (8 mL) was added N,N-dimethylpyridin-4-amine (302 mg, 2.5 mmol). The resultant mixture was stirred at 80 °C for 12 h. The mixture was concentrated under vacuum to give crude product, which was purified by preparative high-performance liquid chromatography over column: Xtimate C18150 x 40 mm, 5 µm to afford 1-(2-(2,2- dimethylpyrrolidin-1-yl)ethyl)-3-(6-methyl-5-nitropyridin-3-yl)urea (110 mg, 34%) as a red oil. LCMS (ESI): mass calcd. for C15H23N5O3: 321.2; m/z found, 322.0 [M+H]+. 1H NMR (400MHz, METHANOL-d4) δ 8.65 (s, 1H), 8.41 (br s, 1H), 3.63 - 3.51 (m, 3H), 3.27 - 3.09 (m, 3H), 2.70 (s, 3H), 2.09 (br d, J=7.7 Hz, 2H), 2.05 - 1.91 (m, 2H), 1.49 - 1.25 (m, 6H). Step c: 1-(5-Amino-6-methylpyridin-3-yl)-3-(2-(2,2-dimethylpyrrolidin-1- yl)ethyl)urea
[00438] A mixture of 1-(2-(2,2-dimethylpyrrolidin-1-yl)ethyl)-3-(6-methyl-5- nitropyridin-3-yl)urea (110 mg, 0.33 mmol) in MeOH (10 mL) was hydrogenated with Pt/C (14.1 mg, 0.01 mmol) in the presence of hydrogen . The resultant mixture was stirred at 20 °C for 3 h. The catalyst was filtered off, and the filtrate was evaporated to give 1-(5-amino-6- methylpyridin-3-yl)-3-(2-(2,2-dimethylpyrrolidin-1-yl)ethyl)urea (100 mg, 87%) as a yellow oil. LCMS (ESI): mass calcd. for C15H25N5O: 291.2; m/z found, 292.2 [M+H]+.
Step d: Lithium 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate
[00439] To a solution of ethyl 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate (6.6 g, 24.4 mmol) in THF (200 mL) was added LiOH (2.1 g, 48.9 mmol) in water (40 mL). The resultant mixture was stirred at 20 °C for 1.5 h. The reaction mixture was concentrated to give lithium 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate (6.1 g, 95%) as a red solid. LCMS (ESI): mass calcd. for C7H4BrN3O2: 242.03; m/z found, 243.8 [M+H]+. Step e: 7-Bromo-N-(5-(3-(2-(2,2-dimethylpyrrolidin-1-yl)ethyl)ureido)-2- methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00440] To a solution of 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid (1.6 g, 3.8 mmol), 7-bromo-N-(5-(3-(2-(2,2-dimethylpyrrolidin-1-yl)ethyl)ureido)-2- methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (1.7 g, 7.6 mmol) in DMF (50 mL) was added HATU (101 mg, 0.24 mmol) and N,N-diisopropylethylamine (69.0 mg, 0.53 mmol). The resultant mixture was stirred at 25 °C for 12 h. The mixture was concentrated under vacuum to give crude product, which was purified by preparative high-performance liquid chromatography over column: Xtimate C18150 x 40 mm, 5 µm to give 7-bromo-N-(5- (3-(2-(2,2-dimethylpyrrolidin-1-yl)ethyl)ureido)-2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3- a]pyridine-3-carboxamide (45 mg, 14%) as a yellow oil. LCMS (ESI): mass calcd. for C22H27BrN8O2: 514.1; m/z found, 515.0 [M+H]+. Step f: N-(5-(3-(2-(2,2-dimethylpyrrolidin-1-yl)ethyl)ureido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
[00441] To a solution of 7-bromo-N-(5-(3-(2-(2,2-dimethylpyrrolidin-1- yl)ethyl)ureido)-2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (45 mg, 0.04 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (8.7 mg,
0.04 mmol) and sodium hydrogencarbonate (69.8 uL, 0.14 mmol) in 1,4-dioxane (0.4 mL) was added PdCl2(dppf).CH2Cl2 (2.9 mg, 0.003 mmol). The mixture stirred at 100 °C for 2 h and concentrated under vacuum to give crude product, which was purified by preparative high- performance liquid chromatography over column: Phenomenex Gemini-NX 80 x 30 mm, 3 µm to give N-(5-(3-(2-(2,2-dimethylpyrrolidin-1-yl)ethyl)ureido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (6.6 mg, 36%) as a white solid. LCMS (ESI): mass calcd. for C26H32N10O2: 516.3; m/z found, 517.1 [M+H]+.1H NMR (400MHz, METHANOL-d4) δ 8.87 (br d, J=7.3 Hz, 1H), 8.00 (br d, J=2.4 Hz, 1H), 7.93 (br d, J=2.2 Hz, 1H), 7.91 (s, 1H), 7.71 (s, 1H), 7.65 (s, 1H), 7.12 (br dd, J=1.5, 7.3 Hz, 1H), 3.59 (s, 3H), 2.57 - 2.44 (m, 2H), 2.30 - 2.19 (m, 2H), 2.14 (s, 3H), 1.57 - 1.37 (m, 3H), 1.36 - 1.17 (m, 3H), 0.77 - 0.52 (m, 6H). Example 195 (S)-6-(3,5-dimethyl-1-(oxetan-3-yl)-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2- methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide
[00442] (S)-6-bromo-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide (101 mg, 0.214 mmol), 3,5-dimethyl-1-(oxetan-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H- pyrazole (136 mg, 0.490 mmol), 1,1'-bis(diphenylphosphino)ferrocene- palladium(II)dichloride dichloromethane complex (27.5 mg, 0.0337 mmol), potassium phosphate (146 mg, 0.675 mmol), and 1,4-dioxane/distilled water (5:1) (4.0 mL) were combined in a 2-5 mL microwave vial, equipped with a stir bar. The vial was sealed with a cap. The contents were sparged with nitrogen with vigorous stirring. The mixture was irradiated in a Biotage Initiator+ microwave reactor at 120 °C for 1 h and allowed to cool to room temperature. The crude residue was dissolved in MeOH and filtered through a metal scavenger. Solvent was removed under reduced pressure. The residue was purified by preparative high- performance liquid chromatography over column: Kinetex EVO C18100 Å, 100 x 30 mm, 5
µm with modifier to give (S)-6-(3,5-dimethyl-1-(oxetan-3-yl)-1H-pyrazol-4-yl)-N-(2-methyl- 5-(2-(2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide (27 mg, 21%) as a white solid. LCMS (ESI): mass calcd. for C28H33N9O3: 543.3; m/z found, 544.3 [M+H]+.1H NMR (CHLOROFORM-d, 400 MHz) δ 9.44 (br s, 1H), 9.0-9.1 (m, 1H), 8.8-8.9 (m, 1H), 8.6-8.7 (m, 2H), 8.4-8.5 (m, 1H), 7.47 (br d, 1H, J=9.3 Hz), 5.4-5.5 (m, 1H), 5.27 (br t, 2H, J=5.9 Hz), 5.0-5.1 (m, 2H), 3.4-3.6 (m, 1H), 3.1-3.3 (m, 2H), 2.6-2.8 (m, 4H), 2.5-2.6 (m, 1H), 2.36 (s, 3H), 2.28 (s, 3H), 2.0-2.1 (m, 1H), 1.9-2.0 (m, 2H), 1.6-1.6 (m, 1H), 1.19 (br d, 3H, J=5.4 Hz). [00443] The following tabulated examples were prepared by a similar method of example 195 from the appropriate starting materials.
Example 211 (S)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-6-(1-(oxetan-3- yl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide
Step a: Ethyl 6-(1-(oxetan-3-yl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine- 3-carboxylate
[00444] 3-Bromo-1-(oxetan-3-yl)-1H-pyrazole (315 mg, 1.55 mmol), ethyl 6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxylate (598 mg, 1.89 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (129 mg, 0.158 mmol), potassium phosphate (1.01 g, 4.66 mmol), and 1,4-dioxane:distilled water (5:1) (5.0 mL) were combined in a 2-5 mL microwave vial, equipped with a stir bar. The vial was sealed with a cap. The contents were sparged with nitrogen. The mixture was heated at 100 °C for 1.5 h and allowed to cool to room temperature. Solvent was removed in vacuo. The residue was dissolved in DCM and filtered through a pad of celite. Filtrate was concentrated and purified with silica gel column chromatography using EtOAc and Heptane to give ethyl 6-(1-(oxetan-3-yl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5- a]pyridine-3-carboxylate (301 mg, 62%) as a white solid. LCMS (ESI): mass calcd. for C15H15N5O3: 313.1; m/z found, 314.1 [M+H]+.1H NMR (DMSO-d6, 400 MHz) δ 9.7-9.7 (m, 1H), 8.2-8.3 (m, 2H), 8.07 (d, 1H, J=2.4 Hz), 7.11 (d, 1H, J=2.2 Hz), 5.68 (quin, 1H, J=7.0 Hz), 4.9-5.0 (m, 4H), 4.43 (q, 2H, J=7.3 Hz), 1.40 (t, 3H, J=7.1 Hz). Step b: 6-(1-(Oxetan-3-yl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxylic acid
[00445] A 2-5 mL microwave vial, equipped with a stir bar, was charged with ethyl 6-(1-(oxetan-3-yl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxylate (159 mg, 0.507 mmol), THF:MeOH (4:1) (4 mL), and NaOH (3M in H2O) (0.60 mL, 1.8 mmol). The vial was sealed with a cap. A nitrogen atmosphere was established. The mixture was heated at 70 °C for 2.25 h and allowed to cool to 21 °C. Solvent was removed under reduced pressure. Water was added. The mixture was acidified with 1 M HCl. The white solid was air-dried using a vacuum to provide 6-(1-(oxetan-3-yl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-
carboxylic acid (116 mg, yield 80%). LCMS (ESI): mass calcd. for C13H11N5O3: 285.1; m/z found, 308.0 [M+Na]+.1H NMR (DMSO-d6, 400 MHz) δ 13.29 (br s, 1H), 9.69 (t, 1H, J=1.1 Hz), 8.2-8.3 (m, 2H), 8.05 (d, 1H, J=2.4 Hz), 7.10 (d, 1H, J=2.4 Hz), 5.6-5.7 (m, 1H), 4.9-5.0 (m, 4H). Step c: (S)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-6- (1-(oxetan-3-yl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide
[00446] A 2-5 mL microwave vial, equipped with a stir bar, was charged with 6-(1- (oxetan-3-yl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxylic acid (32.3 mg, 0.113 mmol), N-(5-amino-6-methyl-3-pyridyl)-2-[(2S)-2-methylpyrrolidin-1-yl]acetamide (35.4 mg, 0.139 mmol), DMF (2.0 mL), N,N-diisopropylethylamine (70 µL, 0.40 mmol), and HATU (66.9 mg, 0.172 mmol). The vial was sealed with a cap. A nitrogen atmosphere was established. The mixture was heated at 70 °C for 2 h and allowed to cool to 22 °C. Solvent was removed in vacuo. The crude residue was purified using Prep-HPLC [Gilson: Kinetex 5 µm EVO C18 100 Å,column] to give (S)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-6-(1-(oxetan-3-yl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5- a]pyridine-3-carboxamide (46.7 mg, yield 80%) as a white solid. LCMS (ESI): mass calcd. for C26H29N9O3: 515.2; m/z found, 516.2 [M+H]+.1H NMR (CHLOROFORM-d, 400 MHz) δ 9.25 (t, 1H, J=1.2 Hz), 9.20 (s, 1H), 9.04 (s, 1H), 8.7-8.8 (m, 2H), 8.44 (dd, 1H, J=1.0, 9.0 Hz), 8.11 (dd, 1H, J=1.3, 9.2 Hz), 7.69 (d, 1H, J=2.4 Hz), 6.74 (d, 1H, J=2.2 Hz), 5.5-5.6 (m, 1H), 5.1- 5.2 (m, 4H), 3.46 (d, 1H, J=16.9 Hz), 3.21 (dt, 1H, J=3.3, 8.7 Hz), 3.11 (d, 1H, J=16.9 Hz), 2.6-2.7 (m, 4H), 2.4-2.5 (m, 1H), 2.0-2.1 (m, 1H), 1.7-2.0 (m, 2H), 1.5-1.6 (m, 1H), 1.15 (d, 3H, J=6.1 Hz). [00447] The following tabulated examples were prepared by a similar method of example 211 from the appropriate starting materials.
Example 221 N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(1-(2- hydroxyethyl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide
Step a: Ethyl 6-(1-(2-hydroxyethyl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5- a]pyridine-3-carboxylate
[00448] A microwave vial was charged with ethyl 6-bromo-[1,2,3]triazolo[1,5- a]pyridine-3-carboxylate (408 mg, 1.51 mmol), 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)-1H-pyrazol-1-yl)ethan-1-ol (359 mg, 1.51 mmol), Pd(PPh3)4 (87.2 mg, 0.0700 mmol), 1,4-dioxane (3.0 mL), and 3M K2CO3 (1.0 mL). The vial was sealed with a cap, and the mixture was stirred at 125 °C for 60 min under microwave irradiation. Upon cooling to room temperature, a white precipitate appeared. The mixture was diluted with 2N HCl. The precipitate was filtered, washed with EtOAc (3 x 5 mL), and dried in vacuo to afford ethyl 6- (1-(2-hydroxyethyl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxylate (410 mg, 90%) as a white solid.1H NMR (DMSO-d6, 400 MHz) δ 9.54-9.60 (m, 1H), 8.41-8.45 (m, 1H), 8.14-8.20 (m, 2H), 8.02-8.07 (m, 1H), 4.38-4.46 (m, 2H), 4.20 (t, J=5.38 Hz, 2H), 3.79 (t, J=5.62 Hz, 2H), 1.39 (t, J=7.09 Hz, 3H). Step b: 6-(1-(2-Hydroxyethyl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxylic acid
[00449] To a suspension of ethyl 6-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)- [1,2,3]triazolo[1,5-a]pyridine-3-carboxylate (410 mg, 1.36 mmol) in a mixture of THF:MeOH
(4:1) (5 mL) was added aqueous NaOH (0.91 mL, 3N). The mixture was heated at 70 °C for 2 h. Solvent was removed under reduced pressure. The residue was diluted with 2 N HCl. The precipitate was filtered, washed with water, and dried in vacuo to yield 6-(1-(2-hydroxyethyl)- 1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxylic acid (360 mg, 97%) as a grey solid. Step c. N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6- (1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide
[00450] A 20 mL disposable scintillation vial was charged with 6-(1-(2- hydroxyethyl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxylic acid (108 mg, 0.400 mmol), N-(5-amino-6-methylpyridin-3-yl)-2-(2,2-dimethylpyrrolidin-1-yl)acetamide (118 mg, 0.400 mmol), and EDCI (106 mg, 0.550 mmol). Pyridine (4.0 mL) was added, and the vial was capped. The mixture was heated at 75 °C for 2 h. The mixture was allowed to cool to room temperature. Solvent was removed under reduced pressure. The residue was purified by reverse phase HPLC (0.1% formic acid in water, 0.1% formic acid in acetonitrile, 10% to 90% gradient over 35 min). Combined pure fractions were lyophilized to yield N-(5-(2-(2,2- dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(1-(2-hydroxyethyl)-1H- pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide (53 mg, 22%) as a white solid. LCMS (ESI): mass calcd. for C26H31N9O3: 517.3; m/z found, 518.3 [M+H]+. 1H NMR (400 MHz, METHANOL-d4) δ 9.34 (t, J=1.22 Hz, 1H), 8.64 (d, J=1.96 Hz, 1H), 8.54 (d, J=2.45 Hz, 1H), 8.32-8.37 (m, 1H), 8.30 (s, 1H), 8.11 (s, 1H), 7.94-7.99 (m, 1H), 4.31-4.36 (m, 2H), 3.95- 3.99 (m, 2H), 3.47-3.52 (m, 2H), 3.08-3.16 (m, 2H), 2.61 (s, 3H), 1.93-2.00 (m, 2H), 1.85-1.92 (m, 2H), 1.21 (s, 6H). [00451] The following tabulated examples were prepared by a similar method of example 221 from the appropriate starting materials.
Example 238 N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(5-pyrazol-1-yl- 3-pyridyl)triazolo[1,5-a]pyridine-3-carboxamide N N N N O N HN H N N N N O [00452] To a 4 mL threaded vial with magnetic stirrer was added [5-(1H-pyrazol-1- yl)pyridin-3-yl]boronic acid hydrochloride (22.9 mg, 0.102 mmol). 6-Bromo-N-[5-[[2-(3,3- dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]triazolo[1,5-a]pyridine-3- carboxamide (30 mg, 0.0635 mmol) in dioxane (600 µL), 1,1'- bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (6.2 mg, 0.00762 mmol), and a solution of potassium phosphate tribasic (40.4 mg, 0.191 mmol) in water (150 µL) were added to the boronic acid sequentially. The vial was sealed, and the reaction mixture was stirred at 100 °C for 17 hours. The reaction mixture was cooled to ambient temperature, filtered through celite, and concentrated in vacuo. The crude product was purified with preparative high-performance liquid chromatography to provide N-[5-[[2-(3,3- dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(5-pyrazol-1-yl-3- pyridyl)triazolo[1,5-a]pyridine-3-carboxamide (14.8 mg, 35.8%) as the trifluoroacetate salt. LCMS (ESI): mass calcd. for C28H28N10O2: 536.2; m/z found: 537.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6): δ 10.82 (s, 1H), 10.57 (br s, 1H), 10.38 (s, 1H), 9.95 (s, 1H), 9.23 (d, J = 2.4 Hz, 1H), 9.07 (d, J = 2.0 Hz, 1H), 8.78 (d, J = 2.4 Hz, 1H), 8.74 (t, J = 2.2 Hz, 1H), 8.57 (d, J = 2.4 Hz, 1H), 8.39 - 8.36 (m, 1H), 8.34 (d, J = 2.0 Hz, 1H), 8.28 (dd, J = 1.5, 9.3 Hz, 1H), 7.89 (d, J = 1.5 Hz, 1H), 6.70 - 6.67 (m, 1H), 4.33 (br d, J = 4.4 Hz, 2H), 3.98 - 3.92 (m, 4H), 2.52 (s, 3H), 1.36 (s, 3H), 1.26 (s, 3H). [00453] The following compounds were made by a similar procedure to example 238
Example 315 N-(5-(2-(2-azabicyclo[2.2.2]octan-2-yl)acetamido)-2-methylpyridin-3-yl)-6-(1-methyl- 1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide
[00454] To a 8 mL threaded vial with magnetic stirrer was added N-(5-(2- chloroacetamido)-2-methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5- a]pyridine-3-carboxamide (40 mg, 0.073 mmol), 2-azabicyclo[2.2.2]octane (15 mg, 0.108 mmol), potassium carbonate (73 mg, 0.528 mmol), sodium iodide (10 mg, 0.067 mmol), and dimethylformamide (2 mL). The reaction mixture was stirred at 50 °C for 16 h. The solvent was concentrated in vacuo to provide the crude product. The crude product was purified with preparative high-performance liquid chromatography to provide N-(5-(2-(2- azabicyclo[2.2.2]octan-2-yl)acetamido)-2-methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-
[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide (13 mg, 32.5%) as a white solid. LCMS (ESI): mass calcd. for C26H29N9O2: 499.2; m/z found: 500.3 [M+H]+. 1H NMR (400MHz, DMSO- d6): δ 10.26 (s, 1H), 9.81 (s, 1H), 9.59 (s, 1H), 8.60 (d, J=2.3 Hz, 1H), 8.41 (s, 1H), 8.32 (d, J=2.3 Hz, 1H), 8.25 (dd, J=0.7, 9.2 Hz, 1H), 8.15 (s, 1H), 8.00 (dd, J=1.4, 9.1 Hz, 1H), 3.92 (s, 3H), 3.28 (s, 2H), 2.78 (s, 2H), 2.46 (s, 3H), 1.95 (d, J=11.1 Hz, 2H), 1.71 - 1.57 (m, 4H), 1.54 - 1.44 (m, 4H). Example 316 N-(5-(2-(4-cyano-4-methylpiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(1-methyl- 1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide
[00455] To a 8 mL threaded vial with magnetic stirrer was added N-(5-(2- chloroacetamido)-2-methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5- a]pyridine-3-carboxamide (40 mg, 0.073 mmol) and 4-methylpiperidine-4-carbonitrile hydrochloride (20 mg, 0.124 mmol) dissolved in dimethylformamide (2 mL). Potassium carbonate (70 mg, 0.506 mmol) and sodium iodide (15 mg, 0.100 mmol) were added to the mixture. The reaction mixture was stirred at 50 °C for 16 h. The solvent was concentrated in vacuo to provide the crude product. The crude product was purified with preparative high- performance liquid chromatography to provide N-(5-(2-(4-cyano-4-methylpiperidin-1- yl)acetamido)-2-methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5- a]pyridine-3-carboxamide (20 mg, 50.9%) as a white solid. LCMS (ESI): mass calcd. for C26H28N10O2: 512.2; m/z found: 513.3 [M+H]+. 1H NMR (400MHz, DMSO-d6): δ 10.25 (s, 1H), 9.92 (s, 1H), 9.60 (s, 1H), 8.59 (d, J=2.3 Hz, 1H), 8.41 (s, 1H), 8.31 (d, J=2.3 Hz, 1H), 8.24 (d, J=9.3 Hz, 1H), 8.15 (s, 1H), 8.02 - 7.96 (m, 1H), 3.91 (s, 3H), 3.21 (s, 2H), 2.87 (br d, J=12.0 Hz, 2H), 2.46 (s, 3H), 2.42 - 2.34 (m, 2H), 1.87 (br d, J=13.1 Hz, 2H), 1.73 - 1.62 (m, 2H), 1.35 (s, 3H). [00456] The following compounds were made by a similar procedure to example 315 or 316.
Example 387 N-[5-[[2-(7-azaspiro[3.3]heptan-7-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)-1,2-benzoxazole-3-carboxamide
Step a, tert-Butyl (5-(6-bromobenzo[d]isoxazole-3-carboxamido)-6- methylpyridin-3-yl)carbamate
[00457] tert-Butyl (5-amino-6-methylpyridin-3-yl)carbamate (2 g, 8.96 mmol), 6- bromobenzo[d]isoxazole-3-carboxylic acid (2.8 g, 11.57 mmol), dichloromethane (100 mL), and pyridine (11 g, 139.07 mmol) were charged into a 250 mL round-bottom flask. The reaction was cooled to 0°C then phosphorous oxychloride (2.7 g, 17.61 mmol) was added dropwise with syringe over 5 minutes. The reaction was stirred for 2 hours at ambient temperature. The reaction mixture was slowly added to sat’d aqueous sodium bicarbonate (200 mL). The layers were separated, and the water layer was extracted twice with dichloromethane (150 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The crude yellow oil was purified by silica gel chromatography (gradient elution: 0-70% ethyl acetate in petroleum ether). tert-Butyl (5-(6- bromobenzo[d]isoxazole-3-carboxamido)-6-methylpyridin-3-yl)carbamate (2015.5 mg, 4.45 mmol, 49.7%) was obtained as light yellow solid. LCMS (ESI): mass calcd. for C19H19BrN4O4: 446.1; m/z found: 447.0 [M+H]+. 1H NMR (400MHz, DMSO-d6): δ 10.75 (s, 1H), 9.61 (s, 1H), 8.41 (d, J=2.0 Hz, 1H), 8.33 (s, 1H), 8.09 - 7.99 (m, 2H), 7.72 (dd, J=1.2, 8.4 Hz, 1H), 2.39 (s, 3H), 1.48 (s, 9H). Step b. tert-Butyl (6-methyl-5-(6-(1-methyl-1H-pyrazol-4-yl)benzo[d]isoxazole-3- carboxamido)pyridin-3-yl)carbamate
[00458] A mixture of tert-butyl (5-(6-bromobenzo[d]isoxazole-3-carboxamido)-6- methylpyridin-3-yl)carbamate (232 mg, 0.52 mmol), 1-methylpyrazole-4-boronic acid, pinacol ester (235 mg, 1.13 mmol), potassium phosphate tribasic (349 mg, 1.64 mmol), and Mesylate[(di(1-adamantyl)-n-butylphosphine)-2-(2′-amino-1,1′-biphenyl)]palladium(II),
[(Di(1-adamantyl)-butylphosphine)-2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate (36 mg, 0.049 mmol) in 1,4-dioxane (4 mL) and water, distilled (1 mL) under nitrogen in a capped 5 mL microwave vial was sparged with nitrogen for 10 min and heated at 60°C in a heating block. The bright orange reaction mixture was filtered through an isolute HM-N 3 mL column, washing with 10% MeOH/DCM till most of the color is out. The white solid at the head of the column was combined with 1:1 methanol:dichloromethane washes and concentrated to give tert-Butyl (6-methyl-5-(6-(1-methyl-1H-pyrazol-4- yl)benzo[d]isoxazole-3-carboxamido)pyridin-3-yl)carbamate as a yellow-tinted white solid (202 mg, 0.45 mmol, 86.7%). LCMS (ESI): mass calcd. for C23H24N6O4: 448.2; m/z found: 449.0 [M+H]+. Step c. N-(5-amino-2-methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4- yl)benzo[d]isoxazole-3-carboxamide
[00459] A suspension of tert-butyl (6-methyl-5-(6-(1-methyl-1H-pyrazol-4- yl)benzo[d]isoxazole-3-carboxamido)pyridin-3-yl)carbamate (202 mg, 0.45 mmol) in methanol (5 mL) and 4M hydrochloric acid in dioxane (3 mL, 4 M, 12 mmol) was heated at 50°C for 4.5 h. The reaction was concentrated, diluted with ethyl acetate, and concentrated again. N-(5-amino-2-methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)benzo[d]isoxazole-3- carboxamide (190 mg, 0.45 mmol) was used in the next step without purification. LCMS (ESI): mass calcd. for C18H16N6O2: 348.1; m/z found: 349.0 [M+H]+. Step d. N-(5-(2-chloroacetamido)-2-methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol- 4-yl)benzo[d]isoxazole-3-carboxamide
[00460] To a slurry of N-(5-amino-2-methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4- yl)benzo[d]isoxazole-3-carboxamide (196 mg, 0.47 mmol) in dichloromethane (7.5 mL) and diisopropylethylamine (0.25 mL, 0.75 g/mL, 1.44 mmol) under nitrogen in a 50 mL round- bottom flask was added 2-chloroacetyl chloride (0.041 mL, 1.42 g/mL, 0.51 mmol). The resulting dark uniform suspension was stirred for 2.75 hour. An additional charge of diisopropylethylamine (0.1 mL, 0.75 g/mL, 0.58 mmol) and 2-chloroacetyl chloride (0.041 mL, 1.42 g/mL, 0.51 mmol) were added. The reaction continued stirring at ambient temperature for 18 hours. An additional charge of diisopropylethylamine (0.25 mL, 0.75 g/mL, 1.44 mmol) and 2-chloroacetyl chloride (0.1 mL, 1.42 g/mL, 1.26 mmol) were added. The reaction was stirred for 4 h then poured into water and stirred vigorously. The resulting slurry was filtered to give N-(5-(2-chloroacetamido)-2-methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4- yl)benzo[d]isoxazole-3-carboxamide (87 mg, 0.21 mmol, 44.0%) as a tan solid. The filtrate was acidified filtrate with sat'd ammonium chloride, the layers were separated. The water layer was extracted aqueous with methylene chloride (3 x). The combined organics were washed with brine, filtered, and concentrated to give a dark brown residue. The residue was purified by preparative HPLC, 20% - 40% acetonitrile in water (10 mM ammonium hydroxide) to yield N-(5-(2-chloroacetamido)-2-methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4- yl)benzo[d]isoxazole-3-carboxamide (48 mg, 0.11 mmol, 24.3%) as a brown solid. The combined batches of N-(5-(2-chloroacetamido)-2-methylpyridin-3-yl)-6-(1-methyl-1H- pyrazol-4-yl)benzo[d]isoxazole-3-carboxamide (135 mg, 0.32 mmol, 68.3%). LCMS (ESI): mass calcd. for C20H17ClN6O3: 424.1; m/z found: 425.0 [M+H]+. Step e. N-[5-[[2-(7-azaspiro[3.3]heptan-7-yl)acetyl]amino]-2-methyl-3-pyridyl]-6- (1-methylpyrazol-4-yl)-1,2-benzoxazole-3-carboxamide
[00461] A mixture of N-(5-(2-chloroacetamido)-2-methylpyridin-3-yl)-6-(1-methyl-
1H-pyrazol-4-yl)benzo[d]isoxazole-3-carboxamide (45 mg, 0.11 mmol), 1- azaspiro[3.3]heptane hydrochloride (26.5 mg, 0.2 mmol), and cesium carbonate (152 mg, 0.47 mmol) in N,N-dimethylformamide (2 mL) was heated at 60°C for 18 hours. The reaction was cooled to ambient temperature and filtered. The crude product was purified by preparative HPLC, 30% - 50% acetonitrile in water (10 mM ammonium hydroxide) to give N-[5-[[2-(7- azaspiro[3.3]heptan-7-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1-methylpyrazol-4-yl)-1,2- benzoxazole-3-carboxamide as an off-white solid (27 mg, 0.0556 mmol, 52.5%). LCMS (ESI): mass calcd. for C26H27N7O3: 485.2; m/z found: 486.2 [M+H]+. 1H NMR (400MHz, METHANOL-d4): δ 8.63 (d, J=2.0 Hz, 1H), 8.41 (d, J=2.0 Hz, 1H), 8.17 (s, 1H), 8.14 (d, J=8.3 Hz, 1H), 8.00 (s, 1H), 7.94 (s, 1H), 7.73 (d, J=8.3 Hz, 1H), 3.96 (s, 3H), 3.36 (s, 2H), 3.32-3.34 (m, 2H), 2.54 (s, 3H), 2.24-2.37 (m, 4H), 1.95-2.05 (m, 2H), 1.60-1.71 (m, 2H). Example 388 N-[2-Methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(1- methylpyrazol-4-yl)-1,2-benzoxazole-3-carboxamide
[00462] To an 8 mL threaded vial with magnetic stirrer was added (S)-2- methylpyrrolidine (17.0 mg, 0.20 mmol). A stock solution of N-(5-(2-chloroacetamido)-2- methylpyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)benzo[d]isoxazole-3-carboxamide (42.5 mg, 0.10 mmol) in acetonitrile (1 mL) was added to the amine followed by sodium iodide (10 mg, 0.067 mmol) and cesium carbonate (97.7 mg, 0.30 mmol). The reaction mixture was stirred at 55°C for 16 hours. The solvent was concentrated in vacuo to provide the crude product. The crude product was purified with preparative high-performance liquid chromatography to provide N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(1- methylpyrazol-4-yl)-1,2-benzoxazole-3-carboxamide (24.0 mg, 0.507 mmol, 50.7%). LCMS (ESI): mass calcd. for C25H27N7O3: 473.2; m/z found: 474.1 [M+H]+. 1H NMR (400MHz, DMSO-d6): δ 10.83 (s, 1H), 10.73 (s, 1H), 9.70 (br s, 1H), 8.61 (d, 1H, J=2.4 Hz), 8.38 (s, 1H), 8.21 (d, 1H, J=2.4 Hz), 8.1-8.1 (m, 2H), 8.04 (d, 1H, J=8.3 Hz), 7.78 (dd, 1H, J=1.5, 8.3 Hz), 3.91 (s, 3H), 3.5-3.7 (m, 1H), 3.1-3.4 (m, 2H), 2.54 (s, 1H), 2.5-2.5 (m, 3H), 2.19 (td, 1H,
J=6.2, 13.0 Hz), 1.9-2.1 (m, 2H), 1.6-1.7 (m, 1H), 1.38 (d, 3H, J=6.8 Hz), 1.23 (m, 1H) The following compounds were made by a similar procedure to example 388
Biological Assays [00463] PDGFRβ HTRF assay [00464] I. Materials [00465] Reagents
[00466] Instrumentation: a. Compound liquid handling: LabCyte Echo; b. Reagent liquid handling: Thermo Scientific Multidrop Combi; c. BMG PHERAStar multilabel plate reader. [00467] Protein Reagent: His6-TEV-PDGFRβ Protein Prep prepared at Accelagen. [00468] II. Methods and Procedures [00469] Stock solutions:
[00470] Assay buffer stock solution, contains 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, and 0.01% Brij-35, 0.01% ovalbumin, 2 mM DTT at pH 7.5, in molecular biology grade water. Store at room temperature. [00471] DTT, 2 M in molecular biology grade water, store at -20°C in aliquots. [00472] Ovalbumin, 10% or 100 mg/mL, prepare fresh on experimental day. [00473] PDGFRβ, 116 µM (PDGFRb_08 Prep 02), produced at Accelagen. Store at -80°C in aliquots. [00474] TK-biotin peptide, 0.5 µM in molecular biology grade water, store at - 20°C in aliquots. [00475] ATP, 100 mM in molecular biology grade water, store at -20°C in aliquots. [00476] HTRF KinEASE-TK kit: Allow the contents of the Cisbio kit to warm up to room temperature before use. This kit contains HTRF detection buffer, TK-Antibody labeled with Eu3+-cryptate, TK-substrate biotin and Streptavidin-XL665. [00477] TK Substrate-Biotin, reconstitute 500 µg lyopholized with 574 µL molecular biology grade water to prepare a 500 µM stock; After use, aliquot the rest and store at -20°C. [00478] TK Antibody-Cryptate, reconstitute lyophilized with 1 mL of molecular biology grade water (100x solution) then add 99 mL detection buffer to prepare a ready to use TK-antibody-cryptate solution; the concentration of the TK-antibody-cryptate reagent is not known. After use, aliquot the rest and store at -20°C. [00479] Streptavidin-XL665, reconstitute 3 mg lyophilized with 3 mL molecular biology grade water to prepare a 1 mg/mL or 16.67 µM stock; MW = 60 kDa; After use, aliquot the rest and store at -20°C. [00480] Freshly prepared solutions: [00481] Assay buffer. Dilute 5x Kinase buffer 5-fold with molecular biology grade water and add DTT to 2 mM and ovalbumin to 0.1 mg/mL (or 0.01%). [00482] 2X protein solution. Make a working solution of 100 pM PDGFRβ in assay buffer. Keep on ice until use to maintain enzyme stability. [00483] 2X substrate solution. Make a working solution of 1.6 mM ATP and 1 µM TK-substrate biotin peptide in assay buffer.
[00484] 3X quench/detection solution. Make a working solution of 0.1875 µM SA-XL665 and the TK-antibody cryptate diluted by ½ of total quench/detection volume in assay buffer. [00485] Keep final streptavidin/biotin ratio at 1 to 8. [00486] Example of 3x quench/detection solution preparation: 8 mL total volume. [00487] 1x assay buffer – 3910 µL [00488] TK antibody-cryptate in detection buffer – 4000 µL [00489] 0.1875 µM SA-XL665 – 90 uL [00490] The kinase reaction is stopped by the addition of the detection reagents which contain EDTA (detection step). [00491] Assay Procedure: [00492] Assay in white ProxiPlate 384-well [00493] Step 1. Dispensing inhibitors/DMSO and low control: Using the ECHO 555 acoustic dispenser, spot desired compound serial dilutions in DMSO, NEAT DMSO to represent the uninhibited enzyme control, and 10 µM final [imatinib] to the represent the 100% inhibited enzyme control [00494] Step 2. PDGFRβ E + I pre-incubation: Add 2 µL 2x protein solution to columns 1-24 using the Multidrop Combi. Centrifuge at 1000 rpm for 1 min. Incubate 30 min at RT [00495] Step 2. Enzymatic reaction: Add 2 µL substrate solution to columns 1-24 to initiate the reaction using the Multidrop Combi; cover/seal the assay plate to reduce evaporation. Centrifuge at 1000 rpm for 1 min. Incubate at room temperature for 3 hours. [00496] Final concentrations of components in PDGFRβ cascade assay: [00497] 50 mM Hepes, pH 7.5 [00498] 10 mM MgCl2 [00499] 0.01% Brij-35 [00500] 1 mM EGTA [00501] 2 mM DTT [00502] 0.01% Ovalbumin [00503] 50 pM inactive PDGFRβ [00504] 0.5 µM TK-substrate biotin peptide
[00505] 62.5 nM SA-XL-665 [00506] TK antibody-Eu3+-cryptate (diluted by 1/3 final from stock) [00507] 800 µM ATP [00508] ≤ 1% DMSO [00509] Step 3. Quench/Detection: Add 2 µl 3x quench/detection solution to columns 1-24 using the Multidrop Combi; cover/seal the plate. Centrifuge 1 min 1000 rpm. Incubate at RT for 60 min. Read the plate in PHERAstar (or similar instrument) on HTRF setting at excitation 337nm - dual emission - 665/620 nm ratio. [00510] III. Calculations and Formulas [00511] HTRF ratio values calculated by the instrument (Ratio is acceptor counts/donor counts * 10,000) is exported from the plate reader and used in data analysis. The exported data will be used to calculate 1) compound activity and 2) assay statistics. Compound activity is represented by % Inhibition when testing a single dose of a compound or IC50 when testing a dose response of a compound. Assay statistics can include Robust Z’ and Signal to Background. [00512] % Inhibition Calculation: Percent inhibition will be calculated for sample wells based on the equation:
[00513] Where, x: sample activity; cr: central reference is calculated based on wells containing all assay components and no compound (DMSO only); sr: scale reference is calculated based on wells inhibited with 10 µM Imatinib (these wells will contain the enzyme and substrate solutions) [00514] IC50 Calculation: For IC50 determination, full 11- point dose response data will be processed using the following equation:
[00515] Where S0=Activity level at zero concentration of test compound; SInf=Activity level at infinite concentration; IC50: Concentration at which activity reaches 50% of maximum level; c= Concentration in logarithmic units corresponding to the values on the x-axis of the dose-response curve plot; Hill coefficient n= Measure of the slope at IC50. See Table 1, below.
[00516] Registered Parameters (when applicable): % Activity, IC50, nHill Slope, Sinf, S0, and Comments [00517] Robust Z’ Calculation: Robust Z prime (RZ’) value will be calculated as defined by the following equation:
[00518] Where, RSD: Robust standard deviation; cr: central reference is calculated based on wells containing all assay components and no compound (DMSO only); sr: scale reference is calculated based on wells inhibited with 10 µM Imatinib compound (these wells will contain the enzyme and substrate solutions) [00519] Signal to Background, S/B, Calculation
[00520] Where, CR, Central Reference (no compound wells); SR, Scale Reference (inhibitor control wells). [00521] PDGFRβ LanthaScreen assay [00522] I. Materials
[00523] II. Methods and Procedures [00524] Stock solutions: [00525] Assay buffer stock contains 50 mM HEPES pH7.5, 10 mM MgCl2, 0.01% Brij- 35, 1 mM EGTA. [00526] Tb-labeled inactive PDGFRβ.3.6 µM in 50 mM HEPES, pH 7.4, 150 mM NaCl, 0.005% Tween-20 and 10% glycerol. Store at -80 oC in aliquots. [00527] Tracer 222, 50 µM in DMSO, store at -20 oC. [00528] Freshly prepared solutions: [00529] Assay buffer. Add DTT to 2 mM and ovalbumin to 0.1 mg/mL to Assay buffer stock. [00530] Kinase-Tracer solution. Make a working solution of 0.2 nM Tb-labeled inactive PDGFRβ and 40 nM Tracer 222 in Assay buffer. Keep on ice until use. [00531] Assay Procedure: [00532] Step 1. Dispensing inhibitors: Using Echo, dispense 40nL/well (or less) compound serial dilutions in DMSO onto the assay plate. [00533] Step 2. Dispensing Kinase-Tracer solution: Add 4 µL/well Kinase-Tracer solution. Seal the plate with optically transparent plate seal. Centrifuge at 1000 rpm for 1 min. [00534] Final concentrations of components in the assay: [00535] [Tb-PDGFRβ] = 0.2 nM; [00536] [Tracer 222] = 40 nM; [00537] [DMSO] ^ 1%. [00538] Step 3. Detection: Read TR-FRET signals after 18 hours incubation at room temperature. [00539] III. Calculations and Formulas [00540] % Inhibition: % Inhibition = (NC – sample) / (NC – PC) * 100 where NC is the mean of negative control (reactions without inhibitor), and PC is the mean of positive control (1µM sunitinib). [00541] IC50 determination: Compounds are serially diluted 3-fold and tested in an 11- point dose response. IC50 values are determined from a 4-parameter fit, using the following equation: Y = Bottom + (Top – Bottom) / (1+10((Log IC50-X)*Hill slope)), where X = log10
of the compound concentration; top can be defined by PC; bottom defined by NC. See Table 1, below. [00542] PDGFRβ cellular assay [00543] I. Materials
[00544] II. Methods and Procedures [00545] Cell Culture and Preparation: Cells are cultured according to ATCC procedure (5) with the addition of the antibiotic penicillin-streptomycin. If working from frozen, cells should be thawed according to ATCC procedure. Depending on the cell density of frozen vial, cells will need time to recover from thaw. An 80% confluent T75 flask should be enough for one 384 well plate. [00546] Stock Solutions: Rat PDGFBB. A 100ug/mL stock is prepared by reconstituting 50ug in 500uL of 4mM HCl and 0.1% BSA. It can be stored for a month at 4°C, or aliquoted out and frozen in the -20/-80°C to avoid multiple free-thaw cycles. [00547] Freshly Prepared Solutions: [00548] 1x Cisbio cell lysis buffer. The cell lysis buffer is diluted 4-fold with molecular grade water. The blocking agent is then diluted 25-fold in the diluted lysis buffer. [00549] Antibody solutions. Equal amounts d2 and cryptate antibody are diluted 20-fold in detection buffer.
[00550] Rat PDGFBB. A working stock of 100ng/mL is created from the stock solution in 10%FBS culture media. [00551] Assay Steps [00552] Step 1: Plating Cells: Media from the A10 cell flask is aspirated. The cells are rinsed with PBS and then trypsinized to disperse the cell layer. The cells are then pelleted are resuspended to 1.25e5 cells/mL. 40uL of cells are then plated in 384 Greiner TC treated plates at a density of 5000 cells/well using the Combi. Plates are covered and placed in the incubator (37°C 5% CO2) overnight to allow cells to adhere. [00553] Step 2: Compound Dispense: Approximately 18 hours after plating, dispense 40nL compound onto cells using Echo. Column 12 is the neutral control DMSO, column 24 is the inhibitor control 10 mM Imatinib (10uM final assay concentration). The plate is returned to the incubator for 3 hours. [00554] Step 3: Activation by PDGFbb: 6uL of the working stock of 100ng/mL PDGFbb is dispensed using the Tempest to give a final assay concentration of 15ng/mL (EC80). After 10 minutes the media is removed by flicking the plate. [00555] Step 4: Cell lysis and antibody addition: 20uL lysis buffer per well is added to the plate via Tempest. 5uL antibody solution is added per well via the Tempest. The plate is placed on the shaker at 230 rpm for 1 hour at room temperature. [00556] Step 5: Detection: The plate is read using the HTRF module on the BMG Pherastar. Data is analyzed using Genedata Screener. [00557] III. Calculations and Formulas: [00558] % Inhibition: % Inhibition = (NC – sample) / (NC – PC) * 100 where NC is the mean of negative control (reactions without inhibitor), and PC is the mean of positive control (10µM imatinib). [00559] IC50 determination: Compounds are serially diluted 3-fold and tested in an 11- point dose response. IC50 values are determined from a 4-parameter fit, using the following equation: Y = Bottom + (Top – Bottom) / (1+10((Log IC50-X)*Hill slope)), where X = log10 of the compound concentration; top can be defined by PC; bottom defined by NC. See Table 1, below. [00560] VEGFR ADP GLO assay [00561] I. Materials
[00562] II. Methods and Procedures [00563] Stock solutions: [00564] Assay buffer stock contains 50mM HEPES pH7.5, 10mM MgCl2, 0.01% Brij-35, and 1mM EGTA. [00565] Unphosphorylated VEGFR2.52.6 µM in 50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 5% Glycerol, 0.5 mM TCEP. Store at -80 oC in aliquots. [00566] 10mg/mL srctide solution, prepared in Assay buffer (Assay buffer stock with 2mM DTT, 0.1% Pluronic F-127, and 0.1mg/mL ovalbumin). Sonicate 10 mg/ml Srctide solution for 10 minutes and then vacuum filter. [00567] Freshly prepared solutions
[00568] Assay buffer. Add DTT to 2mM, Pluronic F-127 to 0.1% and ovalbumin to 0.1mg/mL to Assay buffer stock. [00569] 2X kinase solution. Make a working solution of 10 nM unphosphorylated VEGFR2 in Assay buffer. Vacuum filter 2x kinase solution prior to running assay. Keep on ice until use. [00570] 2X substrate/ATP solution. Make a working solution of 2mg/mL srctide and 2.4mM ATP in Assay buffer. Keep on ice until use. [00571] Assay Procedure: [00572] Step 1. Dispensing inhibitors/controls: Using Echo, dispense 10nL/well compound serial dilutions in DMSO to columns 1-22 (in 384-well plates) or columns 1-44 (in 1536-well plates). Dilution series = 11 pt, 3-fold dilutions. The top compound concentration in the source plate is 4 mM. The top compound concentration in the assay plate is 10 uM. Using Echo, dispense 10 nl/well DMSO to column 23 (in 384-well plates) or columns 45-47 (in 1536-well plates). These wells will serve as negative control wells Using Echo, dispense 10 nl/well 400 uM TAK-593 in DMSO to column 24 (in 384-well plates) or column 48 (in 1536-well plates). The final concentration of TAK-593 in the assay should be 1 uM. These wells will serve as positive control wells. [00573] Step 2. Pre-incubation of inhibitors with kinase: Add 2 µL/well 2X kinase solution. Centrifuge at 1000 rpm for 1 min. Incubate at room temperature for 30 min. [00574] Step 3. Kinase cascade reaction: Add 2 µL/well 2X substrate/ATP solution to initiate kinase reactions. Centrifuge at 1000 rpm for 1 min. Incubate at room temperature for 180 min. [00575] Final concentrations of components in the assay: [00576] [VEGFR2] = 5 nM; [00577] [ATP] = 1.2 mM; [00578] [Srctide] = 1 mg/mL; [00579] [DMSO] ^ 1%. [00580] Step 4. Quench: Add 2 uL/well ADP Glo Reagent + 0.05% CHAPS. Centrifuge at 1000 rpm for 1 min; Incubate at room temperature for one hour. [00581] Step 5. Detection: Add 2uL/well Kinase Detection Reagent + 0.05% CHAPS. Centrifuge at 1000 rpm for 1 min; Incubate at room temperature for 1 hour; Read Luminescence on a plate reader.
[00582] III. Calculations and Formulas [00583] % Inhibition: % Inhibition = (NC – sample) / (NC – PC) * 100 where NC is the mean of negative control (reactions without inhibitor), and PC is the mean of positive control (1µM TAK-593). [00584] IC50 determination: Compounds are serially diluted 3-fold and tested in an 11- point dose response. IC50 values are determined from a 4-parameter fit, using the following equation: Y = Bottom + (Top – Bottom) / (1+10(Log IC50-X)*Hill slope), where X = log10 of the compound concentration; top can be defined by PC; bottom defined by NC. See Table 1, below. [00585] Table 1:
Claims
What is claimed: 1. A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein A is or
wherein *2 is the point of attachment to R2, and *1 is the point of attachment to the amide carbonyl carbon atom; R1 is H, C1-C6alkyl, C3-C6cycloalkyl, halogen, -CN, or C1-C4fluoroalkyl; R2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted fused heterocycloalkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, halo, -O-(3- to 5-membered heterocycloalkyl), -NH-(3- to 5-membered heterocycloalkyl), or optionally substituted heterocycloalkyl; R3 and R4 are each independently optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; or one of R3 or R4 may be H; or R3 and R4, together with the nitrogen atom to which they are both attached, form an optionally substituted 3-12-membered heterocycloalkyl ring, an optionally substituted 5-12-membered bridged heterocycloalkyl ring, an optionally substituted 4- 12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12- membered spiroheterocycloalkyl ring system, wherein said 3-12-membered
heterocycloalkyl ring, 5-12-membered bridged heterocycloalkyl ring, 4-12-membered fused heterocycloalkyl ring system, or 5-12-membered spiroheterocycloalkyl ring system may include, in addition to the nitrogen atom to which both R3 and R4 are attached, 1-3 other heteroatoms that are each independently O, S, or N; each R5 and each R6 is independently H, C1-C6alkyl, or C3-C5cycloalkyl; or an R5 and R6 attached to the same carbon atom, together with that carbon atom, may form a C3-C6cycloalkyl ring; or an R5 or R6, together with an R3 or R4 may form an optionally substituted 3- 12-membered heterocycloalkyl ring, an optionally substituted 5-12-membered bridged heterocycloalkyl ring, an optionally substituted 4-12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12-membered spiroheterocycloalkyl ring system; n is 1,
2,
3,
6. The compound according to any one of the preceding claims, wherein R1 is C1- C6alkyl, preferably -CH3.
7. The compound according to any one of the preceding claims, wherein R2 is optionally substituted heteroaryl.
8. The compound according to claim 7, wherein the optionally substituted heteroaryl is an optionally substituted 5-membered heteroaryl.
9. The compound according to claim 8, wherein the optionally substituted 5-membered heteroaryl is an optionally substituted pyrazolyl, an optionally substituted triazolyl, an optionally substituted isoxazolyl, an optionally substituted oxadiazolyl, an optionally substituted thiophenyl, or an optionally substituted thiazolyl
10. The compound according to claim 7, wherein the optionally substituted heteroaryl is an optionally substituted 6-membered heteroaryl.
11. The compound according to claim 10, wherein the optionally substituted 6-membered heteroaryl is an optionally substituted pyridinyl, or an optionally substituted pyrimidinyl.
12. The compound according to any one of claims 7 to 11, wherein the optionally substituted heteroaryl is substituted with C1-C6alkyl, C1-C6haloalkyl, C1- C6haloalkoxyl, C1-C6alkoxyl, -C1-C6alkyl-O-C1-C6alkyl, hydroxyl, hydroxyalkyl, halo, cyano, cyclopropyl, 6-membered heterocycloalkyl, 5-membered heterocycloalkyl, 4-membered heterocycloalkyl, -C1-C6alkyl-SO2-C1-C6alkyl, 6- membered heteroaryl, 5-membered heteroaryl, -C(O)NH2, hydroxy-substituted-4- membered heterocycloalkyl, -C1-C6alkyl-CO2H, or -NH2.
13. The compound according to any one of claims 1 to 6, wherein R2 is optionally substituted aryl.
14. The compound according to claim 13, wherein the optionally substituted aryl is an optionally substituted phenyl.
15. The compound according to claim 13 or claim 14, wherein the optionally substituted aryl is substituted with -C1-C6alkyl-NHS(O)2-C1-C6alkyl, hydroxyalkyl, -NHC(O)C1- C6alkyl, 5-membered heterocycloalkyl, -SO2NH2, -C(O)NH2, -S(O)C1-C6alkyl, SO2- C1-C6alkyl, C1-C6alkylC(O)NH2, -C(O)N(C1-C6alkyl)2, 5-membered heteroaryl, or hydroxy-substituted-4-membered heterocycloalkyl.
16. The compound according to any one of claims 1 to 6, wherein R2 is -O-(3- to 5- membered heterocycloalkyl).
17. The compound according to any one of claims 1 to 6, wherein R2 is halo.
18. The compound according to any one of claims 1 to 6, wherein R2 is optionally substituted alkenyl.
19. The compound according to any one of claims 1 to 6, wherein R2 is -NH-(3- to 5- membered heterocycloalkyl).
20. The compound according to any one of claims 1 to 6, wherein R2 is optionally substituted heterocycloalkyl.
21. The compound according to claim 20, wherein the optionally substituted heterocycloalkyl is an optionally substituted dihydropyran, an optionally substituted tetrahydropyran, or an optionally substituted morpholine.
22. The compound according to claim 20 or claim 21, wherein the optionally substituted heterocycloalkyl is substituted with hydroxy, hydroxyalkyl, C1-C6alkoxyl, or -C1- C6alkyl-O-C1-C6alkyl.
23. The compound according to any one of the preceding claims, wherein L is -C(O)NH-.
24. The compound according to any one of claims 1-22, wherein L is -NHC(O)-.
25. The compound according to any one of claims 1-22, wherein L is -NHC(O)O-.
26. The compound according to any one of claims 1-22, wherein L is or -NHC(O)NH-.
27. The compound according to any one of the preceding claims, wherein n is 1.
28. The compound according to any one of claims 1-26, wherein n is 2.
29. The compound according to any one of claims 1-26, wherein n is 3.
30. The compound according to any one of claims 1-26, wherein n is 4.
31. The compound according to any one of claims 1-26, wherein n is 5.
32. The compound according to any one of the preceding claims, wherein each R5 and each R6 is H.
33. The compound according to any one of the preceding claims, wherein R3 and R4 are each independently optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; or one of R3 or R4 may be H.
34. The compound according to claim 33, wherein R3 is optionally substituted alkyl or optionally substituted C4-C5cycloalkyl; and R4 is optionally substituted C4- C5cycloalkyl or optionally substituted heteroaryl.
35. The compound according to any one of claims 1 to 34, wherein R3 and R4, together with the nitrogen atom to which they are both attached, form an optionally substituted 3-12-membered heterocycloalkyl ring, an optionally substituted 5-12-membered bridged heterocycloalkyl ring; an optionally substituted 4-12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12-membered spiroheterocycloalkyl ring system, wherein said 3-12-membered heterocycloalkyl ring, 5-12-membered bridged heterocycloalkyl ring, 4-12-membered fused heterocycloalkyl ring system, and 5-12-membered spiroheterocycloalkyl ring system optionally includes, in addition to the nitrogen atom to which both R3 and R4 are attached, 1-3 heteroatoms that are each independently O, S, or N.
36. The compound according to claim 35, wherein R3 and R4, together with the nitrogen atom to which they are both attached, form an optionally substituted 3-12-membered heterocycloalkyl ring.
37. The compound according to claim 36, wherein the optionally substituted 3-12- membered heterocycloalkyl ring is an optionally substituted azetidinyl, an optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted azepanyl, optionally substituted piperazinyl, optionally substituted oxazepanyl, optionally substituted thiomorpholinyl 1,1-dioxide, or optionally substituted morpholinyl.
38. The compound according to claim 36 or claim 37, wherein the optionally substituted 3-12-membered heterocycloalkyl ring is substituted with C1-C6alkyl, C1-C6alkoxyl, -
C1-C6alkyl-O-C1-C6alkyl, hydroxyl, hydroxyalkyl, halo, carbonyl (i.e., (=O)), cyano, cyclopropyl, or 5-membered heteroaryl.
39. The compound according to claim 35, wherein R3 and R4, together with the nitrogen atom to which they are both attached, form an optionally substituted 5-12-membered bridged heterocycloalkyl ring.
40. The compound according to claim 39, wherein the optionally substituted 5- to 12- membered bridged heterocycloalkyl ring is an optionally substituted 7- azabicyclo[2.2.2]octan-7-yl, an optionally substituted 7-azabicyclo[2.2.1]heptan-7-yl, an optionally substituted 2-azabicyclo[2.2.1]heptan-2-yl, an optionally substituted azabicyclo[3.1.1]heptane, an optionally substituted 8-azabicyclo[3.2.1]octan-8-yl, an optionally substituted 2,5-diazabicyclo[2.2.1]heptan-5-yl, an optionally substituted 6- azabicyclo[3.2.1]octan-6-yl, an optionally substituted 3-azabicyclo[3.2.1]octan-3-yl, an optionally substituted 2-azabicyclo[2.2.2]octan-2yl, an optionally substituted diazabicyclo[2.2.1]heptanyl, an optionally substituted 2-oxa-5- azabicyclo[2.2.2]octan-5-yl, an optionally substituted 2-oxa-5- azabicyclo[2.2.1]heptan-5-yl, an optionally substituted 3-oxa-8- azabicyclo[3.2.1]octan-8-yl, an optionally substituted 6-oxa-3- azabicyclo[3.1.1]heptan-3-yl, an optionally substituted 8-oxa-3- azabicyclo[3.2.1]octan-3-yl, an optionally substituted 3,9-diazabicyclo[4.2.1]nonan-3- yl, an optionally substituted 2-oxa-6-azaadamantan-6-yl, (an optionally substituted 3- oxa-azabicyclo[3.2.1]octanyl, or an optionally substituted 2-oxa- azabicyclo[2.2.1]heptanyl.
41. The compound according to claim 39 or claim 40, wherein the optionally substituted 5-12-membered bridged heterocycloalkyl ring is substituted with C1-C6alkyl, hydroxy, or hydroxyalkyl.
42. The compound according to claim 35, wherein R3 and R4, together with the nitrogen atom to which they are both attached, form an optionally substituted 5-12-membered spiroheterocycloalkyl ring.
43. The compound according to claim 42, wherein the optionally substituted 5-12- membered spiroheterocycloalkyl ring is an optionally substituted 7- azaspiro[3.5]nonan-7-yl, an optionally substituted 4-azaspiro[2.4]heptan-4-yl, an optionally substituted 1-azaspiro[3.3]heptan-1-yl, an optionally substituted 2- azaspiro[3.3]heptan-2-yl, an optionally substituted 6-azaspiro[2.5]octan-6-yl, an optionally substituted 2-oxa-7-azaspiro[4.4]nonan-7-yl, an optionally substituted 1- oxa-7-azaspiro[4.4]nonan-7-yl, an optionally substituted 2-oxa-6-azaspiro[3.4]octan- 6-yl, an optionally substituted 5-azaspiro[2.4]heptan-5-yl, an optionally substituted 4- azaspiro[2.4]heptan-4-yl, an optionally substituted 2-azaspiro[4.5]decan-2-yl, an optionally substituted 8-azaspiro[4.5]decan-8-yl, an optionally substituted 2- azaspiro[4.4]nonan-2-yl, an optionally substituted 5-azaspiro[3.5]nonan-5-yl, an optionally substituted 7-oxa-4-azaspiro[2.5]octan-4-yl, an optionally substituted 5- azaspiro[3.4]octan-5-yl, an optionally substituted 1-oxa-7-azaspiro[3.5]nonan-7-yl, an optionally substituted 2-oxa-6-azaspiro[3.4]octan-6-yl, an optionally substituted 2- oxa-7-azaspiro[3.5]nonan-7-yl, an optionally substituted 2-oxa-5-azaspiro[3.4]octan- 5-yl, an optionally substituted 8-oxa-5-azaspiro[3.5]nonan-5-yl, an optionally substituted 1-azaspiro[4.4]nonan-1-yl, an optionally substituted 7-oxa-4- azaspiro[2.5]octan-4-yl, an optionally substituted 2,5-dioxa-8-azaspiro[3.5]nonan-8- yl, an optionally substituted 8-oxa-2-azaspiro[4.5]decan-2-yl, an optionally substituted 2-oxa-5-azaspiro[3.5]nonan-5-yl, an optionally substituted 4-oxa-7- azaspiro[2.5]octan-7-yl, an optionally substituted 1-azaspiro[4.5]decan-1-yl, an optionally substituted 6-azaspiro[4.5]decan-6-yl, an optionally substituted 7- azaspiro[3.5]nonan-7-yl, an optionally substituted 3-oxa-9-azaspiro[5.5]undecane-9- yl, an optionally substituted 8-oxa-1-azaspiro[4.5]decan-1-yl, an optionally substituted 1,8-diazaspiro[4.5]decan-1-yl, or an optionally substituted 5-oxa-8- azaspiro[3.5]nonan-8-yl.
44. The compound according to claim 42 or claim 43, wherein the optionally substituted 5-12-membered spiroheterocycloalkyl ring is substituted with C1-C6alkyl, halo, or hydroxyalkyl.
45. The compound according to claim 35, wherein R3 and R4, together with the nitrogen atom to which they are both attached, form an optionally substituted 4-12-membered fused heterocycloalkyl ring system.
46. The compound according to claim 45, wherein the optionally substituted 4-12- membered fused heterocycloalkyl ring system is an optionally substituted 3- azabicyclo[3.2.0]heptan-3-yl, an optionally substituted 3-azabicyclo[3.1.0]hexan-3-yl, an optionally substituted 2-azabicyclo[3.1.0]hexan-2-yl, an optionally substituted hexahydro-1H-2-pyrrolo[2,1-c]pyrazinyl, an optionally substituted 5,8-dihydro-6H-7- 1,7-naphthyridinyl, an optionally substituted hexahydro-2H-6-furo[2,3-c]pyridinyl, an optionally substituted tetrahydro-1H,3H-5-furo[3,4-c]pyrrolyl, an optionally substituted 2-oxa-5-azabicyclo[4.1.0]heptanyl, an optionally substituted 4,7-dihydro- 5H-6-thieno[2,3-c]pyridinyl, an optionally substituted 2-isoindolinyl, an optionally substituted 3,4-dihydro-1H-2-2,7-naphthyridinyl, an optionally substituted 3,4- dihydro-1H-2-2,6-naphthyridinyl, an optionally substituted 1,4,5,7-tetrahydro-6- pyrazolo[3,4-c]pyridinyl, 3,4,6,7-tetrahydro-5-imidazo[4,5-c]pyridinyl, an optionally substituted 5,6-dihydro-8H-7-imidazo[2,1-c]pyrazinyl, an optionally substituted 3,4- dihydro-1H-2-2,6-naphthyridinyl, an optionally substituted 6,7-dihydro-4H-5- thiazolo[4,5-c]pyridinyl, an optionally substituted 7,8-dihydro-5H-6-pyrido[3,4- b]pyrazinyl, an optionally substituted 5,8-dihydro-6H-7-pyrido[3,4-d]pyrimidinyl, an optionally substituted 1,4,6,7-tetrahydro-5-pyrazolo[4,3-c]pyridinyl, an optionally substituted 3,4-dihydro-1H-2-isoquinolinyl, an optionally substituted 1,4,6,7- tetrahydro-5-pyrrolo[3,2-c]pyridinyl, an optionally substituted 6,7-dihydro-4H-5- thiazolo[5,4-c]pyridinyl, an optionally substituted 5,7-dihydro-6-pyrrolo[3,4- b]pyridinyl, an optionally substituted 5,6-dihydro-8H-7-[1,2,4]triazolo[5,1- c]pyrazinyl, an optionally substituted 7,8-dihydro-5H-6-pyrido[4,3-d]pyrimidinyl, an optionally substituted 4,6-dihydro-5-pyrrolo[3,4-d]thiazolyl, an optionally substituted 6,7-dihydro-4H-5-[1,2,3]triazolo[5,1-c]pyrazinyl, an optionally substituted 5,7- dihydro-6-pyrrolo[3,4-d]pyrimidinyl, an optionally substituted 5,6-dihydro-8H-7- imidazo[5,1-c]pyrazinyl, an optionally substituted 6,7-dihydro-4H-5-pyrazolo[5,1- c]pyrazinyl, an optionally substituted 5,6-dihydro-8H-7-[1,2,4]triazolo[3,4- c]pyrazinyl, an optionally substituted 6,7-dihydro-4H-5-oxazolo[4,5-c]pyridinyl, an
optionally substituted 1,3-dihydro-2-pyrrolo[3,4-c]pyridinyl, an optionally substituted 6,7-dihydro-4H-5-oxazolo[5,4-c]pyridinyl, or an optionally substituted 4- azatricyclo[3.3.0.01,3]octanyl.
47. The compound according to claim 45 or claim 46, wherein the optionally substituted 4-12-membered fused heterocycloalkyl ring system is substituted with a C1-C6alkyl, halo, carbonyl (i.e., (=O)), or spirocyclopropyl
48. The compound according to any one of claims 1 to 33, wherein an R5 or R6, together with an R3 or R4 form an optionally substituted 3-12-membered heterocycloalkyl ring, an optionally substituted 5-12-membered bridged heterocycloalkyl ring, an optionally substituted 4-12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12-membered spiroheterocycloalkyl ring system. 49. The compound according to claim 48, wherein an R5 or R6, together with an R3 or R4 form an optionally substituted 3-12-membered heterocycloalkyl ring. 50. The compound according to claim 49, wherein the optionally substituted 3-12- membered heterocycloalkyl ring is a 4-8 membered heterocycloalkyl ring. 51. The compound according to claim 49, wherein the optionally substituted 3-12- membered heterocycloalkyl ring is an optionally substituted piperidinyl, an optionally substituted pyrrolidinyl, an optionally substituted azetidinyl. 52. The compound according to claim 48, wherein an R5 or R6, together with an R3 or R4 form an optionally substituted 4-12-membered fused heterocycloalkyl ring system. 53. The compound according to claim 52, wherein the optionally substituted 4-12- membered fused heterocycloalkyl ring system is a hexahydropyrrolizin-7a-yl. 54. The compound according to any one of claims 49 to 53, wherein the optionally substituted 3-12-membered heterocycloalkyl ring, an optionally substituted 5-12-
membered bridged heterocycloalkyl ring, an optionally substituted 4-12-membered fused heterocycloalkyl ring system, or an optionally substituted 5-12-membered spiroheterocycloalkyl ring system is substituted with a C1-C6alkyl. 55. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is: 7-(1-Methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2-methylpiperidin-1- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-((2S,6R)-2,6-dimethylpiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(isoindolin-2-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol- 4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(4,7-dihydrothieno[2,3-c]pyridin-6(5H)-yl)acetamido)-2-methylpyridin-3-yl)- 7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(2-azaspiro[4.5]decan-2-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(3,4-dihydroisoquinolin-2(1H)-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(2,2-dimethylpiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(1-azaspiro[4.4]nonan-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(5-azaspiro[3.5]nonan-5-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(2-azabicyclo[2.2.2]octan-2-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(7-oxa-4-azaspiro[2.5]octan-4-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(5-azaspiro[3.4]octan-5-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(2-oxa-6-azaspiro[3.4]octan-6-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide;
N-(5-(2-(1,4-oxazepan-4-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(3,3-dimethylmorpholino)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(1-oxa-7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-morpholinoacetamido)pyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(8-oxa-5-azaspiro[3.5]nonan-5-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(2,6-dimethylmorpholino)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(2,2-dimethylmorpholino)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(2-(methoxymethyl)pyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)acetamido)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(4-methoxypiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(3,5-dimethylmorpholino)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(2-oxa-5-azaspiro[3.4]octan-5-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(4-azaspiro[2.4]heptan-4-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)acetamido)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide;
7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(1-methyl-1,4,5,7-tetrahydro-6H- pyrazolo[3,4-c]pyridin-6-yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide; N-(5-(2-(5,8-dihydro-1,7-naphthyridin-7(6H)-yl)acetamido)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(3,4-dihydro-2,6-naphthyridin-2(1H)-yl)acetamido)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide; N-(5-(2-(6,7-dihydrothiazolo[4,5-c]pyridin-5(4H)-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)acetamido)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(3-methyl-3,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide; N-(5-(2-(7,8-dihydropyrido[3,4-b]pyrazin-6(5H)-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2-methyl-6,7-dihydrooxazolo[4,5- c]pyridin-5(4H)-yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide; N-(5-(2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(1-methyl-1,4,6,7-tetrahydro-5H- pyrrolo[3,2-c]pyridin-5-yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(1-methyl-1,4,6,7-tetrahydro-5H- pyrazolo[4,3-c]pyridin-5-yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide; N-(5-(2-(5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide;
N-(5-(2-(3',4'-dihydro-2'H-spiro[cyclopropane-1,1'-isoquinolin]-2'-yl)acetamido)-2- methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide; N-(5-(2-(7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(3,3-difluoropiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(5,7-dihydro-6H-pyrrolo[3,4-b]pyrazin-6-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(5,7-dihydro-6H-pyrrolo[3,4-b]pyrazin-6-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(tetrahydro-1H-furo[3,4-c]pyrrol- 5(3H)-yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(4,4-difluoropiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(4-fluoropiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2-methyl-6,7-dihydrooxazolo[5,4- c]pyridin-5(4H)-yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide N-(5-(2-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)acetamido)-2- methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide N-(5-(2-(4,6-dihydro-5H-pyrrolo[3,4-d]thiazol-5-yl)acetamido)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
(R)-7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2-methylpiperidin-1- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (S)-7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2-methylpiperidin-1- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-5(4H)-yl)acetamido)-2- methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide N-(5-(2-(4-hydroxypiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(4-azaspiro[2.4]heptan-4-yl)acetamido)-2-methylpyridin-3-yl)-7-(6- (hydroxymethyl)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(4-azaspiro[2.4]heptan-4-yl)acetamido)-2-methylpyridin-3-yl)-7-(6- aminopyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(4-azaspiro[2.4]heptan-4-yl)acetamido)-2-methylpyridin-3-yl)-7-(2-methyl- 2H-1,2,3-triazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(4-azaspiro[2.4]heptan-4-yl)acetamido)-2-methylpyridin-3-yl)-7-(pyrazin-2- yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(4-azaspiro[2.4]heptan-4-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-(2- hydroxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide 7-((2R,3S,4R)-3,4-dimethoxy-2-(methoxymethyl)-3,4-dihydro-2H-pyran-6-yl)-N-(5- (2-(4,4-dimethylpiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3- a]pyridine-3-carboxamide N-(5-(2-(4,4-Dimethylpiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-(2- hydroxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(3,6-dihydro- 2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(5,6-dihydro- 2H-pyran-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-(oxetan-3- yl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide;
N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(3- hydroxyprop-1-en-2-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(tetrahydro- 2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(3,4-dihydro- 2H-pyran-5-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(3,4-dihydro- 2H-pyran-6-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (R)-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (S)-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-(2- hydroxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-(2- fluoroethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (R)-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2-methylpiperidin-1- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (S)-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2-methylpiperidin-1- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(thiazol-2- yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-imidazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (R)-7-(5-(hydroxymethyl)thiophen-2-yl)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (R)-7-(5-(hydroxymethyl)thiophen-3-yl)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (R)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-7-(1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (R)-7-(5-(hydroxymethyl)furan-2-yl)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (R)-7-(6-(3-hydroxyoxetan-3-yl)pyridin-3-yl)-N-(2-methyl-5-(2-(2-methylpyrrolidin- 1-yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(5- (hydroxymethyl)-1-methyl-1H-pyrazol-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(2- (hydroxymethyl)-1-methyl-1H-imidazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(4- (hydroxymethyl)-5-methylthiazol-2-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(2-(1- hydroxyethyl)-1-methyl-1H-imidazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-7-(5- (hydroxymethyl)-4-methylthiazol-2-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(2-carbamoyl-1-methyl-1H-imidazol-4-yl)-N-(5-(2-(3,3-dimethylazetidin-1- yl)acetamido)-2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(oxetan-3- ylamino)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-morpholino- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7-(oxetan-3- yloxy)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(7-azaspiro[3.5]nonan-7-yl)acetamido)-2-methylpyridin-3-yl)-7- ((tetrahydrofuran-3-yl)oxy)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(3,3-dimethylmorpholino)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-((2-(2,2-dimethylmorpholino)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(2-azabicyclo[2.2.2]octan-2-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-((2-(8-methyl-1,8-diazaspiro[4.5]decan- 1-yl)ethyl)carbamoyl)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(8-azabicyclo[3.2.1]octan-8-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(5-oxa-8-azaspiro[3.5]nonan-8-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide;
N-(5-((2-(1-azaspiro[4.4]nonan-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(2-(hydroxymethyl)-2-methylmorpholino)ethyl)carbamoyl)-2-methylpyridin- 3-yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(8-oxa-5-azaspiro[3.5]nonan-5-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(7-oxa-4-azaspiro[2.5]octan-4-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(2-azabicyclo[2.2.1]heptan-2-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(8-oxa-2-azaspiro[4.5]decan-2-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(7-azabicyclo[2.2.1]heptan-7-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(5-azaspiro[3.5]nonan-5-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(2-oxa-5-azaspiro[3.5]nonan-5-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(2-(hydroxymethyl)-2-methylpiperidin-1-yl)ethyl)carbamoyl)-2- methylpyridin-3-yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3- carboxamide; N-(5-((2-(4-oxa-7-azaspiro[2.5]octan-7-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(6-azaspiro[2.5]octan-6-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)-2-oxoethyl)carbamoyl)-2-methylpyridin-3-yl)- 7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-((2-(2-oxopiperidin-1- yl)ethyl)carbamoyl)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(2,2-dimethyl-5-oxopyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)- 7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide;
N-(5-((2-(1-azaspiro[4.5]decan-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(1-azaspiro[4.5]decan-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(7-azaspiro[3.5]nonan-7-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(2-oxa-5-azaspiro[3.4]octan-5-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-((2-(4-methyl-3-oxopiperazin-1- yl)ethyl)carbamoyl)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(3-oxa-9-azaspiro[5.5]undecan-9-yl)ethyl)carbamoyl)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(2,5-dioxa-8-azaspiro[3.5]nonan-8-yl)ethyl)carbamoyl)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(1,1-dioxidothiomorpholino)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(isoindolin-2-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-((2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)-3,4-dihydro-2H-pyran-6-yl)-N-(5- ((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-((2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)-3,4-dihydro-2H-pyran-6-yl)-N-(5- ((2-(4,4-dimethylpiperidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-((2R,3S,4R)-3,4-dimethoxy-2-(methoxymethyl)-3,4-dihydro-2H-pyran-6-yl)-N-(5- ((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-((2R,3S,4R)-3,4-dimethoxy-2-(methoxymethyl)-3,4-dihydro-2H-pyran-6-yl)-N-(5- ((2-(4,4-dimethylpiperidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-((2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)-3,4-dihydro-2H-pyran-6-yl)-N-(5- ((2-((2S,6R)-2,6-dimethylpiperidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide;
N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(8-oxa-1-azaspiro[4.5]decan-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7- (1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-((2-(2,2-dimethylpiperidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-((2-(4-azaspiro[2.4]heptan-4-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 2-(4-(3-((5-((2-(2,2-Dimethylpyrrolidin-1- yl)ethyl)carbamoyl)-2-methylpyridin-3- yl)carbamoyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1H-pyrazol-1-yl)acetic acid N-(5-((2-((2R,6S)-2,6-dimethylpiperidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3- yl)-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-((2-(5-azaspiro[3.4]octan-5-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(3-(6-azaspiro[2.5]octan-6-yl)propanamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide N-(5-(3-(1-azaspiro[4.4]nonan-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(isoindolin-2-yl)propanamido)-2-methylpyridin-3-yl)-7-(1-methyl-1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(3,4-dihydroisoquinolin-2(1H)-yl)propanamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(7-azabicyclo[2.2.1]heptan-7-yl)propanamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(1,1-dioxidothiomorpholino)propanamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(5-azaspiro[3.4]octan-5-yl)propanamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(5-azaspiro[3.5]nonan-5-yl)propanamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(4-azaspiro[2.4]heptan-4-yl)propanamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide;
7-((2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)-3,4-dihydro-2H-pyran-6-yl)-N-(5- (3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-((2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)-3,4-dihydro-2H-pyran-6-yl)-N-(5- (3-(4,4-dimethylpiperidin-1-yl)propanamido)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-((2R,3S,4R)-3,4-dimethoxy-2-(methoxymethyl)-3,4-dihydro-2H-pyran-6-yl)-N-(5- (3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-((2R,3S,4R)-3,4-dimethoxy-2-(methoxymethyl)-3,4-dihydro-2H-pyran-6-yl)-N-(5- (3-(4,4-dimethylpiperidin-1-yl)propanamido)-2-methylpyridin-3-yl)- [1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(2-azabicyclo[2.2.2]octan-2-yl)propanamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(cyclobutyl(cyclopentyl)amino)propanamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(cyclopentyl(isopropyl)amino)propanamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(methyl(pyridin-2- yl)amino)propanamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(1-methylpiperidin-4- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(1-methylpyrrolidin-3- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(1-methylpiperidin-3- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(tetrahydro-1H-pyrrolizin-7a(5H)- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(1-methylpyrrolidin-2- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(1-isopropylpiperidin-4-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(2-(1-isopropylpiperidin-3-yl)acetamido)-2-methylpyridin-3-yl)-7-(1-methyl- 1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide;
7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(1-methylpiperidin-4- yl)propanamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(1-methylpiperidin-2- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (R)-N-(5-(2-(1-isopropylpyrrolidin-3-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (S)-N-(5-(2-(1-isopropylpyrrolidin-3-yl)acetamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; 7-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(1-methylazetidin-3- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (S)-N-(2-methyl-5-(2-(1-methylpyrrolidin-2-yl)acetamido)pyridin-3-yl)-7-(thiophen- 3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (S)-N-(5-(2-(1-isopropylpyrrolidin-2-yl)acetamido)-2-methylpyridin-3-yl)-7- (thiophen-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (S)-7-(5-(hydroxymethyl)thiophen-3-yl)-N-(2-methyl-5-(2-(1-methylpyrrolidin-2- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (S)-7-(5-(hydroxymethyl)thiophen-3-yl)-N-(5-(2-(1-isopropylpyrrolidin-2- yl)acetamido)-2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (R)-N-(2-methyl-5-(2-(1-methylpyrrolidin-2-yl)acetamido)pyridin-3-yl)-7-(thiophen- 3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (R)-7-(5-(hydroxymethyl)thiophen-3-yl)-N-(2-methyl-5-(2-(1-methylpyrrolidin-2- yl)acetamido)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(1H- pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(1H- pyrrol-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(5- (hydroxymethyl)thiophen-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(5- (hydroxymethyl)thiophen-2-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(2- (hydroxymethyl)thiophen-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-indazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide;
N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(2- morpholinopyridin-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(5- (hydroxymethyl)furan-2-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(6-(3- hydroxyoxetan-3-yl)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(4-(3- hydroxyoxetan-3-yl)phenyl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(2,2-dimethylpyrrolidin-1-yl)propanamido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; N-(5-(3-(2-(2,2-dimethylpyrrolidin-1-yl)ethyl)ureido)-2-methylpyridin-3-yl)-7-(1- methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide; (S)-6-(3,5-dimethyl-1-(oxetan-3-yl)-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2- methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide; (S)-6-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)-N-(2-methyl-5-(2-(2- methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide; (S)-6-(5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazin-3-yl)-N-(2-methyl-5-(2-(2- methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide; (S)-6-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(4- (methylsulfonyl)phenyl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(3- (methylsulfonyl)phenyl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; (R)-6-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(2-methylpyrrolidin-1- yl)propanamido)pyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-(2-((cis-2,6-dimethylmorpholino)acetamido)-2-methylpyridin-3-yl)-6-(1-methyl- 1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide;
N-(5-(2-((cis-2,6-dimethylmorpholino)acetamido)-2-methylpyridin-3-yl)-6-(5- (hydroxymethyl)thiophen-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-(2-(2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2-methylpyridin-3-yl)-6-(1- methyl-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(1-(2- methoxyethyl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6-(1- (oxetan-3-yl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6-(3- methyl-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6-(1- (2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide; N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6-(1- (oxetan-3-yl)-1H-pyrazol-5-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; (S)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-6-(1-(oxetan- 3-yl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide (S)-6-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)-N-(2-methyl-5-(2-(2- methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide; N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(1-(oxetan- 3-yl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6-(1- (oxetan-3-yl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; (S)-6-(2-(hydroxymethyl)thiazol-5-yl)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(2- (hydroxymethyl)thiazol-5-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(2- (hydroxymethyl)thiazol-5-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(1-(oxetan-3- yl)-1H-pyrazol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-(2-(2-azabicyclo[2.2.1]heptan-2-yl)acetamido)-2-methylpyridin-3-yl)-6-(2- (hydroxymethyl)thiazol-5-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide;
N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6-(2- (hydroxymethyl)thiazol-5-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(1-(2- hydroxyethyl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; (S)-6-(1-(2-hydroxyethyl)-1H-pyrazol-3-yl)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(1-(oxetan- 3-yl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; (S)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-6-(1-(oxetan- 3-yl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; (S)-6-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(2-(2-methylpyrrolidin-1- yl)acetamido)pyridin-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(2-methyl-5-(2-((R)-2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-6-(1- (tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(1- (tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide; N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(1- (tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide; N-(2-methyl-5-(2-((S)-2-methylpyrrolidin-1-yl)acetamido)pyridin-3-yl)-6-(1- (tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide; N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6-(1H- pyrrol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-((2-((1s,4s)-2-azabicyclo[2.2.2]octan-2-yl)ethyl)carbamoyl)-2-methylpyridin-3- yl)-6-(1H-pyrrol-3-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6-(5- (hydroxymethyl)thiophen-2-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6-(2- morpholinopyridin-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-((2-((1s,4s)-2-azabicyclo[2.2.2]octan-2-yl)ethyl)carbamoyl)-2-methylpyridin-3- yl)-6-(2-morpholinopyridin-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide;
N-(5-((2-((1s,4s)-2-azabicyclo[2.2.2]octan-2-yl)ethyl)carbamoyl)-2-methylpyridin-3- yl)-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-((2-((1s,4s)-2-azabicyclo[2.2.2]octan-2-yl)ethyl)carbamoyl)-2-methylpyridin-3- yl)-6-(1-((R)-tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide; (R)-N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-methylpyridin-3-yl)-6- (1-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3- carboxamide; N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(5-pyrazol- 1-yl-3-pyridyl)triazolo[1,5-a]pyridine-3-carboxamide; 6-(2-cyano-3-furyl)-N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3- pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(2,5- dimethyl-4-pyridyl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-[2- (hydroxymethyl)-3-thienyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(2-cyclopropyloxazol-5-yl)-N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2- methyl-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(4- methoxypyrimidin-5-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrrolo[2,3-b]pyridin-5-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-(5-(2-(3,3-dimethylazetidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(3-methyl- 1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(2- methylpyrimidin-5-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(2,5- dimethyltriazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(2- morpholinopyrimidin-5-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(5-methyl- 1H-indazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-[1-(4- pyridyl)pyrazol-4-yl]triazolo[1,5-a]pyridine-3-carboxamide;
N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(4-methyl- 3-oxo-1,4-benzoxazin-8-yl)triazolo[1,5-a]pyridine-3-carboxamide; 6-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-N-[5-[[2-(3,3-dimethylazetidin-1- yl)acetyl]amino]-2-methyl-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3,3-dimethylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-[5- (hydroxymethyl)-3-thienyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(5- pyrazol-1-yl-3-pyridyl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-[3-[(5- methyl-1,3,4-oxadiazol-2-yl)methyl]phenyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-[4-(1-hydroxyethyl)phenyl]-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(5-methoxy-3-pyridyl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(2- tetrahydropyran-4-ylpyrimidin-5-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(5-oxo- 3,4-dihydro-2H-1,4-benzoxazepin-7-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(4,5,6,7- tetrahydropyrazolo[1,5-a]pyridin-3-yl)triazolo[1,5-a]pyridine-3-carboxamide; 6-([1,3]dioxolo[4,5-b]pyridin-6-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(1,5-dimethylpyrazol-4-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(3-cyclopropyl-1-methyl-pyrazol-4-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin- 1-yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-[5-(methoxymethyl)-3-thienyl]-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(1,3-dimethylpyrazol-4-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-[1-(2-methoxyethyl)-3,5-dimethyl-pyrazol-4-yl]-N-[2-methyl-5-[[2-[(2S)-2- methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3- carboxamide;
N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6- quinoxalin-6-yl-triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-[2-(3- pyridyl)pyrazol-3-yl]triazolo[1,5-a]pyridine-3-carboxamide; 6-[1-(difluoromethyl)pyrazol-3-yl]-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-[2-(hydroxymethyl)-3-thienyl]-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(2- methylpyrimidin-5-yl)triazolo[1,5-a]pyridine-3-carboxamide; 6-(2,5-dimethyltriazol-4-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(2- oxoindolin-7-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(2- tetrahydropyran-4-ylpyrazol-3-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(1- methylpyrrolo[2,3-b]pyridin-5-yl)triazolo[1,5-a]pyridine-3-carboxamide; 6-[3-(dimethylcarbamoyl)phenyl]-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-[5-(difluoromethyl)-1-methyl-pyrazol-4-yl]-N-[2-methyl-5-[[2-[(2S)-2- methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3- carboxamide; 6-[5-(difluoromethoxy)-3-pyridyl]-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-[4-(2- oxooxazolidin-3-yl)phenyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(5-methyl-1H-indazol-4-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-N-[2-methyl-5-[[2-[(2S)-2- methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3- carboxamide; 6-(3-ethyl-1-methyl-pyrazol-4-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide;
6-[4-(2-amino-2-oxo-ethyl)phenyl]-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl)acetyl]amino]-3-pyridyl]-6-(4- methylsulfinylphenyl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(4- methylsulfonylphenyl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(3- sulfamoylphenyl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(4- sulfamoylphenyl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(1,3,5- trimethylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; 6-(3-carbamoylphenyl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(3- methyl-4-sulfamoyl-phenyl)triazolo[1,5-a]pyridine-3-carboxamide; 6-(3-isopropyl-1-methyl-pyrazol-4-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(1-isopropyl-3-methyl-pyrazol-4-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(1-ethyl-3-methyl-pyrazol-4-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(1-ethyl-5-methyl-pyrazol-4-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-[2-(methoxymethyl)-4-pyridyl]-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-[3-(methoxymethyl)-5-methyl-isoxazol-4-yl]-N-[2-methyl-5-[[2-[(2S)-2- methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3- carboxamide; 6-(4-carbamoyl-3-methyl-phenyl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(1- methylpyrazolo[3,4-b]pyridin-5-yl)triazolo[1,5-a]pyridine-3-carboxamide;
6-(2,6-dimethyl-4-pyridyl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(3- pyridyl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(1,5- naphthyridin-3-yl)triazolo[1,5-a]pyridine-3-carboxamide; 6-[3-(hydroxymethyl)phenyl]-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(4- methyl-3-pyridyl)triazolo[1,5-a]pyridine-3-carboxamide; 6-[4-(hydroxymethyl)phenyl]-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(4,5-dimethyl-3-pyridyl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(4-acetamidophenyl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(4-carbamoylphenyl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(2- methyl-4-pyridyl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-[2-(1H- tetrazol-5-yl)phenyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(2-ethyl-5-methyl-triazol-4-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(4-cyclopropyl-1H-pyrazol-5-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-[4-[(1S)-1-(methanesulfonamido)ethyl]phenyl]-N-[2-methyl-5-[[2-[(2S)-2- methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3- carboxamide; 6-(5,6-dimethyl-3-pyridyl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(4-fluoro-2-methyl-pyrazol-3-yl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide;
N-(5-(2-(2-azabicyclo[2.2.2]octan-2-yl)acetamido)-2-methylpyridin-3-yl)-6-(1- methyl-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-(5-(2-(4-cyano-4-methylpiperidin-1-yl)acetamido)-2-methylpyridin-3-yl)-6-(1- methyl-1H-pyrazol-4-yl)-[1,2,3]triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-azabicyclo[2.2.1]heptan-3-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(7-azaspiro[3.3]heptan-7-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(6-azaspiro[2.4]heptan-6-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-(5-oxa-2-azabicyclo[4.1.0]heptan-2-yl)acetyl]amino]-3-pyridyl]-6- (1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]acetyl]amino]-3- pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-methoxy-3-methyl-azetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-hydroxy-3-methyl-pyrrolidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6- (1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-hydroxy-1-piperidyl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-cyano-1-piperidyl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)acetyl]amino]-3-pyridyl]-6- (1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-(2-oxa-7-azaspiro[3.4]octan-7-yl)acetyl]amino]-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-cyclopropyl-3-fluoro-azetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6- (1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(2-fluoro-6-azaspiro[3.3]heptan-6-yl)acetyl]amino]-2-methyl-3-pyridyl]-6- (1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-[3-(methoxymethyl)pyrrolidin-1-yl]acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-isopropoxyazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide;
N-[5-[[2-(6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl)acetyl]amino]-2-methyl-3- pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-[(1S,5R)-3-azabicyclo[3.2.1]octan-3-yl]acetyl]amino]-2-methyl-3-pyridyl]- 6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(1,3,3a,4,6,6a-hexahydrofuro[3,4-c]pyrrol-5-yl)acetyl]amino]-2-methyl-3- pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-ethylmorpholin-4-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-azabicyclo[3.2.0]heptan-3-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-[8-(2-hydroxyethyl)-3-azabicyclo[3.2.1]octan-3-yl]acetyl]amino]-2-methyl- 3-pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-fluoro-3-methyl-azetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(7-azabicyclo[2.2.1]heptan-7-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-cyclopropylpyrrolidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-(4-oxa-8-azaspiro[4.4]nonan-8-yl)acetyl]amino]-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-(8-oxa-3-azaspiro[4.4]nonan-3-yl)acetyl]amino]-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3,3a,4,5,7,7a-hexahydro-2H-furo[2,3-c]pyridin-6-yl)acetyl]amino]-2- methyl-3-pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; 6-(1-methylpyrazol-4-yl)-N-[2-methyl-5-[[2-[(2S,5R)-2,4,5-trimethylpiperazin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-[5-(hydroxymethyl)-2-methyl-1-piperidyl]acetyl]amino]-2-methyl-3- pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(6,8-dihydro-5H-1,7-naphthyridin-7-yl)acetyl]amino]-2-methyl-3-pyridyl]-6- (1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-[(8aS)-4-oxo-1,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2- yl]acetyl]amino]-2-methyl-3-pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5- a]pyridine-3-carboxamide;
N-[5-[[2-[2-(2-hydroxyethyl)-6-azaspiro[2.5]octan-6-yl]acetyl]amino]-2-methyl-3- pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(4-tert-butyl-3-oxo-piperazin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-(2-oxa-6-azatricyclo[3.3.1.13,7]decan-6-yl)acetyl]amino]-3- pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-[3-(1-piperidyl)azetidin-1-yl]acetyl]amino]-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-(9-methyl-4,9-diazabicyclo[4.2.1]nonan-4-yl)acetyl]amino]-3- pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; 6-(1-methylpyrazol-4-yl)-N-[2-methyl-5-[[2-(4-pyrrolidin-1-yl-1- piperidyl)acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-[4-(3-fluoroazetidin-1-yl)-1-piperidyl]acetyl]amino]-2-methyl-3-pyridyl]-6- (1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(4-azabicyclo[3.1.0]hexan-4-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(6-azaspiro[3.3]heptan-6-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-[(1R,4S)-3-azabicyclo[2.2.1]heptan-3-yl]acetyl]amino]-2-methyl-3-pyridyl]- 6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-(4-methyl-1-piperidyl)acetyl]amino]-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(2-isopropylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(azepan-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1-methylpyrazol-4- yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)acetyl]amino]-3-pyridyl]-6- (1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[2-methyl-5-[[2-(2-oxa-5-azabicyclo[2.2.2]octan-5-yl)acetyl]amino]-3-pyridyl]-6- (1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(5,5-dimethyl-1,4-oxazepan-4-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-isoxazol-5-ylpyrrolidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide;
N-[5-[[2-(2-isopropyl-2,5-diazabicyclo[2.2.1]heptan-5-yl)acetyl]amino]-2-methyl-3- pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octan-8-yl)acetyl]amino]-2-methyl- 3-pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-[8-(hydroxymethyl)-6-azabicyclo[3.2.1]octan-6-yl]acetyl]amino]-2-methyl- 3-pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-[2-(2-methoxyethyl)morpholin-4-yl]acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(4-isoxazol-5-yl-1-piperidyl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(4-fluoroazepan-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(6,6-dimethyl-3-azabicyclo[3.1.0]hexan-3-yl)acetyl]amino]-2-methyl-3- pyridyl]-6-(1-methylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; 6-(1-methylpyrazol-4-yl)-N-[2-methyl-5-[[2-(3,3,4-trimethylpiperazin-1- yl)acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; 6-(2-methoxy-3-pyridyl)-N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1- yl]acetyl]amino]-3-pyridyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(azepan-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1-tetrahydrofuran-3- ylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(azepan-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-[4-(2-oxooxazolidin-3- yl)phenyl]triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(7-azabicyclo[2.2.1]heptan-7-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- tetrahydrofuran-3-ylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-cyclopropylpyrrolidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- tetrahydrofuran-3-ylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(7-azaspiro[3.3]heptan-7-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- tetrahydrofuran-3-ylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(6-azaspiro[2.4]heptan-6-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- tetrahydrofuran-3-ylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-azabicyclo[2.2.2]octan-3-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- tetrahydrofuran-3-ylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(2-isopropylazetidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- tetrahydrofuran-3-ylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide;
N-[5-[[2-(3-azabicyclo[3.2.0]heptan-3-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- tetrahydrofuran-3-ylpyrazol-4-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(azepan-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(5,6-dihydro-4H- pyrrolo[1,2-b]pyrazol-3-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(7-azabicyclo[2.2.1]heptan-7-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(5,6- dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(3-cyclopropylpyrrolidin-1-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(5,6- dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)triazolo[1,5-a]pyridine-3-carboxamide; or N-[5-[[2-(3-azabicyclo[2.2.2]octan-3-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(5,6- dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)triazolo[1,5-a]pyridine-3-carboxamide; N-[5-[[2-(7-azaspiro[3.3]heptan-7-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)-1,2-benzoxazole-3-carboxamide; N-[2-Methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(1- methylpyrazol-4-yl)-1,2-benzoxazole-3-carboxamide; N-[5-[[2-(7-azabicyclo[2.2.1]heptan-7-yl)acetyl]amino]-2-methyl-3-pyridyl]-6-(1- methylpyrazol-4-yl)-1,2-benzoxazole-3-carboxamide; N-[5-[[2-(rac-(1R,5S)-3-azabicyclo[3.2.0]heptan-3-yl)acetyl]amino]-2-methyl-3- pyridyl]-6-(1-methylpyrazol-4-yl)-1,2-benzoxazole-3-carboxamide; or N-[2-methyl-5-[[2-[(2S)-2-methylpyrrolidin-1-yl]acetyl]amino]-3-pyridyl]-6-(1- methylpyrazol-4-yl)-2,1-benzoxazole-3-carboxamide. 56. A compound according to any one of the preceding claims, wherein the compound has an IC50< 20 nM in a PDGFR cellular assay. 57. The compound according to claim 56, wherein the compound has an IC50< 5 nM in a PDGFR cellular assay. 58. A pharmaceutical composition comprising a compound according to any one of claims 1-57, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 59. A method of treating a disease or disorder in which PDGFR signaling is implicated in a subject in need thereof, comprising administering to said subject an amount of a
compound according to any one of claims 1-57, or a pharmaceutically acceptable salt thereof, that is effective to treat said disease or disorder. 60. The method according to claim 59, wherein the disease or disorder is pulmonary hypertension (PH). 61. The method according to claim 60, wherein the pulmonary hypertension is pulmonary arterial hypertension (PAH); PH secondary to heart failure; PH secondary to lung diseases and/or hypoxia; PH due to pulmonary artery obstruction; or PH due to unknown or rare diseases. 62. The method according to claim 61, wherein the pulmonary hypertension is pulmonary arterial hypertension (PAH).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263354343P | 2022-06-22 | 2022-06-22 | |
US63/354,343 | 2022-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023247590A1 true WO2023247590A1 (en) | 2023-12-28 |
Family
ID=87059761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/066725 WO2023247590A1 (en) | 2022-06-22 | 2023-06-21 | Triazolopyridine and benzoisoxazole carboxamides and their uses as pdgfr inhibitors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023247590A1 (en) |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
US4739762A (en) | 1985-11-07 | 1988-04-26 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
US5451233A (en) | 1986-04-15 | 1995-09-19 | Yock; Paul G. | Angioplasty apparatus facilitating rapid exchanges |
US5496346A (en) | 1987-01-06 | 1996-03-05 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
WO2013030802A1 (en) | 2011-09-01 | 2013-03-07 | Novartis Ag | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
-
2023
- 2023-06-21 WO PCT/EP2023/066725 patent/WO2023247590A1/en unknown
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
US4739762A (en) | 1985-11-07 | 1988-04-26 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4739762B1 (en) | 1985-11-07 | 1998-10-27 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5451233A (en) | 1986-04-15 | 1995-09-19 | Yock; Paul G. | Angioplasty apparatus facilitating rapid exchanges |
US5496346A (en) | 1987-01-06 | 1996-03-05 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
US5879382A (en) | 1989-08-24 | 1999-03-09 | Boneau; Michael D. | Endovascular support device and method |
US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
WO2013030802A1 (en) | 2011-09-01 | 2013-03-07 | Novartis Ag | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
Non-Patent Citations (6)
Title |
---|
"Handbook of Clinical Drug Data", 2002, MCGRAW-HILL |
"Pharmaceutical Sciences", 2000, LIPPINCOTT WILLIAMS & WILKINS. |
"Principles of Drug Action", 1990, CHURCHILL LIVINGSTON |
"The Pharmacological Basis of Therapeutics", 2001, MCGRAW HILL |
MARTINDALE: "The Extra Pharmacopoeia", 1999, THE PHARMACEUTICAL PRESS |
SHAW DUNCAN E. ET AL: "Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 17, 19 August 2016 (2016-08-19), US, pages 7901 - 7914, XP093069286, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b00703 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020202707B2 (en) | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity | |
US10787452B2 (en) | Compounds useful as inhibitors of ATR kinase | |
AU2023233205A1 (en) | SHP2 phosphatase inhibitors and methods of use thereof | |
KR101787680B1 (en) | Kinase Inhibitor and Use Thereof | |
KR101793807B1 (en) | Fused heterocyclic compounds as protein kinase inhibitors | |
JP2018150358A (en) | Tank-binding kinase inhibitor compounds | |
CA3139821A1 (en) | Compounds for treating huntington's disease | |
KR20130006625A (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
KR20150028999A (en) | 5-azaindazole compounds and methods of use | |
CA3085460A1 (en) | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
TW202330529A (en) | Heterocyclic compounds and methods of use | |
TW202233629A (en) | Heterocyclic spiro compounds and methods of use | |
TW202104230A (en) | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease | |
AU2022249824A1 (en) | (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo [1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer | |
US20240109917A1 (en) | Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors | |
WO2023247590A1 (en) | Triazolopyridine and benzoisoxazole carboxamides and their uses as pdgfr inhibitors | |
WO2023247593A1 (en) | Pyrrolopyridine carboxamides and their uses as pdgfr inhibitors | |
WO2023247595A1 (en) | Pyrazolopyrazine carboxamides and their uses as pdgfr inhibitors | |
WO2023247596A1 (en) | Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors | |
WO2023007009A1 (en) | Pyrazolopyrimidines and their uses as pdgfr inhibitors | |
WO2024086809A1 (en) | Methods for treating cancer | |
CN116802184A (en) | Pyrazolothiazole carboxamides and their use as PDGFR inhibitors | |
WO2024091370A1 (en) | 5,6-fused bicyclic heteroaromatic compounds | |
CN117881397A (en) | Heterocyclic compounds and methods of use | |
TW202342483A (en) | Imidazole macrocycles for the treatment of autoimmune disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23734582 Country of ref document: EP Kind code of ref document: A1 |